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“Allora dovresti dire quello a cui credi”, riprese la Lepre Marzolina. 
 “È quello che faccio”, rispose subito Alice; “almeno credo a quello che dico, che poi è la 
stessa cosa.” 
“Non è affatto la stessa cosa!” disse il Cappellaio. “Scusa, è come se tu dicessi che vedo quello 
che mangio è la stessa cosa di mangio quello che vedo!” 
 
Alice nel Paese delle Meraviglie, Lewis Carroll 
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Summary 
The functionality of tissues is guaranteed by the capillaries, which supply the microvascular 
network providing a considerable surface area for exchanges between blood and tissues. 
Microcirculation is affected by any pathological condition and any change in the blood supply 
can be used as a biomarker for the diagnosis of lesions and the optimization of the treatment. 
Nowadays, a number of techniques for the study of perfusion in vivo and in vitro are 
available. Among the several imaging modalities developed for the study of microcirculation, 
the analysis of the tissue kinetics of intravenously injected contrast agents or tracers is the 
most widely used technique. Tissue kinetics can be studied using different modalities: the 
positive enhancement of the signal in the computed tomography and in the ultrasound 
dynamic contrast enhancement imaging; T1-weighted MRI or the negative enhancement of 
T2* weighted MRI signal for the dynamic susceptibility contrast imaging or, finally, the 
uptake of radiolabelled tracers in dynamic PET imaging. Here we will focus on the perfusion 
quantification of dynamic PET and MRI data. The kinetics of the contrast agent (or the tracer) 
can be analysed visually, to define qualitative criteria but, traditionally, quantitative 
physiological parameters are extracted with the implementation of mathematical models. 
Serial measurements of the concentration of the tracer (or of the contrast agent) in the tissue 
of interest, together with the knowledge of an arterial input function, are necessary for the 
calculation of blood flow or perfusion rates from the wash-in and/or wash-out kinetic rate 
constants. The results depend on the acquisition conditions (type of imaging device, imaging 
mode, frequency and total duration of the acquisition), the type of contrast agent or tracer 
used, the data pre-processing (motion correction, attenuation correction, correction of the 
signal into concentration) and the data analysis method.   
As for the MRI, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a 
non-invasive imaging technique that can be used to measure properties of tissue 
microvasculature. It is sensitive to differences in blood volume and vascular permeability that 
can be associated with tumour angiogenesis. DCE-MRI has been investigated for a range of 
clinical oncologic applications (breast, prostate, cervix, liver, lung, and rectum) including 
cancer detection, diagnosis, staging, and assessment of treatment response. Tumour 
microvascular measurements by DCE-MRI have been found to correlate with prognostic 
factors (such as tumour grade, microvessel density, and vascular endothelial growth factor 
expression) and with recurrence and survival outcomes. Furthermore, DCE-MRI changes 
measured during treatment have been shown to correlate with outcome, suggesting a role as 
a predictive marker. The accuracy of DCE-MRI relies on the ability to model the 
pharmacokinetics of an injected contrast agent using the signal intensity changes on 
sequential magnetic resonance images. DCE-MRI data are usually quantified with the 
application of the pharmacokinetic two-compartment Tofts model (also known as the 
standard model), which represents the system with the plasma and tissue (extravascular 
extracellular space) compartments and with the contrast reagent exchange rates between 
them. This model assumes a negligible contribution from the vascular space and considers 
the system in, what-is-known as, the fast exchange limit, assuming infinitely fast 
transcytolemmal water exchange kinetics. In general, the number, as well as any assumption 
about the compartments, depends on the properties of the contrast agent used (mainly 
gadolinium) together with the tissue physiology or pathology studied. For this reason, the 
choice of the model is crucial in the analysis of DCE-MRI data. 
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The value of PET in clinical oncology has been demonstrated with studies in a variety of 
cancers including colorectal carcinomas, lung tumours, head and neck tumours, primary and 
metastatic brain tumours, breast carcinoma, lymphoma, melanoma, bone cancers, and other 
soft-tissue cancers. PET studies of tumours can be performed for several reasons including 
the quantification of tumour perfusion, the evaluation of tumour metabolism, the tracing of 
radiolabelled cytostatic agents. In particular, the kinetic analysis of PET imaging has showed, 
in the past few years, an increasing value in tumour diagnosis, as well as in tumour therapy, 
through providing additional indicative parameters. Many authors have showed the benefit 
of kinetic analysis of anticancer drugs after labelling with radionuclide in measuring the 
specific therapeutic effect bringing to light the feasibility of applying the kinetic analysis to 
the dynamic acquisition. Quantification methods can involve visual analysis together with 
compartmental modelling and can be applied to a wide range of different tracers. The 
increased glycolysis in the most malignancies makes 18F-FDG-PET the most common 
diagnostic method used in tumour imaging. But, PET metabolic alteration in the target tissue 
can depend by many other factors. For example, most types of cancer are characterized by 
increased choline transport and by the overexpression of choline kinase in highly proliferating 
cells in response to enhanced demand of phosphatidylcholine (prostate, breast, lung, ovarian 
and colon cancers). This effect can be diagnosed with choline-based tracers as the 18F-
fluoromethylcholine (18F-FCH), or the even more stable 18F-D4-Choline. Cellular 
proliferation is also imaged with 18F-fluorothymidine (FLT), which is trapped within the 
cytosol after being mono phosphorylated by thymidine kinase-1 (TK1), a principal enzyme 
in the salvage pathway of DNA synthesis. 18F-FLT has been found to be useful for non-
invasive assessment of the proliferation rate of several types of cancer and showed high 
reproducibility and accuracy in breast and lung cancer tumours. 
The aim of this thesis is the perfusion quantification of dynamic PET and MRI data of patients 
with lung, brain, liver, prostate and breast lesions with the application of advanced models. 
This study covers a wide range of imaging methods and applications, presenting a novel 
combination of MRI-based perfusion measures with PET kinetic modelling parameters in 
oncology. It assesses the applicability and stability of perfusion quantification methods, 
which are not currently used in the routine clinical practice. 
The main achievements of this work include: 1) the assessment of the stability of perfusion 
quantification of D4-Choline and 18F-FLT dynamic PET data in lung and liver lesions, 
respectively (first applications in the literature); 2) the development of a model selection in 
the analysis of DCE-MRI data of primary brain tumours (first application of the extended 
shutter speed model); 3) the multiparametric analysis of PET and MRI derived perfusion 
measurements of primary brain tumour and breast cancer together with the integration of 
immuohistochemical markers in the prediction of breast cancer subtype (analysis of data 
acquired on the hybrid PET/MRI scanner). 
 The thesis is structured as follows:   
- Chapter 1 is an introductive chapter on cancer biology. Basic concepts, including the causes 
of cancer, cancer hallmarks, available cancer treatments, are described in this first chapter. 
Furthermore, there are basic concepts of brain, breast, prostate and lung cancers (which are 
the lesions that have been analysed in this work).   
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- Chapter 2 is about Positron Emission Tomography. After a brief introduction on the basics 
of PET imaging, together with data acquisition and reconstruction methods, the chapter 
focuses on PET in the clinical settings. In particular, it shows the quantification techniques 
of static and dynamic PET data and my results of the application of graphical methods, 
spectral analysis and compartmental models on dynamic 18F-FDG, 18F-FLT and 18F-D4-
Choline PET data of patients with breast, lung cancer and hepatocellular carcinoma.   
- Chapter 3 is about Magnetic Resonance Imaging. After a brief introduction on the basics of 
MRI, the chapter focuses on the quantification of perfusion weighted MRI data. In particular, 
it shows the pharmacokinetic models for the quantification of dynamic contrast enhanced 
MRI data and my results of the application of the Tofts, the extended Tofts, the shutter speed 
and the extended shutter speed models on a dataset of patients with brain glioma.    
- Chapter 4 introduces the multiparametric imaging techniques, in particular the combined 
PET/CT and the hybrid PET/MRI systems. The last part of the chapter shows the applications 
of perfusion quantification techniques on a multiparametric study of breast tumour patients, 
who simultaneously underwent DCE-MRI and 18F-FDG PET on a hybrid PET/MRI scanner. 
Then the results of a predictive study on the same dataset of breast tumour patients integrated 
with immunohistochemical markers. Furthermore, the results of a multiparametric study on 
DCE-MRI and 18F-FCM brain data acquired both on a PET/CT scanner and on an MR 
scanner, separately. Finally, it will show the application of kinetic analysis in a radiomic 
study of patients with prostate cancer.  
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CHAPTER 1 
 
Cancer biology – Basic concepts 
 
Cancer is the second most common cause of death in the ‘developed’ world; only cardiovascular 
disease mortality exceeds that of malignancy [1]. Cancer is the disease of uncontrolled growth 
and proliferation and it can be considered a multi-step process which requires the accumulation 
of many genetic changes over time. These genetic alterations involve activation of proto-
oncogenes to oncogenes, deregulation of tumour suppressor genes and DNA repair genes and 
‘immortalisation’ [2]. 
Usually, the cell cycle is regulated by proteins that interact with each other in a specific sequence 
of events. They check that each stage of the cycle is competed correctly ensuring that 
incompletely replicated DNA is not passed onto daughter cells. This regulation is influenced by 
transcription receptors in the nucleus, which trigger the start of DNA synthesis. P53 is called the 
“guardian of the genome” and is able to induce apoptosis if the genomic damage is too great to 
be repaired. It also induces the expression of cell cycle inhibitors to prevent cell proliferation of 
a cell until the damage is repaired [2]. Normal mammalian somatic cells proliferate a limited 
number of times before undergoing senescence. Senescent cells may remain metabolically active 
even though they have permanently ceased proliferation. Immortalisation is an essential step in 
the malignant transformation of normal cells and can be attributed, in part, to the presence of 
telomerase, the enzyme responsible for maintaining telomeres at the ends of chromosomes. By 
extending telomeric DNA, telomerase is able to counter the progressive telomere shortening that 
would otherwise lead to cell death. Unlike normal cells that lack detectable levels of telomerase 
activity, approximately 90% of human tumours consist of cells that contain an active telomerase 
enzyme [2]. Tissue homeostasis is regulated by growth factors (GFs), which transmit signals from 
one cell to another. They are sensitive to specific growth factors receptors (GFR), which can 
activate target molecules promoting proliferation. Normal cell proliferation include: 
• the binding of a GF to its specific receptor on the cell membrane 
• transient and limited activation of the GFR, which, activates several signal-transducing 
proteins (e.g. Ras) on the inner leaflet of the plasma membrane 
• transmission of the signal by signal transduction molecules, either to cytosolic targets or 
to the nucleus where they activate transcription of specific genes 
• entry of the cell into the cell cycle, ultimately resulting in cell division. 
This pathway is often derailed in cancer and allows wayward cells to generate their own internal 
signals that stimulate proliferation and become independent of their environments. In fact, cancer 
cells are able to induce their own growth stimulatory signals when mutations in the GFR gene 
occur, which facilitates activation in the absence of GFs or when overproduction of GFs results 
in an autocrine signalling loop [2]. An alternative strategy by which cancer cells can become GF 
independent involves constitutive activation of internal signalling components. 
 
Carcinogenesis 
The genes that have been implicated in carcinogenesis are grouped in oncogenes and tumour 
suppressor genes. 
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- Cellular oncogenes 
Genes that promote autonomous cell growth in cancer cells are called oncogenes, and their normal 
cellular counterparts are called proto-oncogenes. Proto-oncogenes are physiologic regulators of 
cell proliferation and differentiation while oncogenes are characterised by the ability to promote 
cell growth in the absence of normal mitogenic signals. Their products, oncoproteins, resemble 
the normal products of proto-oncogenes with the exception that oncoproteins are devoid of 
important regulatory elements. Their production in the transformed cells becomes constitutive, 
that is, not dependent on growth factors or other external signals. Proto-oncogenes can be 
converted to oncogenes by several mechanisms including point mutation and gene amplification 
resulting in: 
• Overproduction of growth factors 
• Flooding of the cell with replication signals 
• Uncontrolled stimulation in the intermediary pathways 
• Cell growth by elevated levels of transcription factors 
The RAS oncogene is the most frequently mutated oncogene in human cancer. It encodes a GTP-
binding protein Ras that functions as an on-off ‘switch’ for a number of key signalling pathways 
controlling cellular proliferation [2]. Other oncogenes frequently mutated in cancer are listed in 
Table 1. 
 
Table 1: Selected oncogenes and associated cancers 
Category/Protein 
Function 
Proto-
oncogene 
Mode of Activation Associated Cancer 
Growth Factors 
-PDGF (β chain) 
-Fibroblast growth factors 
 
-Transforming growth 
factor α 
 
SIS 
HST-1 
INT-2 
 
TGFα 
 
Overexpression 
Overexpression 
Amplification 
 
Overexpression 
 
Astrocytoma, 
osteosarcoma 
Stomach cancer 
Bladder and breast cancer 
Melanoma 
Astrocytomas 
Hepatocellular carcinomas 
Growth factor Receptors 
-EGF-receptor family 
 
 
-PDGF receptor 
-Receptor for stem cell 
(steel) factor 
 
ERB-B1 
ERB-B2 
PDGF-R 
 
KIT 
 
Overexpression 
Amplification 
Overexpression 
 
Point Mutation 
 
SCC of the lung, gliomas 
Breast and ovarian 
cancers 
Gliomas 
 
Gastrointestinal stromal 
tumours 
Proteins involved in 
Signal Transduction 
-GTP-binding 
 
 
K-RAS 
 
 
Point mutation 
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-Non-receptor tyrosine 
kinase 
-RAS signal transduction 
-WNT signal transduction 
H-RAS 
N-RAS 
 
ABL 
BRAF 
Β-catenin 
Point mutation 
Point mutation 
 
Translocation 
Point mutation 
Point mutation/ 
Overexpression 
Colon, lung, pancreatic 
tumours 
Bladder and kidney 
tumours 
Melanoma, leukaemia, 
lymphoma 
CML, ALL 
Melanomas 
Hepatoblastomas and 
HCC 
Nuclear Regulatory 
Proteins 
Transcriptional activators 
 
C-MYC 
 
N-MYC 
L-MYC 
 
Translocation 
 
Amplification 
Amplification 
 
Burkitt lymphoma 
Neuroblastoma, small cell 
carcinoma of lung 
SCC of the lung 
Cell-cycle Regulators 
Cyclins 
 
 
 
Cyclin-dependent kinase 
 
CYCLIN D 
 
CYCLIN E 
 
CDK4 
 
Translocation 
Amplification 
Overexpression 
Amplification or 
Point mutation 
 
Mantle cell lymphoma 
Brest and oesophageal 
cancers 
Breast cancer 
Glioblastoma, melanoma  
sarcoma 
 
 
 
 
 
- Tumour suppressor genes 
Tumour suppressor genes (Table 2) encode proteins that are: 
• receptors for secreted hormones that function to inhibit cell proliferation• negative 
regulators of cell cycle entry or progression 
• negative regulators of growth signalling pathways (e.g. APC or PTEN) 
• checkpoint-control proteins that arrest the cell cycle if DNA is damaged or chromosomes 
are abnormal  
• proteins that promote apoptosis DNA repair enzymes.  
The transformation of a normal cell to a cancer cell is accompanied by the loss of function of one 
or more tumour suppressor genes and both gene copies must be defective in order to promote 
tumour development [2]. 
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Table 2: Examples of tumour suppressor genes 
Gene Protein function Inherited disease Spontaneous Tumours 
APC Negative regulator of the 
signalling pathway 
Adenomatous 
polyposis coli (APC) 
Most colon cancers 
BRCA1 
BRCA2 
Components of DNA 
repair systems 
Familial breast and 
ovarian cancer 
Spontaneous breast 
cancers 
CDH1 E-cadherin, a cell adhesion 
molecule 
Hereditary diffuse 
gastric cancer 
Many epithelial cancers 
CDKN2A INK4a, inhibitor of cyclin-
dependent kinase Cdk4 
Some familial 
melanomas 
Some esophageal and 
pancreatic cancers 
MEN1 Transcription factor and 
protein kinase 
Multiple endocrine 
neoplasia 
Many metastatic 
cancers 
NF1 Neurofibromin, Ras-
GTPase activation 
Neurofibromatosis type 
1 
Some tumours of neural 
crest origin 
PTEN Negative regulator of PI3K 
growth signalling pathway 
Cowden disease 30%-50% of 
spontaneous cancers 
RB Repression of transcription 
factor E2F 
Retinoblastoma. 
osteosarcoma 
Retinoblastoma, 
sarcomas, several 
cancers 
SMAD4 Signal transducer in TGF-
signalling 
Juveline polyposis Colon and pancreatic 
cancers 
TP53 Transcription factor; 
guardian of the genome 
Li-Fraumeni syndrome Most frequently 
mutated in human 
cancers 
TSC1 
TSC2 
Inhibitor of mTOR Tuberous sclerosis Rare 
VHL Ubiquitin ligase Von Hippel-Lindau 
disease 
Many renal cell 
carcinomas 
WT1 Transcription factor Wilms tumour Some leukaemias 
 
 
Causes of cancer 
Cancer development is based on the accumulation of somatic mutations over lifetime. 
Environmental carcinogens include chemical mutagens, which modify DNA through a range of 
mechanisms (alkylation or deamination of DNA bases, intercalation between base pairs and 
formation of DNA adducts); radiation, which induces DNA double strand breaks and tumour 
viruses, which can be subdivided in oncogenic viruses, viral oncogenes and slowly transforming 
viruses. Usually, viruses tend to use one of the following mechanisms to stimulate proliferation 
of their host cells: 
• insertion of a strong promoter in the vicinity of a host cell proto-oncogene 
• expression of proteins that neutralise host cell tumour suppressor proteins 
• expression of proteins that prevent or delay apoptosis 
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Characteristics of viral carcinogenesis include: 
• Tumour viruses often establish persistent infections in the human host 
• Host factors are important determinants of virus-induced carcinogenesis 
• Viruses are rarely complete carcinogens; they require additional factors to fully activate 
carcinogenesis. 
 
The complex micro-evolutionary process of carcinogenesis requires the accumulation of a range 
of genetic mutations. As a consequence, cells acquire new characteristics such as enhanced 
survival and invasiveness. Three are the main processes involved in carcinogenesis: malignant 
transformation, invasion and metastasis. An example of the early steps of carcinogenesis can be 
done studying colorectal cancer: genetic characterisation of a large number of early, intermediate 
and late adenomas and frank carcinomas led to the establishment of a ‘preferred’ sequence of 
genetic alterations during the adenoma-adenocarcinoma pathway of colorectal cancer. These 
include the activation of the K-ras oncogene from its cellular proto-oncogene and the loss for 
three tumour suppressor genes, where loss of APC (adenomatous polyposis coli) is an early event, 
whereas loss of p53 is normally a late event. 
The spread of cancer cells to distant sites is called metastasis and is the most lethal form of disease. 
Metastatic cells are less adhesive than normal cells and are able to degrade and penetrate tissue 
barriers of surrounding connective tissue and the basement membrane of blood vessels. They can 
invade normal tissues at various sites in the body forming secondary colonies. Usually, the 
invasion – metastasis cascade involves: 
 
1. Acquisition of local invasiveness 
2. Invasion of the cell into blood/ lymph vessels (intravasation) 
3. Transport through the blood/lymph vessels to distant tissue sites 
4. Escape of the cancer cells from circulation (extravasation) 
5. Ability to adapt to the local tissue environment and to proliferate 
 
Cancer can be caused by other different alterations apart from tumour suppressor genes, proto-
oncogenes and DNA repair genes. These include alterations of genetic mechanisms like: 
• Loss of heterozygosity 
• Microsatellite instability 
• DNA hyper or hypomethylation 
Furthermore, there are a wide range of rare familial syndromes that predispose affected family 
members to cancer development (usually based on mutations of tumour suppressor genes).  
 
Cancer hallmarks 
The hallmarks of cancer comprise six biological capabilities acquired during the multistep 
development of human tumours. The hallmarks constitute an organizing principle for 
rationalizing the complexities of neoplastic disease. They include sustaining proliferative 
signalling, evading growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, and activating invasion and metastasis [3].  
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Figure 1: The hallmarks of cancer. 
- Sustaining proliferative signalling: cancer cells sustain chronic proliferation deregulating 
signals which, in normal tissues, carefully control the production and release of growth-
promoting signals ensuring homeostasis and the maintenance of normal architecture and 
function. Cancer cells promote proliferative signalling in many ways: they may produce 
growth factor ligands themselves, to which they can respond via the expression of cognate 
receptors, resulting in autocrine proliferative stimulation. Alternatively, cancer cells may 
send signals to stimulate normal cells within the supporting tumour-associated stroma, 
which reciprocate by supplying the cancer cells with various growth factors. 
- Evading Growth Suppressors: cancer cells must also circumvent powerful programs that 
negatively regulate cell proliferation; many of these programs depend on the actions of 
tumour suppressor genes. The two prototypical tumour suppressors encode the RB 
(retinoblastoma-associated) and TP53 proteins, which operate as central control nodes 
within two key complementary cellular regulatory circuits that govern the decisions of 
cells to proliferate or, alternatively, activate senescence and apoptotic programs. 
- Resisting Cell Death: Programmed cell death is also known as the phenomenon of 
apoptosis. DNA damage sensor operates via the TP53 tumour suppressor which then 
induces apoptosis. Cells with DNA damage die off and the cellular parts reclaimed. 
Tumours find ways around this apoptosis, most commonly by evolving mutations to the 
TP53 pathway which inactivates it. There are many similarities between the pathways 
apoptosis and autophagy — the cellular recycling process of sub cellular parts and 
organelles. Importantly, autophagy has both good and bad effects as it may potentially 
delay the onset of cancer, once established, and enhance cancer survival by putting it into 
a dormant state. 
- Enabling replicative mortality: cancer cells are immortal. Normal cells can only replicate 
a certain number of times before they die. Telomeres protecting the end of chromosomes 
are crucially important in developing immortality. Regular cells have telomeres that 
progressively get shorter the more times they divide. Thus, over time, as telomeres 
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shorten, cells get old. Normal cells don’t have it, and immortal cells, including cancer 
cells, do. This blocks aging (senescence) and apoptosis. 
- Inducing angiogenesis: as the cancer grows, it requires blood vessels to bring nutrients 
into the centre of the tumour and to remove waste products. Without acquiring this ability 
to grow new blood vessels, tumours would die. This led to the development of a number 
of drugs that targeted and blocked specific receptors in this pathway.  
- Activating Invasion and Metastasis: Tumours can invade other tissues through local 
invasion or metastatic spread. In local invasion, a tumour may invade the tissue 
surrounding it. In metastatic spread, the tumour spreads to tissues which are farther away 
from the original tumour.  
Cancer treatment 
The course of treatment depends on the type of cancer, its location, and its state of advancement. 
Surgery, often the first treatment, is used to remove solid tumours. It may be the only treatment 
necessary for early stage cancers and benign tumours. Radiation kills cancer cells with high-
energy rays targeted directly to the tumour. It acts primarily by damaging DNA and preventing 
its replication; therefore, it preferentially kills cancer cells, which rapidly divide. It also kills some 
normal cells, particularly those that are dividing. Surgery and radiation treatment are often used 
together. Chemotherapy drugs are toxic compounds that target rapidly growing cells. Many of 
these drugs are designed to interfere with the synthesis of precursor molecules needed for DNA 
replication. Other drugs cause extensive DNA damage, which stops replication. A class of drugs 
called spindle inhibitors stops cell replication early in mitosis. During mitosis, chromosome 
separation requires spindle fibres made of microtubules; spindle inhibitors stop the synthesis of 
microtubules. Because most adult cells don’t divide often, they are less sensitive to these drugs 
than are cancer cells. Chemotherapy drugs also kill certain adult cells that divide more rapidly, 
such as those that line the gastrointestinal tract, bone marrow cells, and hair follicles. This causes 
some of the side effects of chemotherapy, including gastrointestinal distress, low white blood cell 
count, and hair loss. 
Newer therapies block the activity of hormones often required by the cell for growing. For 
example, some breast cancer cells require estrogen for growth. Drugs that block the binding site 
for estrogen can slow the growth of these cancers. These drugs are called selective estrogen 
receptor modulators (SERMs) or anti-estrogens. Tamoxifen and Raloxifene are examples of this 
type of drug. A ten-year clinical trial of these two drugs with 20,000 women began in 1999 to 
determine their effectiveness in preventing breast cancer. Similarly, testosterone (an androgen 
hormone) stimulates some prostate cancer cells. Selective androgen receptor modulators 
(SARMs) are drugs that block the binding of testosterone to these cancer cells, inhibiting their 
growth and possibly preventing prostate cancer. 
Newer chemotherapeutic drugs target specific, active proteins or processes in cancer cell signal 
transduction pathways, such as receptors, growth factors, or kinases. Because the targets are 
cancer-specific proteins, the hope is that these drugs will be much less toxic to normal cells than 
conventional cancer drugs. 
Another promising target for cancer therapy is angiogenesis. Several drugs, including some 
naturally occurring compounds, have the ability to inhibit angiogenesis. Two compounds in this 
class are angiostatin and endostatin; both are derived from naturally occurring proteins. These 
drugs prevent angiogenesis by tumour cells, restricting tumour growth and preventing metastasis. 
One important advantage of angiogenesis inhibitors is that, because they do not target the cancer 
cells directly, there is less chance that the cancer cells will develop resistance to the drug.  
A technique called chemoimmunotherapy attaches chemotherapy drugs to antibodies that are 
specific for cancer cells. The antibody then delivers the drug directly to cancer cells without 
harming normal cells, reducing the toxic side effects of chemotherapy. These molecules contain 
two parts: the cancer-cell-specific antibody and a drug that is toxic once it is taken into the cancer 
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cell. A similar strategy, radioimmunotherapy, couples specific antibodies to radioactive atoms, 
thereby targeting the deadly radiation specifically to cancer cells. 
1. Brain cancer 
 
Gliomas account for more than 70% of all primary brain tumours, and of these, glioblastoma is 
the most frequent and malignant histologic type (World Health Organization [WHO] grade IV) 
[4]. 
 
Clinical classification 
There are two main types of tumours: malignant or cancerous tumours and benign tumours. 
Cancerous tumours can be divided into primary tumours that start within the brain, and secondary 
tumours that have spread from elsewhere, known as brain metastasis tumours. 
Glioma occurs in the brain and spinal cord and, more precisely, in glial cells, which surround and 
help nerve cells. Tumours can be produced by three different types of cells and gliomas are usually 
classified according to the type of glial cell involved in the tumour. Types of glioma include: 
 
- astrocytomas, including astrocytoma, anaplastic strocytoma and glioblastoma, 
- ependymomas, including anaplastic ependymoma, myxopapillary ependymoma and 
subependymoma, 
- oligodendrogliomas, including oligodendroglioma, anaplastic oligodendroglioma and 
anaplastic oligoastrocytoma. 
 
Secondary brain tumours are metastatic and have invaded the brain from cancers originating in 
other organs. They then circulate through the bloodstream, and are deposited in the brain. There, 
these cells continue growing and dividing, becoming another invasive neoplasm of the primary 
cancer's tissue. Secondary tumours of the brain are very common in the terminal phases of patients 
with an incurable metastasized cancer; the most common types of cancers that bring about 
secondary tumours of the brain are lung cancer, breast cancer, malignant melanoma, kidney 
cancer, and colon cancer (in decreasing order of frequency). Secondary brain tumours are more 
common than primary ones; in the United States there are about 170,000 new cases every year. 
Secondary brain tumours are the most common cause of tumours in the intracranial cavity. The 
skull bone structure can also be subject to a neoplasm that by its very nature reduces the volume 
of the intracranial cavity, and can damage the brain.  
 
Risk factors 
The cause of most brain tumours is unknown [4]. Epidemiological studies are required to determine 
risk factors. Aside from exposure to vinyl chloride or ionizing radiation, there are no known 
environmental factors associated with brain tumours [5]. Mutations and deletions of so-called tumour 
suppressor genes, such as P53, are thought to be the cause of some forms of brain tumour [6]. Inherited 
conditions, such as Von Hippel–Lindau disease, multiple endocrine neoplasia, and neurofibromatosis 
type 2 carry a high risk for the development of brain tumours [7]. People with celiac disease have a 
slightly increased risk of developing brain tumours [8]. Although studies have not shown any link 
between cell phone or mobile phone radiation and the occurrence of brain tumours, the World Health 
Organization has classified mobile phone radiation on the IARC scale into Group 2B – possibly 
carcinogenic [9]. Discounting claims that current cell phone usage may cause brain cancer, modern, 
third-generation (3G) phones emit, on average, about 1% of the energy emitted by the GSM (2G) 
phones that were in use when epidemiological studies that observed a slight increase in the risk for 
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glioma – a malignant type of brain cancer – among heavy users of wireless and cordless telephones 
were conducted. 
2. Breast cancer 
 
Breast cancer is the most frequently diagnosed cancer among women in 140 of 184 countries 
worldwide and remains the most common cause of cancer death (322,600 breast cancer deaths have 
been averted in US women  through 2015) [10].  
 
Clinical classification 
Clinically, breast cancer classification is done on the basis of tumour morphological 
characteristics into different types and these include infiltrating ductal carcinoma of no special 
type, and a large number of ‘special types’ such as infiltrating lobular carcinoma, tubular, 
mucinous, medullary, and adenoid cystic carcinoma. Histological grade, including the degree of 
cellular differentiation, nuclear pleomorphism, and mitotic count help in further sub-classification 
of breast tumours. Breast tumours such as smaller size tubular carcinomas are typically associated 
with earlier stage at presentation, compared with infiltrating ductal carcinomas. It is also noted 
that breast tumours of high histological grade are generally large at presentation and are associated 
with local or distant metastasis, compared with tumours of low histological grade. Breast tumours 
have also been identified into five different subtypes based on the expression of estrogen receptors 
(ER) and progesterone receptors (PR), and Her2 oncogene. Overall, the ER positive tumours are 
more common than the ER-negative tumours. Also, the ER positive tumours are smaller and low 
grade and lymph node negative unlike the ER negative tumours [11]. Thus, there are two ER/PR-
positive subgroups, Luminal A and Luminal B, and three ER-negative subgroups. One of the ER 
negative type is characterized by elevated expression of Her2 and related genes, and thus termed 
as the Her2 subtype; the second ER negative type is associated with high expression of genes 
normally identified with myoepithelial or basal cells, termed basal-like subtype; and a third ER 
negative group that shows a varied gene expression profile is termed normal-like subtype [11]. 
Both Her2 and basal-like subtypes of ER negative breast tumours clinically exhibit significantly 
poorer outcome than the luminal and normal-like groups. It has been observed that prognosis is 
worse in a stage-independent manner for both Her2 and basal-like subtypes of ER negative breast 
tumours and that both subtypes are also associated with more advanced stage at presentation [10]. 
Both Her2 and basal-like breast tumours were found to contain a greater percentage of stem cell-
like cells, which seven may contribute to their aggressive clinical behaviour [11]. Her2 oncogene 
is related to epidermal growth factor receptor family and is overexpressed in approximately 20 % 
of the breast tumours. PR negativity among all ER positive tumours independently predicts Her2 
positivity [11]. Breast tumours that do not express either ER, PR, or Her2 are called triple negative 
breast cancers (TNBC) and approximately 15 % of the breast cancers fall into this category. 
Besides the above subtypes, there is another form of breast cancer known as inflammatory breast 
cancer (IBC) that is clinically and biologically distinct [11]. 
 
Risk factors 
For most sporadic breast cancer, age and female sex are the two key risk factors with most women 
diagnosed after menopause (median age 59). Family history especially in first or second-degree 
relatives is also important. Estrogen exposure has a role in the genesis of breast cancer, with early 
menarche, late menopause, and nulliparity being risk factors, and parity, history of breast feeding 
being protective. Although the risk of breast cancer whilst on the oral contraceptive pill is higher, 
the overall risk during one’s lifetime is small due to the young age at which women are on the 
pill. Hormone replacement therapy can increase the risk of breast cancer. Other lifestyle related 
risk factors increase high caloric intake during childhood and adolescence, obesity and alcohol. 
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Some breast pathologies increase the risk of breast cancer such as ductal carcinoma in situ (DCIS), 
lobular carcinoma in situ and atypical ductal hyperplasia. 
It is well recognized that while the breast cancer incidence is higher in developed countries and 
also in women of higher socioeconomic status, the mortality due to breast cancer is higher in 
women from poorer countries and also from lower socioeconomic status [11]. This can be partly 
because of the lower screening rates in poor women compared with relatively affluent women, 
despite much progress in increasing mammography utilization. For example, in 2008, about 21 
% more non-poor women had undergone screening than the poorer women [11]. 
 
3. Lung cancer 
 
Lung cancer is the leading cause of cancer death in the United States and around the world. 
Almost as many Americans die of lung cancer every year than die of prostate, breast, and colon 
cancer combined [12]. Globally, lung cancer is the largest contributor to new cancer diagnoses 
(1,350,000 new cases and 12.4% of total new cancer cases) and to death from cancer (1,180,000 
deaths and 17.6% of total cancer deaths). The 5-year survival rate in the United States for lung 
cancer is 15.6%, and although there has been some improvement in survival during the past few 
decades, the survival advances that have been realized in other common malignancies have yet to 
be achieved in lung cancer. There has been a large relative increase in the numbers of cases of 
lung cancer in developing countries. Approximately half (49.9%) of the cases now occur in 
developing countries whereas in 1980, 69% of cases were in developed countries. The estimated 
numbers of lung cancer cases worldwide has increased by 51% since 1985 (a 44% increase in 
men and a 76% increase in women) [12]. 
 
Clinical classification 
There are two broad categories of lung cancer: 
 
1. Small-cell lung cancer (SCLC), which accounts for about 20% of all lung cancers. It has a very 
aggressive behaviour and is considered a “systemic” disease at diagnosis. It develops in 3-5 years 
and has a doubling time of 30 days. Up to 15 % of patients with limited stage SCLC will have 
long-term survival. The commonest location of SCLC is around the hilum and central areas of 
the lungs. SCLC is most frequently associated with several para-neoplastic syndromes. Small cell 
carcinomas arise from neuroendocrine cells and secrete many different polypeptides. Some of the 
polypeptides have an auto feedback loop which induces further tumour growth. Often the initial 
presentation of patients with SCLC is with a paraneoplastic syndrome, such as Cushing’s 
syndrome or Addison’s disease. SCLC is extremely aggressive and spreads very early. Surgery 
does not play a part in most cases. Although SCLC responds extremely well and quickly to 
chemotherapy and radiation therapy, even those patients who respond usually relapse within 12 
months. 
 
2. Non-small cell lung cancer, which has 3 broad categories of histology. In non-small cell lung 
cancer histology is now considered very important as treatment choices vary significantly 
between the various histologies.  
- Adenocarcinoma: Now the most common non-small cell lung cancer and is the dominant 
lung cancer amongst females. Non-smokers with lung cancer most often have adenocarcinoma. 
Approximately 40% of all lung cancers would be adenocarcinoma. Adenocarcinomas are 
typically slow growing and take over 15 years to develop with a tumour doubling time in excess 
of 200 days. Adenocarcinomas are more often found peripherally and therefore often present late 
with distant metastases present at time of diagnosis in most patients. Adenocarcinomas arise from 
mucous cells in the bronchial epithelium. Adenocarcinoma involves mediastinal lymph nodes and 
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the pleura and spreads to bone and brain. They are sometimes confused with mesothelioma and 
are most likely to cause pleural effusions. 
- Squamous cell: Incidence is declining and now accounts for approximately 25% of all 
lung cancers. There are various subtypes, with some differences in presentation, behaviour and 
treatments. Squamous cell cancers are somewhat more aggressive than adenocarcinoma and take 
8 or more years to develop. With doubling time in excess of 100 years, squamous cell carcinomas 
usually cause bronchial obstruction leading to infections. Up to 10% of squamous cell carcinomas 
may have cavitation. The cavitation occurs due to central necrosis of tumour mass due to rapid 
growth of lung cancer. These cavitating lesions are often labelled as abscess or TB cavity. 
- Large cell carcinoma: The least common variety accounts for about 10% of all lung 
cancer and is more undifferentiated with clear cell and giant cell variants. These are considered 
variants of adenocarcinoma and squamous cell carcinoma but because of poorly differentiated 
histology cannot be ascribed either. Large cell carcinomas metastasise early and have poor 
prognosis. 
- A small number of lung cancers have mixed histology consisting either of 
adenocarcinoma and squamous cell carcinoma admixed or less common a combination of small 
cell and non-small cell variant. 
Tumours arising in the main bronchi tend to present earlier than those arising peripherally and 
frequently are associated with haemoptysis. About 80% of lung cancers are found in the lobar 
bronchi; the remainder are in larger bronchi. 
 
Risk factors 
Smoking is responsible for over 90% of lung cancers. Tobacco smokes contains over 60 known 
carcinogens. Passive smoking increases the risk of lung cancer by 1.5 fold and possibly accounts 
for about 5% of lung cancers. Other risk factors include exposure to arsenic, radon, radiation, iron 
oxide, chromium, petroleum products and possibly coal mining. 
4. Prostate cancer 
 
Prostate cancer is the most common non-skin cancer diagnosed among American males, affecting 
roughly one in six men (16.15%) over the course of their lifetime. Prostate cancer is also the 
second leading cause of cancer-related deaths in American men. The incidence of prostate cancer 
spiked in the United States in the early 1990s because of the advent of more aggressive prostate-
specific antigen (PSA) screening [13]. This was followed by a sharp decline from 1992 to 1995 
during which incidence rates returned to a new baseline which remained approximately two and 
a half times the pre-PSA era rate, likely due to the fact that increased screening in prior years had 
successfully diagnosed much of the previously undetected prostate cancer patients in the 
population. 
 
Risk factors 
Advancing age is the principal risk factor for acquiring prostate cancer. From 2005 to 2009, the 
median age of diagnosis was 67 years, with approximately 90% of diagnoses occurring at the age 
of 55 years and above [13]. In addition, older men are more likely to be diagnosed with high-risk 
prostate cancer leading to lower overall and cancer-specific survival. Race is a major risk factor 
for prostate cancer, both with respect to incidence and mortality; however, reasons are less clear. 
African-Americans have the highest incidence of prostate cancer than any other race or ethnicity 
in the United States. Family history is one of the strongest risk factors when considering who will 
develop prostate cancer. Having an affected relative, the number of affected relatives, and the age 
of onset of prostate cancer in the affected relative are all risk factors for developing prostate 
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cancer. Risk of prostate cancer doubles for a male who has one affected first-degree relative. 
Other risk factors are related to cigarettes smoking, obesity, and alcohol [13].  
By far the most common pathological subtype is adenocarcinoma; grading is by the Gleason 
system; numbered from 1-5 (from well differentiated glandular structures to anaplastic) and the 
scoring of the two most common histological growth patterns is added together, i.e. 4+3 = 7. 
Grading is a strong predictor of prognosis.  
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CHAPTER 2 
The basics of PET 
 
Positron emission tomography is a nuclear medical imaging technique for quantitative 
measurement of physiologic parameters in vivo, based on the detection of small amounts of 
positron-emitter-labelled biologic molecules 1.  
 
 
Figure 2: The principle of PET imaging shown schematically, including: (a) the decay of a neutron-deficient, 
positron-emitting isotope, (b) the detection in coincidence of the annihilation photons within a time window of 
2τ ns, (c) the glucose analogue deoxyglucose labelled with the positron-emitter 18F to form the 
radiopharmaceutical FDG, (d) the injection of the labelled pharmaceutical and the detection of a pair of 
annihilation photons in coincidence by a multi-ring PET camera, (e) the collection of the positron annihilation 
events into sonograms where each element of the sonogram contains the number of annihilations in a specific 
projection direction and (f) a coronal section of the final, reconstructed whole-body image mapping the 
utilisation of glucose throughout the patient. 
The most commonly used emitters are carbon-11, oxygen-15, nitrogen-13, and fluorine-18. 
Advantages of positron labelled substances are their very high specificity (molecular targeting), 
the possibility of using biological active substances without changing their behaviour by the label, 
and fulfilment of the tracer principle. Target structures of these molecules are e.g. glucose 
metabolism, receptor binding potential, catecholamine transport, amino acid transport, or protein 
synthesis.  
42 
 
PET imaging consists on several steps: 1) the selection and production of a suitable molecular 
probe, a pharmaceutical labelled with a positron-emitting radionuclide, 2) the administration of 
the probe to the patient and finally 3) the imaging of the distribution of the probe in the patient 
(Figure 2) 2. Positron emitters are neutron-deficient isotopes that achieve stability through the 
nuclear transmutation of a proton into a neutron. The process involves the emission of a positive 
electron, or positron (e+) and electron neutrino (ve). The energy spectrum of the emitted positron 
depends on the specific isotope, with typical endpoint energies varying from 0.6 MeV for 18F up 
to 3.4 MeV for 82Rb 2. After emission, the positron loses energy through interactions with the 
surrounding tissue until it annihilates with an electron. The range the positron travels in tissue 
obviously depends on the energy with which it is emitted, and that, in turn, depends on the 
particular isotope. The annihilation produces two gamma rays, which are emitted in opposite 
directions and are detected in coincidence 2. PET imaging is based on the annihilation coincidence 
detection (ACD) of these two collinear 511-keV gamma rays traveling in opposite directions, 
corresponding to equal-magnitude, opposite-sign (positive and negative) momenta.  
 
 
Figure 3: The various events associated with ACD of positron-emitting radionuclides, illustrated for two opposed 
banks of coincidence detectors and assuming only one opposed pair of detectors are in coincidence. (A) A true 
coincidence (“true”) is counted only when each of the two 511-keV annihilation gamma-rays for a single 
positron-negatron annihilation are not scattered and are detected within the timing window τ of the two 
coincidence detectors. (B) A random or accidental coincidence (“random”) is an inappropriately detected and 
positioned coincidence (the dashed line) that arises from two separate annihilations, with one gamma-ray from 
each of the two annihilations detected within the timing window τ of the coincidence-detector pair. (C) A 
scattered coincidence (“scatter”) is a mispositioned coincidence (the dashed line) resulting from a single 
annihilation, with one of the gamma-rays undergoing a small-angle Compton scatter but retaining sufficient 
energy to fall within the 511-keV energy window. (D) A spurious coincidence is an inappropriately detected and 
positioned coincidence (the dashed line) which arises from an annihilation and a cascade gamma-ray, scattered 
or unscattered but having sufficient energy to fall within the 511-keV energy window. Spurious coincidences 
occur only for radionuclides which emit both positron and prompt cascade gamma-ray(s). 
The pairs of coincident photons, or events, are detected by a circular configuration of detectors  
and are stored in matrices or sonograms where each row in the matrix represents a parallel 
projection p(s, φ) of the activity distribution in the patient at a specific angle (φ) and axial position 
(z) 2. An output is generated only when signals from the two coincidence detectors simultaneously 
trigger the coincidence circuit. It is called a “true coincidence event” (or just “true”). The volume 
between the opposed coincidence detectors is referred to as “line of response (LOR)” and the time 
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interval allowed for coincidence detection is called the “coincidence timing window τ” (typically 
6 to 12 ns) 3. The finite timing window is necessitated by several considerations. First, depending 
on the exact position of the positron negatron annihilation, the annihilation photons reach the 
detectors at slightly different times. However, because these photons travel at the speed of light 
(c = 3 x 1010 cm/s), this effect is very small. Second, the transit and processing of the signal pulses 
through the detector circuitry is rapid but not instantaneous. Third, the light signal emitted by the 
scintillation detectors used in PET is emitted not instantaneously but over a finite time interval, 
called the “scintillation decay time”, of the order of 10 to 100 ns. In addition to the true 
coincidence events (Figure 3A), a number of other types of events occur in PET, events that 
degrade quantitative accuracy as well as image quality. Random or accidental coincidence events 
(“randoms”) occur when annihilation gamma-rays from two separate positron-negatron 
annihilations are detected in two different detectors within the coincidence timing window τ 
(Figure 3B). Randoms thus increase the detected coincidence count rate by contributing 
spuriously placed coincidence events 3. Because the total activity-containing volume is typically 
much greater than the LOR, random coincidences are common and the randoms count rate may 
actually exceed the trues count rate. Clinically, the ratio of the randoms-to-true count rates range 
from 0.1 to 0.2 for brain imaging to greater than 1 for whole-body imaging 4. The randoms count 
rate is actually proportional to the product of the singles count rate and therefore the square of the 
activity present 4: 
 
Crandoms = 2τC1C2 1) 
 
where Crandoms is the randoms count rate (cps), τ is the coincidence timing window (sec), and C1 
and C2 are the detector 1 and detector 2 singles count rates (cps), respectively. Importantly, 
because the trues count rate is only linearly proportional to the activity, the ratio of the randoms 
to-trues count rates increases linearly with activity. Therefore, imaging times cannot be reduced 
simply by using higher and higher administered activities, as the randoms count rate will increase 
more rapidly than the trues count rate and at some point prohibitively degrade image quality. By 
using absorptive septa to restrict the activity-containing region sampled by coincidence detectors 
to a volume defined by the cross-sectional area of the detectors—as in two-dimensional, the 
randoms-to-true count rate ratio can be reduced substantially. By using “faster” detectors and 
therefore shorter coincidence timing windows, the randoms-to-true count rate can be reduced 
further 3. Annihilation gamma-rays traveling out of an LOR may undergo Compton scatter and 
be re-directed back into the LOR. The scattered photon may, however, retain sufficient energy to 
fall within the energy window set for the 511-keV annihilation gamma-rays and produce a 
coincidence event. Such scatter coincidences (“scatter”) result in mispositioned events. The 
scatter count rate as well as the trues count rate are proportional to the activity present and 
therefore the scatter-to-trues count rate ratio is independent of activity. Because trues and scatter 
each result from single annihilation events, the scatter-to-trues count rate ratio is likewise 
independent of the coincidence timing window. On the other hand, inter detector septa used in 
2D PET reduce the scatter count rate considerably 3. Many positron-emitting radioisotopes also 
emit significant numbers of high-energy prompt gamma-rays, and such gamma-rays may be in 
cascade with each other or with the positrons 5. These can result in spurious coincidences which 
are spatially uncorrelated but nonetheless counted as true events (Figure 3D) 3. Table 3 includes, 
for selected positron emitters, the energy and abundance of gamma- (and x-) rays with sufficient 
energy (i.e., greater than 250 keV) to fall within the 511-keV energy windows typically used to 
count annihilation gamma-rays in PET. 
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Table 3: Individual attenuation contributions and total attenuation coefficients (mass and linear) for various 
materials and energy levels. Water constitutes the majority of the body material and most tissue attenuation is 
near to that of water. BGO and LSO are commonly used scintillator material used in PET detectors. The values 
smaller than 10-3 are neglected. 
Material Radio-
nuclide 
Photon 
Energy 
(keV) 
Scattering attenuation 
coefficient 
Photoelectric 
attenuation 
coefficient 
Total attenuation 
coefficient 
   Rayleigh Compton  cm2/g cm-1 
WATER 
Zeff = 7.89 
ρ = 1 g/cm3 
125I 27.5 0.054 0.182 0.194 0.430 
0.154 
0.096 
99mTc 140 0.003 0.150 0.000 
PET 511 0.000 0.096 0.000 
LEAD 
Zeff = 82 
ρ = 11.35 
g/cm3 
125I 27.5 1.550 0.079 36.3 37.9 393 
99mTc 140 0.119 0.096 2.18 2.39 27.1 
PET 511 0.011 0.067 0.078 0.156 1.77 
NaI(TI) 
Zeff = 50 
ρ = 3.67 
g/cm3 
125I 27.5 0.473 0.122 5.24 5.84 21.4 
99mTc 140 0.032 0.117 0.332 0.481 1.76 
PET 511 0.003 0.077 0.009 0.089 0.33 
BGO 
Zeff = 74 
ρ = 7.13 
g/cm3 
125I 27.5 0.439 0.136 0.108 11.4 81.3 
99mTc 140 0.032 0.124 0.497 0.652 4.65 
PET 511 0.003 0.081 0.018 0.101 0.72 
LSO 
(Lu2SiO5) 
Zeff = 66 
ρ = 7.4 
g/cm3 
125I 27.5 0.376 0.140 6.34 6.85 50.7 
99mTc 140 0.027 0.126 0.379 0.532 3.93 
PET 511 0.002 0.082 0.012 0.096 0.71 
 
Detector materials 
 
To date, only four detector materials, all inorganic scintillators, have been widely used in PET 
scanners: thallium-doped sodium iodide (NaI(Tl)), bismuth germanate (BGO), cerium-doped 
lutetium oxyorthosilicate (LSO(Ce) or simply LSO), and cerium-doped gadolinium 
oxyorthosilicate (GSO(Ce)or simply GSO) 3. Annihilation photons interact within the scintillator 
through Rayleigh, Compton, and photoelectric effects. Only the latter two release energy to the 
detector, making the photons “detectable”. Rayleigh scattering can be ignored at typical PET 
energies. The annihilation photon could deposit a fraction or all of its energy within the crystal. 
The deposition can occur in one location by photoelectric effect, or at several points within the 
same crystal by successive Compton interactions, or in different (usually adjacent) crystals in a 
pixelated matrix 6. The absorbed energy causes the crystal lattice to make a transition to a higher 
energy state, from which it may undergo decay after a characteristic time by emitting lower energy 
photons, the “scintillation photons”, which are detected by the photocathode of a photomultiplier 
tube. Self-absorption of the scintillation photons by the scintillator must be minimal, i.e., the 
attenuation length must be much longer than the crystal thickness. The amplitude of the electronic 
signal produced is proportional to the number of scintillation photons, and thus to the energy 
deposited within the crystal. Energy thresholding can then allow the rejection of a large fraction 
of events scattered within the patient, which have sufficiently low energy to fall below the energy 
discrimination window 6. The most important practical features of scintillation detectors include 
high mass density (ρ) and effective atomic number (Zeff), high light output, and speed (Table 4). 
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Table 4: Physical properties of scintillator materials commonly used for PET. 
Scintillator 
material 
Composition density 
(g/cm3) 
Zeff Attenuation 
length for 511-
keV gammas 
(mm) 
Probability 
of PET (%) 
Light 
output 
(ph/MeV) 
Decay 
time 
(ns) 
Scint. 
emission 
wave length 
(mm) 
Hygroscopic Refractive 
index 
BGO Bi4Ge3O12 7.1 75 10.4 40 9,000 300 480 no 2.15 
LSO Lu2SiO5:Ce 7.4 66 11.4 32 30,000 40 420 no 1.82 
NaI:TI NaI:TI 3.67 51 29.1 17 41,000 230 410 yes 1.85 
CsI:TI CsI:TI 4.51 52 22.9 21 66,000 900 550 slightly 1.80 
GSO Gs2SiO5:Ce 6.7 59 14.1 25 8,000 60 440 no 1.85 
LGSO Lu1,8O2SiO3:Ce     23,000 40 420 no  
LuAP LuAlO3:Ce 8.3 64.9 10.5 30 12,000 18 365 no 1.94 
YAP YAlO3:Ce 5.5 33.5 21.3 4.2 17,000 30 350 no 1.95 
LPS Lu2Si2O7:Ce 6.2 63.8 14.1 29 30,000 30 380 no  
LuAG Lu3Al5O12:Ce 6.7 62.9 13.4 27 5,606  510 no  
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A high mass number and high effective atomic number maximize the crystal stopping power (i.e., 
linear attenuation coefficient µ) and therefore the detection of radiations. In addition, a higher-
atomic number crystal will have a higher proportion of photoelectric than Compton interactions, 
facilitating energy discrimination of scattered photons. High light output reduces statistical 
uncertainty (noise) in the scintillation and associated electronic signal and thus improves energy 
resolution and scatter rejection. A fast crystal (i.e., a crystal with a short scintillation decay time) 
allows the use of a narrow coincidence timing window, τ, reducing the randoms count rate 3. 
Other detector considerations include: transparency of the crystal to its own scintillations (i.e., 
minimal self-absorption); matching of the index of refraction (η) of the crystal to that of the 
photodetector (specifically, the entrance window [η = 1.5] of a photomultiplier tube [PMT]); 
matching of the scintillation wavelength to the light response of the photodetector (the PMT 
photocathode, with maximum sensitivity in the 390-410 nm, or blue, wavelength range); and 
minimal hygroscopic behaviour 6. NaI(Tl) crystals were used in the original PET scanners.  
Higher-density and -effective atomic materials, such as BGO, LSO, and GSO, have emerged as 
the detectors of choice for PET because of their greater stopping power for 511-keV annihilation 
gamma-rays (Table 2). Note, for example, that the attenuation length for 511-keV gamma-rays is 
at least twice as long in NaI(Tl) as in BGO, GSO, or LSO. Among the latter three materials, GSO 
and LSO have a faster light output—nearly 10-fold faster—than BGO, with LSO having a much 
greater light output—approximately 3-fold greater—than either BGO or GSO. GSO has 
somewhat better energy resolution, and scatter rejection capability, than either BGO or LSO. A 
notable disadvantage of LSO is the presence of a naturally-occurring long-lived radioisotope of 
lutetium, lutetium-177 3. Lutetium-177 has an isotopic abundance of 2.6% and a half-life of ~4 x 
1010 years and emits two prompt gamma-rays (88% abundance) of 201 and 306 keV in energy; 
the summed energy of 507 keV falls well within the 511-keV energy windows commonly used 
in PET scanners. The presence of lutetium-177 results in a measured background count rate of 
240 cps/cm3 of LSO and singles and trues count rates of 100,000 and 10,000 cps, respectively, 
in clinical LSO PET scanners. Although the former has a negligible effect on typical emission 
scans, the latter would significantly increase the statistical uncertainty (noise) in single-photon 
transmission scans (e.g., with cesium-137) used for attenuation correction 3. 
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Detector configurations 
 
Most commonly in dedicated PET scanners, detectors are arranged in rings or polygonal arrays 
of discrete, small-area detectors completely encircling the patient (Figure 4A–C).  
 
 
Figure 4: PET scanner detector configurations. (A) Multiple full rings of detector blocks comprised of discrete, 
small-area detector elements. (B) Multiple partial rings of detector blocks comprised of small-area detector 
elements. (C) Hexagonal array of detectors banks comprised of small-area detector elements. (D) Opposed large-
area detectors such as Anger cameras. (E) Hexagonal array of large-area detectors. (F) Circular arrangement 
of six large-area, curved detectors. Inset: Multi-coincidence fan beam detection used in detector rings and arrays 
of small-area detectors. Such fan beam transverse sampling data are generally treated as parallel-beam data.  
In such systems, multi-coincidence fan beam detection is used, with each detector element 
operated in coincidence with multiple opposed detector elements. For a ring comprised of N 
detector elements, a total of N/4 to N/2 fan beams is acquired. In rings, each element is typically 
in coincidence with about half of the total detectors in the ring and in polygonal arrays with the 
opposed detector bank. PET systems with only partial detector rings are less expensive but require 
rotation of the detector assembly about the longitudinal axis of the patient to complete acquisition 
of the projection data (Figure 4B). In addition, continuous, large-area detectors, have now been 
appropriately modified and are used for coincidence imaging of positron emitters (Figure 4D). 
With two or even three such detectors, rotation (180 or 120°, respectively) is required for 
complete angular sampling. Alternatively, large-area detectors may be arranged in a polygon (if 
flat) or in a circle (if curved) completely encircling the patient (Figure 4E and F); such systems 
have been manufactured using GSO as well as NaI(Tl) 3. A block detector consists of a large 
cubic piece of scintillator (2 x 2 to 3 x 3 cm in cross section by 2 to 3 cm in depth) partially cut, 
or scored, depth-wise into a rectangular array of detector elements. The cuts are filled with 
reflective material to optically isolate the detector elements from one another and to maximize 
light collection efficiency by the PMTs backing the scintillator. Crystal elements with a somewhat 
smaller cross-section improve spatial resolution—but only to a certain point. As the cross-section 
of detector elements is reduced and the number of elements increased, the number of cuts and 
therefore the fraction of the scintillator face occupied by the filling material increase. As a result, 
the detector element packing fraction (i.e., the fraction of the scintillator face occupied by 
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scintillation material) and therefore the intrinsic sensitivity decrease 3. In modern ring-detector 
PET scanners, there are typically three to four rings of 100 to 200 block detectors each. There are 
about 6 to 8 cuts per block detector, yielding an array of 6 x 6 x 36 to 8 x 8 x 64 elements 4 x 4 
to 6 x 6 mm each. Overall, therefore, there are a total of 10,000 to 20,000 detector elements. Ring 
diameters range from 80 to 90 cm, the patient ports and trans axial fields of view from 50 to 70 
cm, and the axial (or longitudinal) fields of view from 20 to 30 cm, typically yielding about 50 
trans axial image planes each 2 to 4 mm thick 3. A recently developed alternative to the block 
detector is the pixelated detector matrix 7, wherein individual small-area detectors elements 
(typically 4 x 6 mm in cross-section by 20 mm in depth) are fixed onto a continuous light guide 
backed by a close-packed array of PMTs 3. 
 
Data acquisition 
 
The detector block is formed by a number of crystals viewed by four PMTs. When the block is 
hit, a fast electronic circuit determines the start time of the pulse, which is integrated to obtain the 
deposited energy. Localization electronics decide which crystal in the detector block was hit and 
if the energy was outside or inside the energy window for each element. All this information is 
stored in a data block and is compared with opposite detector blocks in the detector in order to 
decide whether there was a coincidence or not. Most of this analysis is done by hardwired 
electronics, a real-time sorter (RTS). Modern electronics add the possibility to perform analysis 
of the depth of interaction in the crystals (DOI) and time of flight (TOF) on line 8. Annihilation 
photons are randomly detected by two crystals in the tomograph. These two crystals define a 
coincidence channel, a straight line, through the body. However, the coincidence channels can 
also be organized into parallel channels which define a projection of an integrated radioactivity 
distribution through the object from a specific angle. Such projections taken at angles around the 
object are usually the input into the reconstruction algorithms. Each activated coincidence channel 
belongs to one such projection. Every time a coincidence is detected a scaler is incremented by 
one in the right projection position. Data are collected in this so-called ‘histogram mode’ for a 
pre-set time which can vary from one second to infinity. Usually a protocol is made in advance 
where a number of pre-set times defines the histograms to be measured. Another way to collect 
the data is called ‘list mode’. The coincidences are sorted out by RTS electronics. Data 
characterizing one single event are registered in one data block (crystal position, running time, 
single rate, etc.). After the end of the data acquisition the data set can be sorted in histograms but 
with a free choice of sampling times 9. In early PET systems the number of coincidence channels 
was usually small compared with the number of events collected during one experiment. It was 
an advantage to sort the data on line in histograms since it minimized the storage volume and 
handling times. Modern technology today allows a maximum data throughput of about 4 x 106 
events per second but in most investigations the total number of counts rarely exceeds 107 and it 
is likely that list mode will be an important way to store data in the next generation of PET systems 
9. 
 
Reconstruction algorithms 
 
In 2D systems the predominant reconstruction method is filtered back-projection, which is fast 
and reliable 10. However, since it is an approximation, it also introduces some noise in the 
reconstructed image. It is also difficult to enter system related parameters into the algorithms. A 
problem with using filtered back-projection in 3D systems is that the algorithms need full 4! data 
sampling, which is not available (there are holes in the 4π geometry). However, the 3D sampling 
is an overestimation which is easily understood, since a subset of the 2D dataset can be made 
which is sufficient to make a three-dimensional description of the radioactivity distribution. In 
theory the missing data set can be calculated from this 2D reconstruction, after which we can 
apply the 3D algorithms. In practice the data handling is done by using different weighting factors 
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for different angles. A new, elegant way to perform 3D reconstruction uses the fact that the solid 
angle inmost 3D PETs is fairly small. In Fourier space, an approximate method to sum projections 
indifferent angles can be applied. This technique is called Fourier rebinning (FORE) 11 and it 
accurately converts a 3D data set to a 2D data set, after which a 2D statistically-based 
reconstruction algorithm can be applied. It is the ordered-subset expectation-maximization 
algorithm (OSEM) 12. An alternative to filtered back-projection methods is to use iterative 
reconstruction methods. They have several advantages: there is no reconstruction noise and the 
physics of the PET systems related to the measured object (geometry, scatter, etc.) can be built 
into the algorithms 9. Furthermore, Bayesian methods attempt to improve the quality of the 
reconstructed image by taking advantage of prior knowledge, which can be obtained, for example, 
from a co-registered anatomical image (CT or MR)13. This information is known a priori and is 
often incorporated into a maximum a posteriori (MAP) objective function. These reconstruction 
methods lead to improvements of contrast and noise properties of the reconstructed PET images. 
This a-priori known anatomical information can be introduced into the reconstruction algorithm 
by using probabilistic image models or similarity measures between the anatomical and the 
functional images13. 
 
Data correction 
 
PET can give an accurate quantification of the radioactivity distribution in Bq cm−3 after several 
corrections. 
 
Count rate correction 
The total uncorrected count rate in each coincidence channel can be written as Rtot. From this 
value is subtracted the randoms, Rrandom, to obtain the number of true coincidences either by 
calculations or by measuring delayed coincidences. The true coincidence rate is composed by 
unscattered and scattered coincidences and a formula can be derived, RT = (Ttot − Rscatter)(1 – SF), 
where RT is the corrected count rate and SF is the scattered fraction of coincidences 9. Randoms 
are easy to correct for but the scatter fraction RT, heavily dependent on the object’s geometry and 
the radioactivity distribution, is more difficult to estimate. Reliable corrections (e.g., the 
convolution method) for scatter in 2D mode have been established, but are more difficult to apply 
in 3D mode. A possible improvement may be obtained in 3D by using a two-energy window, i.e. 
to monitor scatter just outside the coincidence energy window and then to use scatter correlation 
between the two sets of data 14. 
 
Attenuation correction 
Since most annihilation events are scattered and the fraction varies substantially with the path 
length of the photons, it is important to measure the geometry and the density variation of the 
object 9. The common way to do this in PET is by performing a transmission scan where one or 
more linear radioactive sources are rotated around the object. The radioactive source, usually 
68Ge/68Ga, is also a positron emitter and the coincidence rate with and without the object gives a 
measure of the object thickness. Only one of the annihilation photons penetrates the object but it 
is easily seen that this is equivalent to the emission situation where the annihilation is detected in 
the same coincidence channel. It is important that the transmission scan and the emission scan 
represent the same geometry, i.e. that the object is not moved. Alternative ways to do attenuation 
correction is to combine PET and morphological techniques like CT or MRI 9. As for the CT, the 
attenuation values are energy dependent. Hence, the correction factors derived from a CT scan at 
mean photon energy of 70keV must be scaled to the PET energy of 511 keV (typically with 
bilinear functions) 2. As for the MR, there are three methods available: segmentation-based 
methods, atlas based methods and reconstruction based methods (for more details ref 15). 
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PET in the clinical setting 
 
The value of PET in clinical oncology has been demonstrated with studies in a variety of cancers 
including colorectal carcinomas, lung tumours, head and neck tumours, primary and metastatic 
brain tumours, breast carcinoma, lymphoma, melanoma, bone cancers, and other soft-tissue 
cancers 16. PET studies of tumours can be performed for several reasons including: 
 
1. Quantification of tumour perfusion; 
2. Evaluation of tumour metabolism; 
3. Tracing of radiolabeled cytostatic agents. 
 
Despite its quantitative potential, however, in daily clinical practice, PET is used almost 
exclusively with 2-deoxy-2-[18F] fluoro-D-glucose ([18F]FDG) and, in addition, [18F]FDG data 
are normally assessed visually or using simple indices as the standardised uptake value (SUV) 17. 
Quantitative assessment is superior to visual inspection as it is less user-dependent, it can be fully 
automated and it allows an easier comparison between centres, thus facilitating multi-centre trials. 
Visual assessment is normally considered adequate for initial diagnosis and staging, whereas the 
comparison of (semi)quantitative indices before and after treatment might be better applied o 
early response assessment or interim evaluation of therapeutic efficacy 17. When PET is used for 
the evaluation of the pharmacokinetic properties and efficacy of drugs, only a quantitative data 
analysis can provide the parameters necessary to this aim, such as peak time, clearance, area-
under-the-curve (AUC) in plasma, healthy tissue and tumour 17. Furthermore, the increasing 
number of available tracers will allow in the future the selection of the most appropriate according 
to the application (type of tumour and physiological process to be monitored). In order to properly 
analyse data coming from a variety of tracers having different kinetic properties, visual inspection 
and SUV are not sufficient. 
 
Quantification techniques 
 
- SUV 
The SUV is the most widely used parameter for the analysis not only of [18F] FDG but also of 
most tracers in oncology. The SUV is the ratio between the radiotracer concentration in a certain 
ROI (or group of voxels) and the injected activity, divided by a normalization factor (NF): 
 "#$ = 	 '()*+,'(-.'	-+/-./,'(,*+/01234536	74508059:;  2) 
 
where radiotracer concentration (e.g. kBq/ml) and injected activity (e.g. MBq) indicate, 
respectively, the concentration measured with PET in the region or voxels of interest and the total 
injected activity. In Eq. 1 the radiotracer concentration is computed by scanning the patient for a 
short interval (typically from 5 to 15 min) after a certain predefined time (e.g. 60 min) after tracer 
administration. Three normalization factors are commonly used: they are body weight (BW, e.g. 
kilograms), body surface area (BSA) and lean body mass (LBM). The benefit of the SUV is 
related to the fact that no arterial cannulation is required (the scan is less expensive and less 
uncomfortable for the patient) 18. On the other hand, the SUV is significantly dependent on many 
different factors so that it is very difficult to compare SUVs acquired in different centres when 
even slight differences in the experimental procedure are present. Among the factors affecting the 
SUV are (a) the dependency on the time interval between injection and scanning; (b) the settings 
characterising image acquisition (scanner, scatter and attenuation correction, reconstruction 
algorithm) and (c) the algorithm through which the tumour is defined 17. Despite its limits, 
however, the SUV, when computed in the same centre with the same settings, has been shown 
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effective in assessing the response to therapy by comparing its value in a given tumour before and 
after treatment, especially with [18F] FDG 17.  
 
- Compartmental modelling 
Compartmental modelling (CM), also known as kinetic modelling, is the most accurate method 
to analyse PET data. In CM the PET radiotracer is assumed to be exchanged between 
compartments, each compartment representing a homogeneous physiological or biochemical 
entity, and the rates at which the tracer is transferred between compartments are described by 
first-order differential equations 17. Through a numerical procedure known as non-linear least 
squares (NLLS), the so called rate constants (aka kinetic parameters, or micro parameters)can be 
estimated; these parameters can be then used to obtain physiological measures of interest, such 
as blood flow 19, metabolic rate of glucose 20 and receptor–ligand binding 21.  
CM requires dynamic scanning (multiple frames) from the time of injection and, generally, 
arterial blood sampling to measure the time course of tracer concentration in plasma (time activity 
curve, TAC), used as input function 17. 
 
-- One tissue compartmental model 
This model describes the bidirectional flux of tracer between blood and tissue. In kinetic 
modelling, flow is generally not measured in terms of volume per time, as one might expect, but 
rather in terms of perfusion of tissue, which is described as volume per unit time per unit volume 
of tissue. Thus, the words flow and perfusion are used interchangeably in PET 22.  
 
 
Figure 5: One tissue compartment model. It describes the bidirectional flux of tracer between the blood (Ca) and 
the tissue (Ct). The net tracer flux into tissue equals the flux entering the tissue (K1Ca) minus the flux leaving the 
tissue (k2Ct). 
The model is characterized by the time-varying tracer concentration in tissue, Ct(t), and arterial 
blood, Ca(t) and two first-order kinetic rate constants (K1, k2). The tracer concentrations are 
measured in nano curies per millilitre (nCi/ml). Throughout the remainder of this chapter, we 
suppress the explicit time dependence of the concentration functions for notational simplicity. For 
example, Ca(t) and Ct(t) will be written simply as Ca and Ct. It is assumed that within each 
compartment (blood and tissue) the tracer is homogeneously distributed. The unidirectional tracer 
flux from blood to tissue is K1Ca, and the flux from tissue to blood is k2Ct; therefore, the net tracer 
flux into tissue is:  
 )<5), = =>?( − AB?,  3) 
 
This equation can be solved for Ct to obtain: 
 ?, = =>?( × DEFG,   4) 
 
where the symbol × denotes one-dimensional convolution. If Ca and Ct are radioactivity 
concentrations, then k2, implicitly, includes a component for radioactive decay. For a PET scan, 
Ct is the radioactivity concentration that is measured in a given tissue region. Blood samples may 
be drawn during a PET scan in order to measure Ca. If the tracer distribution in a tissue region is 
a
d
e
q
u
a
t
e
l
52 
 
H?IHI==1?K−A2?I 3) can be applied using standard nonlinear regression techniques to 
estimate the values of K1and k2 for that region 22.   
K1 is an expression of both permeability and flow. The exchange of tracer between blood and 
tissue occurs either via diffusion or active transport across the capillary wall. For this purpose we 
can apply the model in figure 4 on its smallest scale, such that the blood compartment represents 
a single capillary and the tissue compartment is the tissue in the immediate vicinity. Because some 
tracer is removed from the blood via extraction into tissue, the tracer blood concentration 
diminishes as it passes through the capillary 22. K1 is closely related to blood flow when the 
extraction fraction is large, but is more related to permeability when the extraction fraction is 
small. Accordingly, the best tracers for studying blood flow have large extraction fractions. When 
blood flow is expected to be higher than normal, there is an added burden on the permeability-
surface area product to be high. When flow is high (provoked by the breathing of carbon dioxide), 
the measured K1 of the tracer with the higher capillary permeability is better able to reflect the 
true flow value22. 
In the tissue, tracer will accumulate with a time course described by Eq. (3). After sufficient time 
the net tracer flux between compartments is zero, and the system is said to be in equilibrium. At 
this point the blood and tissue concentrations are constant and the ratio of these concentrations Ct 
/Ca is called the equilibrium volume of distribution VD (alternatively called the distribution 
volume, or partition coefficient). Although VD is a ratio of concentrations (and hence 
dimensionless), it is called a volume because it equals the volume of blood that contains the same 
activity as 1 ml of tissue. Because the net tissue flux at equilibrium is zero, VD can be expressed 
as: 
 $M = <5<7 = NOFG  5) 
 
For the one-tissue model, the volume of distribution is a macroparameter equal to K1/k2. In 
general, the precise formulation of VD in terms of the kinetic rate constants (K1, k2 …) depends 
on the particular compartmental model employed. From the physiological interpretations of K1 
(the product of blood flow and extraction) and VD (the ratio of Ct /Ca at equilibrium), k2 can be 
defined as the ratio of K1 to VD. In most experimental paradigms, it is easier to measure VD than 
its constituent parameters, and this is often just as useful for interpreting results. A common 
experimental technique used to measure VD is to deliver tracer via continuous infusion in order 
to maintain Ca at a constant level. Once tissue equilibrium is achieved, VD is easily obtained from 
blood and tissue measurements using Eq. (5)22. 
An important application of the one-tissue model is the measurement of regional blood flow, 
which can be described as the volume of blood that passes through a blood vessel per unit time 
(e.g., ml/min) 22. The tracer that is most commonly used to measure blood flow with PET is 15O-
water 23. Because 15O-water is rapidly diffusible, the tissue concentration equilibrates with the 
venous outflow, such that these concentrations are related by VD = Ct /Cv. 
 
-- Two tissue compartmental model – 3 rate constants 
The main example of a two tissue compartmental is given by the model for the measurement of 
cerebral glucose with [18F]FDG in a homogeneous tissue in brain, based on that of [14C]DG 20. 
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Figure 6: Model for measurement of cerebral glucose use with [18F]FDG in a homogeneous tissue. Cp* and Cp 
represents the concentration of [18F]FDG and glucose in the arterial plasma, respectively; Ce* and Ce are the 
concentration of [18F]FDG and glucose in exchangeable pool in the tissue; Cm* and Cm are the concentrations 
of metabolites of [18F]FDG-6-P and glucose in the tissue, respectively.  
Because [18F]FDG and glucose compete for the same carrier, the rate of inward transport of 
[18F]FDG can be described by the classical Michaelis-Menten equation modified to include the 
influence of the competitive substrate, that is 
 P*∗(I) = T5∗<U∗(,)N5∗V>WXU(5)Y5 ZW<U∗(,)  6) 
 
 
where vi* is the velocity of inward transport; Cp* and Cp are the concentrations of [18F]FDG and 
glucose, respectively, in the plasma; Vt* is the maximal velocity of [18F]FDG transport; Kt* and 
Kt are the apparent Michaelis-Menten constants of the carrier for [18F]FDG and glucose, 
respectively; and t is the variable time. Because [18F]FDG is administered in tracer amounts, Cp*(t) 
can be considered negligible compared to Kt* [1 + Cp(t)/Kt]. If the glucose concentration in the 
plasma is constant, then the velocity of inward transport can be expressed as K1*Cp*(t), where K1* 
= Vt*/[ Kt* (1 + Cp(t)/Kt)] is a first-order rate constant. Once [18F]FDG is in the tissue, it can either 
be transported back to the plasma or phosphorylated to [18F]fluorodeoxyglucose-6-phosphate 
([18F]FDG-6-P), processes that follow Michaelis-Menten equations analogous to Eq. (6). When 
cerebral glucose use is in steady state, the concentration of glucose in brain (Cp) is constant and 
both outward transport and phosphorylation of [18F]FDG can be considered first-order processes. 
Thus the rate of change of the [18F]FDG concentration in the exchangeable pool in the tissue can 
be described by the equation: 
 )<3∗), = =>∗?[∗(I) − (AB∗ + A]∗)?.∗(I)  7) 
 
where Cp* (t) (in nCi/ml plasma) represents the concentration of [18F]FDG measured in the arterial 
plasma t minutes after its injection into the venous blood; Ce*(t) (in nCi/g brain tissue) is the 
concentration of unmetabolized tracer in the exchangeable pool in the tissue; K1* (in ml plasma/g 
brain/min) and k2* (in min–1) represent the first order rate constants for transport of [18F]FDG from 
plasma to tissue and back from tissue to plasma, respectively; and k3* (in min–1) represents the 
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first-order rate constant for phosphorylation of [18F]FDG by hexokinase. K1*, k2*, and k3* are 
constant with respect to time, but vary regionally and with different plasma and brain 
concentrations of glucose 22. The advantage of using [18F]FDG rather than labelled glucose as the 
tracer is that the primary and secondary products of its phosphorylation, unlike those of glucose, 
are trapped in the tissue and accumulate where they are formed for reasonably prolonged periods 
of time. Therefore, the rate of change in the concentration of products of [18F]FDG metabolism 
in the tissue, Cm*(t), is  
 )<∗^), = A]∗?.∗(I)  8) 
 
and the total concentration of activity in the tissue, Ci*(t),is the sum of the concentrations in the 
precursor and product tissue pools: 
 ?*∗(I) = ?.∗(I) + ?_∗ (I)  9) 
 
The PET scanner measures all activity in the field of view, both intra- and extravascular. Thus 
the total concentration of activity measured by the scanner, Ct*(t), is 
 ?*∗(I) = (1 − $` )?*∗(I) + $` ?∗`(I)  10) 
 
where VB is the fraction of the measured volume occupied by blood (0 ≤ VB ≤ 1) and CB*(t) is the 
concentration of label in whole blood. In the human, brain–blood volumes in grey and white 
matter are about 4 and 2%, respectively 24.The kinetic model for glucose uptake and metabolism 
in the tissue is equivalent to that of [18F]FDG, except thatglucose-6-phosphate is not trapped in 
the tissue but continues down the glycolytic pathway eventually to CO2 and H2O22. 
This model allows to calculate the fractional uptake of [18F]FDG 25:  
 = = NOFaFGWFa  11) 
 
Once K is known, one can then calculate the local metabolic rate of glucose by assuming a value 
for the lumped constant LC and by using the steady-state glucose concentration in plasma. The 
model was identified from [18F]FDG brain data, using the measured (assumed error-free) plasma 
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 ?b(I) = ?[(I)(1 − 0.9f)  12) 
 
where H is the subject’s measured haematocrit (the assumption is made that H in the capillaries 
equals that of the large vessels) 27. 
 
-- Three compartmental model – four rate constants 
In 1979, Phelps et al. 24 proposed a modification of the model of [18F]FDG kinetics using the 
observation that, following a pulse of [18F]FDG, total tissue activity was observed to decline after 
120 min, thus, indicating a loss of product.  
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Figure 7: Three compartment – four rate constant model. 
This model does not require that [18F]FDG-6-P is irreversibly trapped in tissue for the whole 
duration of the experiment, but that it can be dephosphorylated. The model and input–output 
experiment equations are: 
 H?.(I)HI = A>?[(I) − (AB + A])?.(I) + Ag?_(I) )<^(,)), = A]?.(I) − Ag?_(I)   13) 
 
where k1,k2,k3 and k4 are rate constants, Cp(t) is the concentration of [18F]FDG in plasma, Ce(t) is 
the concentration of [18F]FDG in tissue, and Cm(t) is the concentration of [18F]FDG-6-P in tissue. 
The PET tissue measurement equations were the same as those of the precious model. Like for 
the 3K model, the fractional uptake of [18F]FDG is given by equation (== NOFaFGWFa  11). All 
model parameters are a priori uniquely identifiable 28.  
 
There’s potentially a huge gain from including kinetic parameters in the diagnosis, staging, 
treatment planning, treatment monitoring and follow up of cancerous tumours. Many examples 
in the literature show the ability of pharmacokinetic parameters to differentiate between different 
lesions, to help in the diagnosis and in treatment response evaluation.  
Schiepers et al.29 showed that compartment modelling of 18F-FLT PET produced a k3 parameter 
that could differentiate lesions that were tumour predominant and treatment change predominant 
in patients with glioma and brain metastases. In another glioma 18F-FLT study by Schiepers et 
al.30, they found that some parameters, especially Ki, changed during the course of treatment and 
that changes were correlated to overall survival. Wardak et al.31 found that the ratios of k2, k4, as 
well as the volume of distribution Vd = K1/(k2 + k3), before and after glioma brain tumour 
chemotherapy treatment could predict overall patient survival for 18F-FLT. Muzi et al.32 also 
looked at 18F-FLT in glioma patients, and found that the influx rate constant KFLT (denoted Ki in 
this thesis) and k3 successfully distinguished recurrence from radionecrosis. Sugawara et al.33 
monitored patients with germ cell tumours using 18F-FDG PET, and compared SUVs and 2-tissue 
compartment model parameters before and after chemotherapy. The authors concluded that 
although visual inspection or SUV calculations could differentiate viable tumours from mature 
teratomas and necrotic/scar tissue, these metrics did not manage the finer differentiation between 
mature teratomas and necrotic/scar tissue. Parametric images of the influx rate constant Ki had 
better contrast compared to SUV images, and parameters Ki and K1 did manage to separate 
teratomas from necrosis or scar. Upon studying patients with primary central nervous system 
(CNS) lymphoma, Nishiyama et al.34 found that kinetic analysis of 18F-FDG, especially with 
respect to k3, was helpful for diagnosis and treatment response evaluation. Doot et al.35 concluded 
that kinetic parameters of the transport (K1) and flux (Ki) of 18F-fluoride was found useful for 
evaluating treatment response in breast cancer bone metastases, which is hard for conventional 
CT and MRI techniques. 
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- Graphical methods 
Patlak and Logan plots are graphical analysis methods based on compartmental models. They 
approximate the behaviour of the tracer with two compartments: a "central" compartment, which is in 
rapid equilibrium with the plasma, and a "peripheral" one, where, in case of an irreversible kinetics, 
the net irreversible transfer of the tracer from blood to the tissue at steady state is measured 36. This 
method transforms the model equations into a linear equation evaluated at multiple time points and 
provides fewer parameters (i.e., slope and intercept). In details, Patlak plot involves irreversible tracers 
while Logan plot involves reversible ones. 
 
-- Patlak method 
It assumes the presence of an irreversible compartment and a time t* after which all the reversible 
compartments are in equilibrium with the plasma. =* is the unique parameter this method 
provides. It denotes the so-called irreversible uptake rate constant, which quantifies the rate at 
which the tracer is irreversibly trapped. The Patlak plot is given by the linearization of this 
expression and =*	is simply calculated as the slope of the regression line 37,38: 
 <50hhi3(,)<U(,) ==* ∫ <U(k))k5l <U(,) + $  14) 
 
The plot in Figure 8 shows an example of the Patlak graphical method applied for the analysis of 
an irreversible radiotracer. In particular, after a time t* = 1300 sec, the system is in equilibrium 
and the relationship between Ctissue/Cplasma and ∫Cplasma/Cplasma is linear with a Ki slope value. 
 
 
Figure 8: Patlak plot for an irreversible radiotracer.  
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-- Logan method 
The Logan plot is the counterpart of the Patlak plot for reversible radiotracers. It involves the 
linearization of this expression stating that after a time t* the system is in equilibrium: 
 ∫ <50hhi3(k))k5l <50hhi3(,) =$m 	 ∫ <U(k))k5l<50hhi3(,)  15) 
 $m is the unique parameter provided and it is the distribution volume of the tracer in the tissue. It 
is a measure of the overall uptake of the tracer relative to the plasma compartment 39. 
 
The plot in Figure 9 shows an example of the Logan graphical method applied for the analysis of 
a reversible radiotracer. In particular, after a time t* = 900 sec, the system is in equilibrium and 
the relationship between ∫Ctissue/Ctissue and ∫Cplasma/Ctissue is linear with a VT slope value. 
 
 
Figure 9: Logan plot for a reversible radiotracer. 
 
- Spectral analysis 
The spectral analysis method, introduced by Cunningham and Jones, allows the identification of 
the kinetic components of the tissue tracer activity without specific model assumptions. It 
considers the impulse response function (IRF) of the compartmental models used in PET as an 
analytical sum of exponentials. The tissue tracer activity in a given volume of observation at time 
t,	?,*nno.(I), is then given by the convolution of the plasma time activity curve, ?[(I), with the 
IRF: 
 ?,*nno.(I) = ∑ ?[(I) × qrDEb2,srtu  16) 
 
where qr and vr are assumed to be real values and nonnegative. 
The idea is to fix a grid of vrvalues that covers an appropriate spectral range and then estimate 
their associated amplitudes	qr, which are the spectral contents. Only a few values of qr > 0 are 
detected and they constitute the spectrum of the kinetic components of the tracer. The components 
of the spectrum have different meaning depending on their position in the spectrum, hence on 
their correspondent vr value. Components with very large vr are proportional to ?[(I) and are 
seen as high frequency components, while components corresponding to vr = 0 become 
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proportional to ∫?[(w)Hw	and are seen as low frequency components. In other words, they 
account for a slower kinetic, for the trapping of the tracer in the tissue (irreversible trapping). 
Lastly, the components with intermediate vr values are referred to as the equilibrating components 
and their number corresponds to the number of tissue compartments that exchange material with 
the plasma (Figure 10). 
 
 
 
 
Figure 10: Example of spectral analysis quantification. (a) Representative kinetic spectrum: out of the three 
spectral components reported, one corresponds to the tracer trapping (red) while the remaining ones refer to 
two equilibrating components at different frequencies (green and blue). (b) In this example the measured tracer 
activity (open circles) is described by the sum of the time-activity curves of each individual component of the 
spectrum (red, green, and blue dashed lines) resulting in the SA data model prediction (grey line). It is important 
to note that different positions of the components in the spectrum correspond to different shapes of time-activity 
curves, with the wash-out being slower for low-frequency spectral components and faster for the high-frequency 
ones [34]. 
 
The information given by the spectrum allow the estimation of some macro parameters of interest. 
They are: the influx rate constant [mL/xy]/min]	=> = ∑ qrsrtu ; the net uptake of the tracer in the 
tissue 	[mL/xy]/min],	 that, for irreversible tracers, can be derived by the limit of the IRF→ ∞, =* = lim/→Ö Üáà(I) = qu, and the volume of distribution [mL/xy]], that, for reversible tracers, can 
be derived as the integral of IRF, $m = ∫ Üáà(w)HwÖu  40 . 
 
 
The standard approach for the quantification of dynamic PET studies is represented by 
compartmental modelling, which requires the full mathematical description of the system under 
investigation 41. It is the only method able to provide a detailed understanding of the physiological 
system and it is usually adopted when the compartmental structure of the system is known 42. 
Graphical plots are easy to implement and give a fast solution. On the other hand, these methods 
are affected by several limitations: they allow the estimation of a unique macroparameter but they 
cannot characterize the whole kinetic profile as they rely on the assumption that the system is in 
equilibrium 42. Furthermore, they don’t account for a vascular component of the signal and finally, 
the linearization required by this model may distort the noise level of small resolution images 43. 
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A trade-off between CM and graphical methods is given by the spectral analysis which can be 
applied without any specific model configuration 42. It is applicable only to single-input, noncyclic 
systems (and the majority of compartmental models use the same assumptions) (Figure 11). 
 
 
Figure 11: Quantification in Positron Emission Tomography. The figure shows a schematic summary of the 
major PET quantification methods organized by considering for each approach the information returned as 
function of the application requirements. Clinical and research PET imaging studies are separately reported. 
Within the diagram a diagonal distribution of the methodologies is clearly evident, indicating that more 
information is obtainable only at the cost of more modelling assumptions [34]. 
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Applications 
 
My work involved the kinetic analysis of 18F-FDG, 18F-FLT, 18F-D4-Choline in breast and lung 
cancers. Graphical, spectral and compartmental modelling techniques have been implemented for 
these studies. In the next section I will present the results of the first kinetic analysis of D4-
Choline in lung cancer patients; then I will present the combined study of FDG and FLT for the 
early detection of DCIS. 
 
I. Kinetic analysis of D4-Choline in patients with lung cancer 
 
 
1. Introduction 
 
Choline is the precursor for the biosynthesis of phosphatidylcholine, a key component of the cell 
membrane phospholipids. It is transported intracellularly and phosphorylated by the enzyme 
choline chinase (ChKα) to phosphocholine and it is trapped within the cell. Most types of cancer 
are characterized by increased choline transport and by the overexpression of choline kinase in 
highly proliferating cells in response to enhanced demand of phosphatidylcholine 44-47. In 
particular, this has been reported in prostate, breast, lung, ovarian and colon cancers 48-51. 11C-
choline has been widely used to study metabolic activity in vivo but its short physical half-life 
(20.4 min) is disadvantageous for its routine clinical use. The longer half-life of 18F (109.8 min) 
overcomes this limitation allowing also late imaging of tumours when sufficient clearance of the 
parent tracer in systemic circulation occurs. 18F-fluoromethylcholine (18F-FCH) was developed, 
for the first time in 2001, by DeGrado et al. 52 and has never presented any adverse effect on 
patients 53-55. However, at present, another fluoro-analog choline tracer has been introduced. It is 
the more metabolically stable 18F-fluoromethyl-[1, 2-2H4]-choline (18F-D4-FCH or simply 18F-
D4-Choline) which has been preclinically validated for tumour imaging 56-58 and presented 
encouraging biodistribution results in healthy volunteers 59. 
To our knowledge, we present the first study of 18F-D4-Choline dynamic PET performed on 
patients affected by lung cancer. Kinetic analysis is generally carried out at the region of interest 
(ROI) level as it guarantees accurate results (reduced noise of the regional data) in a minimal 
computational time. On the other hand, biological systems, and in particular cancer tissues, are 
complex and heterogeneous and need to be analysed at the voxel level. In this work, we chose to 
perform the spectral analysis (SA) method developed by Cunningham and Jones in 1993 40 
because it can be applied to both homogeneous and heterogeneous tissues with no previous 
hypothesis related to the number of compartments in the tissue. We started with a ROI level 
analysis to look at the components of the spectrum resulted from the SA. We then compared the 
main voxel-wise quantification methods (spectral and graphical) applied to 18F-D4-Choline PET 
data in lesion, vertebra, node and reference area.   
 
2. Materials and methods 
 
2.1 Patient population 
Eleven patients (age 62.5 ± 6.5) with 11 primary tumours (7 squamous carcinomas and 4 
adenocarcinomas) and 6 hilar nodes were included (Table 5). All patients fulfilled the inclusion 
criteria and provided written informed consent. Patient characteristics and primary treatment 
modalities are shown (Table 5). The mean age and weight ± SD were 64 ± 11y (range 39-84 y) 
and 68.9 ± 15kg (range 49.7-93.3 kg), respectively.  
Patients eligible for surgery underwent either a lobectomy or pneumonectomy or wedge resection 
with hilar and mediastinal lymph node sampling or en bloc resection. Primary chemotherapy 
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consisted of combination chemotherapy with platinum (gemcitabine and cisplatin or carboplatin, 
pemetrexed and cisplatin). Other treatment options included radical radiotherapy, 
chemoradiotherapy, and palliative high–dose radiotherapy. Decision regarding treatment was made 
by the attending clinician as per local hospital policy. 
 
Table 5: Patient population and histology. SqCC, squamous cell carcinoma; Adenoca, adenocarcinoma. 
Patients Sex Age Weight TNM Histology Lesion 
Pt. 1 F 60 55.2 T4N1M0 SqCC Primary tumour, hilar node 
Pt. 2 M 60 72.4 T2bN0M0 SqCC Primary tumour, hilar node 
Pt. 3 F 57 54.4 T1bN1M0 SqCC Primary tumour, hilar node 
Pt.4 M 59 68.5 T4N1M0 SqCC Primary tumour, hilar node 
Pt. 5 M 79 69.5  SqCC Primary tumour 
Pt. 6 F 58 64.8 pT1bN1M0 SqCC Primary tumour 
Pt. 7 F 64 49.7  Adenoca Primary tumour, hilar node 
Pt. 8 M 67 83 T1bN0M0 Adenoca Primary tumour 
Pt. 9 M    Adenoca Primary tumour, hilar node 
Pt. 10 M   T3N1MX SqCC Primary tumour 
Pt. 11 F 59 49.5  Adenoca Primary tumour 
 
 
 
2.2 18F -D4-FCH PET imaging 
[18F]D4-FCH was synthesised from the precursor as described by Smith, G et al, 2011. Patients 
underwent routine standard imaging with CECT of chest and upper abdomen for local staging, 
additionally followed by an [18F]FDG PET/CT for lymph node staging and a bone scan if 
indicated. [18F]D4-FCH PET/CT was performed post routine standard investigations and prior to 
any therapy. Images were acquired on a Siemens Biograph 6 TruePoint PET/CT scanner (with 
TrueV; extended field of view) with 21.6-cm axial and 60.5-cm transaxial fields of view. An 
attenuation CT scan over the thorax (130 kV, exposure, exposure, 15 effective mAs; pitch, 1.5; 
slice thickness, 5 mm; rotation time, 0.6 s; resulting in an effective dose of 2.5 mSv) was 
performed for accurate anatomical localisation. This was then followed by tracer injection (a 
maximum dose of 370MBq of [18F]D4-FCH) and dynamic imaging (single-bed position over 
thorax and mediastinum) over 66 mins followed by a half-body static (mid-thigh to vertex) 
attenuation CT and PET scan. Discrete venous bloods and plasma (at 5, 10, 15, 30, 60, p.i) were 
obtained for radioactivity counting and metabolite analysis. 
 
All Dynamic [18F]D4-FCH PET/CT data were reconstructed using the ordered-subsets 
expectation maximization algorithm (3 iterations and 21 subsets) with corrections for dead time, 
scatter, attenuation, and radioactive decay. All volumes of interest (VOIs) on PET/CT were 
outlined manually on Hermes (Hermes Diagnostics, Stockholm, Sweden) by a single investigator 
(SD) to avoid any interobserver variation. VOIs were drawn manually around visible primary 
lung tumour, and any mediastinal lymph nodes by a single investigator (SD) to avoid any 
interobserver variation. Whole tumour volumes were outlined. VOIs were also drawn in normal 
background organs using a 2cm fixed-sphere (normal lung tissue, bone (vertebral body), and 
muscle) and 1cm in the aorta for the use of an image derived arterial imput function60. 
 
2.3 Quantification of dynamic D4-choline data 
Dynamic PET data has been analysed with Spectral Analysis and graphical methods as described 
in Chapter 2, Quantification techniques. We decided to apply both Patlak and Logan graphical 
methods since the kinetic of the tracer has not been analysed in the present literature yet.  
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2.4 Statistical analysis 
All statistical analysis were performed using Matlab R2015b (Mathworks). The tests chosen were: 
the Kolmogorov - Smirnov test, to assess the normal distribution of each parameter distribution; 
the Wilcoxon Sum Rank test, to assess the statistically significant differences among tumour, 
healthy lung tissue, node and vertebra; the non-parametric Spearman test to verify the correlation 
between parameters evaluated with different modelling approaches. For each map, kurtosis and 
skewness were also evaluated for a distribution analysis 61. 
 
2.5 Reliability analysis 
Method performance was assessed in terms of reliability of the estimates. It was evaluated, for 
each maps, in terms of the fraction of voxel estimates associated with biologically implausible 
results. In details, for =* and 	=> maps, values < 0 and > 1.5 mL/xy]/min were considered 
biologically implausible while for the $m only negative values 62,63. 
 
3. Results 
 
All of the patients had measurable disease in the lung. Six of them presented also small hilar 
nodes. The mean dose of activity injected was 283.95 (±77.92) MBq. D4-Choline localized 
mainly in tumour, node and vertebra (Figure 12). Localization of radioactivity in normal tissue 
was generally low. 
The analysis has been conducted at a region and voxel level to look both at the spectrum and the 
3D parametric maps. Finally, by considering mean, kurtosis and skewness values of the =* 
(Patlak), =* (SA), 	=>(SA) and $m (Logan) estimates for the VOI voxels (tumour, healthy lung, 
node and vertebra), several comparisons were made within patients and among models.  
 
 
Figure 12:  Axial section of summed (last six phases) PET imaging data of patient n.6 (A) and patient n.3 (B) 
showing high uptake of D4-Choline in tumour, node and vertebra.  
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3.1 Region level analysis 
The spectral analysis was conducted for each patient choosing a grid of 100 components with 
0.0001<vr>1 (the values of the grid are arbitrarily chosen, they must be included in the [1/3âä; 
1/â*/3] range where âä is the end time of the experiment and â* is the duration of the first scan 
27,64. Six patients presented an quvalue (correspondent to	vr = 0), revealing an irreversible 
trapping of the tracer in the tissue during the experimental scan (Figure 13, D). The fractional 
retention uptake was evaluated as the ratio of the IRF at 60 minutes and at baseline. The spectral 
model showed that there was a retention component in the tumour but less so in normal lung and 
vertebra (Figure 14). The mean fractional retention of the node is comparable to the tumour one. 
 
Figure 13: Patient n. 2. A, tumour time activity curve with a parent plasma input function (i.e. activity due to 
d4-choline); B, compartmental model used to describe the exchange of D4-choline from the plasma into the 
tissue; C, the unit impulse response function of tumour compared with normal lung, node and vertebra (a 
zoomed part) (in the tab the values of the FRTs); D, spectrum of kinetic components obtained using spectral 
analysis. 
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Figure 14:  Fractional uptake boxplots show the highest retention component in tumour (and in the node). Less 
retention has been seen in the reference lung and in the vertebra. 
 
3.2 Voxel level analysis 
Spectral analysis. As for the region level, spectral analysis was conducted for each patient 
choosing a grid of 100 components with 0.0001<vr>1. It was made on a voxel level allowing the 
calculation of 3D parametric maps of the tumour, the reference area, the node and the vertebra. 
In particular, the influx rate constant [mL/xy]/min]	=> = ∑ qrsrtu , and the =* = lim/→Ö Üáà(I) =qu, that represent only the trapping component of the tumour, were evaluated. Mean values (± 
standard deviation) are: for the tumour, 	=>= 0.82 ± 0.91 and =* = 0.053 ± 0.091; for the reference 
tissue, 	=>= 0.066 ± 0.062 and =* = 0.0022 ± 0.0020; for the node, 	=>= 0.85 ± 0.95 and =* = 
0.014 ± 0.0081; for the vertebra, 	=>= 0.094 ± 0.11 and =* = 0.0045 ± 0.0040. Bearing in mind 
that Spectral =* maps do not cover the entire volume of the tumour (as the Patlak =* does) and 
mean (as kurtosis and skewness) values resulted only by the trapping component of the tissue.    
 
Graphical analysis. Patlak and Logan methods have been applied on tumour, reference lung 
tissue, node and vertebra VOI and resulted in 3D parametric maps of the irreversible uptake rate 
constant =*	and the distribution volume of the tracer in the tissue, $m. The value of t* was set to 
40 min after a visual inspection of Patlak (and Logan) plots. Mean values (± standard deviation) 
are: for the tumour, =* = 0.021 ± 0.010 and $m= 2.44 ± 1.46; for the healthy lung, =*= 0.0045 ± 
0.018 and	$m= 0.43 ± 0.31; for the node =*= 0.011 ± 0.018 and $m= 1.26 ± 0.92; for the vertebra =* = 0.0089 ± 0.012 and $m= 0.63 ± 0.50. 
 
In Figure 15 an example of the evaluated 3D parametric maps in the lesion of patient n. 9. 
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Figure 15 Patient n. 9. Parametric maps for ãå_SA [mL/çéè/min], 	ãê_SA [mL/çéè/min], ãå_Patlak 
[mL/çéè/min] and ëí [mL/çéè]. 
 
 
Statistical analysis. The Wilcoxon rank sum test resulted, for each map, with a good 
discrimination between tumour and healthy lung tissue (p < 0.01). In the same way, the 
discrimination between tumour and vertebral tissue was found statistically significant: 	=> (p < 
0.01); =*_SA (p < 0.01); =*_Patlak (p < 0.05); $m (p < 0.01) (Figure 16). 
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Figure 16: Boxplots of mean, kurtosis and skewness values (in columns) evaluated for each patient and for each 
modelling approach (in rows). Arrows point at the statistical differences resulted from the Wilcoxon test. 
The Spearman test found a good correlation in the tumour between =* of the spectral and Patlak 
analysis (p = 0.013, ρ = 0.74), and between 	=> and =*_Patlak (p = 0.013, ρ = 0.74).  
The distribution analysis was performed for each patient and for each modelling approach on the 
tumour, reference, nodular and vertebral area. In particular, in most of the analysed cases, the 
voxel distribution profiles were non-Gaussian. Hence, they have been modelled with the Kernel 
function (on the y axes, the square root of the number of elements of the input data) (Figure 17, 
Figure 18).  
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Figure 17: Patient 10. Tumour, reference lung tissue, node and vertebra Kernel distribution. On the y axes, the 
square root of the number of elements of the selected parameter. 
 
Figure 18: Distribution analysis of patient n. 9. Tumour, reference lung tissue and vertebra Kernel distribution. 
On the y axes, the square root of the number of elements of the selected parameter. 
 
Reliability analysis. Among the kinetic modelling approaches, the worst performance was 
obtained with the Patlak analysis (reliability in the tumour 65.26%, in the reference lung 54.44 
%, in the node 61.29%, in the vertebra 59.48%) while the best performance was obtained with 
the Logan method (reliability in tumour 90.46%, in the reference tissue 95.68%, in the node 
93.45%, in the vertebra 94.32%) followed by the spectral analysis, in particular in the evaluation 
of the Ki maps (reliability in the tumour 99.91%, in the lung, node and vertebra 100%). All the 
results are shown in Table 6. 
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Table 6: Reliability evaluated as the percentage of biologically plausible voxel values. Ki_SA is the parametric 
map of the irreversible trapping component of the tissue [mL/cm3/min], K1_SA is the global influx rate constant 
[mL/ cm3/min], Ki _Patlak is the irreversible uptake rate constant [mL/cm3/min] and VT [mL/ cm3] is the Logan 
distribution volume of the tracer in the tissue.  
Reliability (%) tumour healthy lung node vertebra =*_SA 99.91 100 100 100 =>_"î 85.60 76.17 83.21 85.95 =*_Patlak 65.26 54.44 61.29 59.48 $m 90.46 95.68 93.45 94.32 
 
4. Discussion 
 
This study focused on the pharmacokinetic analysis of à>ï -fluoromethyl-[1, 2- fB g]-choline in 
lung cancers. Different quantification methods have been applied and compared together with the 
evaluation of the reliability of their estimation. Choline is the precursor for the biosynthesis of 
phospholipids, which are the main component of the cellular membrane. The accumulation of 
radiolabeled choline in tumours is associated with cellular proliferation as it is due to the 
overexpression of choline kinase in support of malignancy-induced increased demand for cellular 
membrane synthesis 65. Compared with 18F-FDG, whose uptake has been reported to be 
influenced by several factors, as the upregulation of glucose transporter 1 receptors 66, the number 
of viable tumour cells 67, microvessel density, or hexokinase expression 68, radiolabeled choline 
is a more selective tracer and it is not trapped in the whole tumour tissue. Figure 12 shows 18F-
D4-FCH summed PET images where high tumour to background contrast is present. In fact, 
choline kinase is up-regulated by overexpression in human lung carcinomas 69. Uptake was also 
seen in the node and vertebra. The retention of the tracer was firstly studied at the region level 
with the application of the standard spectral analysis. It allows the measurement of both the 
impulse response function and the spectral components of the tracer in the tissue. In Figure 13 
ROI analysis results, which confirmed that D4-Choline is delivered and retained to a higher 
degree by lung tumours (as by node and vertebra) compared with normal tissue. Furthermore, the 
spectrum showed, in most cases, the presence of an irreversible trapping component of the tracer 
in the tissue during the time of measurements (8/11 patients).  
In order to have a more exhaustive physiological characterization of tumour tissues that considers 
the complexity and the variability of the kinetics, a voxel wise analysis was necessary. In fact, the 
simplified average description obtained by ROI analysis alone cannot provide a fair description 
of tumour heterogeneity. The voxel level spectral analysis resulted in two different parametric 
maps: =*, that shows only the irreversible trapping part of the tissue in the whole tumour volume 
(Figure 15, first row), and =>, that is the net influx rate constant (Figure 15, second row). =* map 
testified that a part of the tumour tissue actually traps the tracer during the measurement time and 
that the trapping areas have not a preferential location (grey voxels). Reference lung tissue, node 
and vertebra also presented a small trapping component that =* was able to differentiate from the 
lesion (p << 0.0001) (Figure 16). => is a global parameter resulted by the sum of all the αs of the 
spectrum. So it is the expression of the utter kinetics of the tracer in the tissue. It was able to 
provide a good discrimination between lesion and reference lung (p << 0.0001), as between lesion 
and vertebra (p << 0.0145), and finally between healthy lung and node (p << 0.0001) (Figure 16). 
Graphical methods resulted with the Patlak =ñ and the Logan $m maps (Figure 15, last two rows) 
which also provided a good discrimination between tumour and reference tissue (p < 0.05). The 
rationale of applying both graphical methods is explained by the fact that the kinetic behaviour 
of the tracer is not known. In fact, the heterogeneous nature of the lesions presented in the study 
could show a different behaviour of the tracer in different areas of the tumour.  
In terms of percentage of outliers in the estimated maps, the Logan method resulted the most 
reliable one for the lowest number of biologically implausible values detected (93.48 ± 2.20 %), 
immediately followed by spectral analysis (91.36 ± 9.68 %). Spearman test resulted with a good 
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correlation between the rate constants evaluated with these two different methods (p = 0.013, ρ = 
0.74) with the SA =ñ showing the best reliability. This could be due to the fact that SA =ñ covers 
a limited part of the tumour volume since it shows only a particular kinetic behaviour of the tracer 
in the tissue (irreversible trapping). Patlak and Logan based parametric maps showed an 
interesting complementarity (Figure 15, last two rows) as these two methods describe, 
respectively, the irreversible and reversible behaviour of a tracer.  
Perfusion maps show the presence, in tumour tissue, of lower activity spots, possibly due to 
hypoxia. Metabolism of choline in cancer cells is known to be sensitive to its microenvironment. 
Tracer studies in the mouse atrial cardiomyocyte tumour lineage, AT-1 70, and 9L glioma 
allografts 71 have shown that radiolabelled choline phosphorylation and accumulation is 
significantly diminished in hypoxia. Furthermore, hypoxic regions in head and neck cancers, 
resulted with increased asymmetric distributions of the transfer constants in DCE-MRI 
studies72,73.  We also studied the distribution of the parametric maps evaluated in tumour, lung, 
node and vertebra with both spectral and graphical methods in terms of kurtosis and skewness. 
Figure 17 shows the distribution analysis of patient n. 10. The flattened tumour distributions 
profiles testify the wider range of values covered by parametric maps as they describe a 
heterogeneous tissue (lower kurtosis). On the contrary, the profiles of normal lung are picked 
(higher kurtosis) and left located as most of the values of parametric maps evaluated in reference 
tissue are lower (positive skewness) and confined in a smaller range (as for homogeneous tissues). 
Figure 18 confirms these results even though tumour profiles are wider (and less flattened). This 
might be related to the different histological type of the lesion: adenocarcinoma for patient n. 9 
and squamous cell carcinoma for patient n. 10 (Table 5). The Logan $m is the only parameter for 
which kurtosis and skewness were found to be able to statistically differentiate among lesion, 
reference tissue, vertebra and node (Figure 16). The volume of distribution is not a physiological 
value. It is a proportionality factor as it relates the amount of the tracer in the body to its 
concentration measured in the plasma (amount of injected dose/concentration of tracer in the 
plasma). It does not derive from the other pharmacokinetic parameters since it depends on the 
physiological properties of the body and the physiochemical properties of the tracer itself. So, it 
is not a ‘true’ volume expression but it explains where in the body the tracer is distributed as, 
when low, it testifies a difficulty for the tracer to penetrate cell membranes and to diffuse in the 
tissue (it is only in the plasma) and, on the contrary, when high, the extravascular tissues are more 
likely to be diffused by the tracer then the intravascular ones. Boxplots in Figure 16 show higher 
mean, kurtosis and skewness $m values in the lesion (p < 0.0001) compared to reference tissue 
(and vertebra and node). This could be really useful for the localization of the tracer and for the 
understanding of the physiochemical properties of the tracer. Higher mean $m values in the tumour 
testify the presence of D4-Choline in the extravascular tissue (no trouble diffusing through cell 
membranes) and higher kurtosis and skewness strengthen this result adding a significant 
specificity to this preference.   
To our knowledge, this is the first work in which the kinetics of the D4-Choline was analysed 
with spectral and graphical methods. The main limitation of this study is the dataset obtained from 
a small number of subjects. The strength of the analysis is related to the SA that can be applied 
to reversible/irreversible kinetics, single or multicompartment models, homogeneous or 
heterogeneous systems. This way, it is adaptable to different tracers without any a priori 
assumptions and gives a full model description of the entire data time-course.  
This initial study strongly supports further evaluation of 18F-D4-FCH PET in a larger trial to 
fully assess the utility of D4-Choline in lung cancer and substantiate our findings. 
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II. Kinetic analysis of dynamic 18F-FLT PET data in the detection 
of ductal carcinoma in situ 
 
1. Introduction 
 
In the quantification of dynamic positron emission tomography (PET) data, spectral analysis 
(SA), unlike the other graphical and compartmental approaches, allows the identification of the 
kinetic components of the tissue tracer activity without specific model assumptions. It considers 
the impulse response function (IRF) of the compartmental models used in PET as an analytical 
sum of exponentials and evaluates the poles of the Laplace transform of the IRF, which can be 
represented as the spectrum of the kinetic components of the tracer exchanges among 
compartments 40. Since its introduction in 1993, SA has been widely used in a large variety of 
testing conditions, both in preclinical 74-76 and clinical studies considering different tracers 77-82 
and different acquisition protocols 83-86. In particular, many applications involved breast and lung 
cancer patients 63,87,88.  
Ductal carcinoma in situ (DCIS) of the breast is a non-invasive carcinoma with a wide spectrum 
of disease, ranging from low-grade to high-grade malignancy with foci of invasive malignancy. 
Histologically, DCIS is characterized by a proliferation of malignant cells in the ductal epithelium 
that are confined to the basement membrane and are not invading the normal breast parenchyma. 
The biological mechanisms involved in the progression of DCIS to invasive cancer are not yet 
fully understood but they are part of the same process that comes from the similarity in risk factors 
predisposing to both conditions. Gapstur and his colleagues 89 followed for 11 years 37,105 
women enrolled in the Iowa Women’s Health Study. They prospectively collected risk factor 
information and observed 1520 breast carcinomas, 175 of which were DCIS. Those who 
developed DCIS or invasive breast cancers had the same risk factor profiles, and the magnitude 
of risk conveyed by each of the risk factors was similar for both conditions90. Early detection is 
important because of the large proportion of DCIS that can progress to invasive carcinoma. The 
extent of DCIS involvement is frequently underestimated at mammography, which can reliably 
help detect only calcified DCIS; consequently, magnetic resonance imaging (MRI) evaluation 
can alter the course of treatment 91. In addition to mammography, ultrasonography, and magnetic 
resonance imaging, 18F-FDG PET has been recognized as an important modality for detecting the 
hyper metabolic activity of breast tumours. The sensitivity of FDG-PET for detecting primary 
cancer is 64.4%–89.5%. Conversely, sensitivity for the detection of DCIS has been reported at 
25%–76.9% in a small number of articles 92-94. Azuma et al. retrospectively reviewed 386 
consecutive patients who underwent FDG-PET/CT diagnosing 11 pure or predominant DCIS 
patients. In their study they determined that tumour cell density of intraductal carcinoma appears 
strongly correlated with detection by FDG-PET/CT 95.  
Compared with 18F-FDG, whose uptake is not tumour specific, and false-positive findings can 
occur in inflammatory lesions 96, 18F-FLT PET has been shown to image cell proliferation 97. This 
tracer is trapped within the cytosol after being mono phosphorylated by thymidine kinase-1 
(TK1), a principal enzyme in the salvage pathway of DNA synthesis. The accumulation of FLT 
is dependent on the presence of TK1, which is closely associated with cellular proliferation 98. 
18F-FLT has been found to be useful for non-invasive assessment of the proliferation rate of 
several types of cancer and showed high reproducibility and accuracy in breast and lung cancer 
tumours 99-102.  
In this work, a voxelwise SA approach was chosen to study 7 patients who underwent dynamic 
3’-deoxy-3’-[18F] fluorothymidine (18F-FLT) PET scan followed by a dynamic 18F-
fluorodeoxyglucose (FDG) PET scan within a week. 4 of them were diagnosed with ductal 
carcinoma in situ (DCIS) at biopsy. The application of SA allowed the quantification of two 
macroparameters: the steady state irreversible flux constant Ki and the influx rate constant K1 for 
the transfer of the tracer from plasma to tumour.  
 
72 
 
2. Materials and methods 
2.1 Patient population 
A total 12 of breast cancer patients have been enrolled to this study. Written and dated informed 
consent was obtained from all subjects.  
Inclusion criteria comprehended a diagnosis of high grade ductal carcinoma in situ of the breast 
with a minimum size of 1.5cm (measured by mammography or ultrasound). The diagnosis should 
have been documented by a previous histological analysis of a core biopsy. Inclusion criteria were 
also a clinically acceptable (as judged by the investigator) haematological (haemoglobin 
≥11g/dL), renal (eGFR >60ml/min) and hepatic history and physical examination at screening. 
Exclusion criteria comprehended pregnancy, anticoagulation therapy, chemotherapy, 
immunotherapy, biologic therapy or investigational therapy within 14 days or five half-lives of a 
drug (whichever is longer) prior to the first dose of FDG or FLT injection. 
2.2 PET imaging 
Subjects received a single i.v. bolus injection of 1-20 mL injection of FDG or FLT (with at least 
a 24 hour gap between the two radiotracers).  The tracer injection was followed by a saline flush. 
The maximum 18F activity to be administered was 370 MBq of FDG and 300 MBq of FLT. 
Arterial blood samples for 18F activity measurements and 18F metabolite analysis were obtained 
from subjects with breast cancer from baseline up to 60 minutes after FDG and FLT 
administration. An arterial cannula was inserted in the radial artery prior to the start of the scan 
under local anaesthetic to allow arterial blood sampling during the scan.  Continuous arterial 
blood sampling at 5mL/min were performed for the first 10 minutes.  Discrete blood samples 
(5ml) from baseline to 60 minutes post administration were taken for analysis of 18F metabolites.  
The total blood volume required for all analyses in the study did not exceed 200mls. 18F activity 
was measured using a gamma counter according to the working instructions at the site.  Volumes 
were adjusted to avoid counter saturation.   
Aliquots of each whole blood sample were assayed for 18F content. Following removal of blood 
for whole-blood assay, the remaining blood sample was centrifuged to obtain plasma.  
Immediately thereafter, the resulting supernatant (ie, plasma) was transferred to a pre-labelled 
tube using a fresh disposable pipette. Aliquots of each plasma sample were assayed for 18F.  
 
For each subject and each PET scan, VOIs were manually drawn by the same experienced 
physician on the summed PET image using Analyze image analysis software (Biomedical 
Imaging Resource, Mayo Foundation, Rochester, MN). For tumour segmentation, only the planes 
with identifiable abnormal tracer uptake were chosen.  
 
2.3 Quantification of dynamic FLT data 
Dynamic PET data has been analysed with Spectral Analysis as described in Chapter 2, 
Quantification techniques.  
 
2.4 Statistical analysis 
All statistical analysis were performed using Matlab R2015b (Mathworks). The tests chosen were: 
the Kolmogorov - Smirnov test, to assess the normal distribution of each parameter distribution; 
the Wilcoxon Sum Rank test, to assess the statistically significant differences among tumour, 
healthy lung tissue, node and vertebra; the non-parametric Spearman test to verify the correlation 
between parameters evaluated with different modelling approaches. For each map, kurtosis and 
skewness were also evaluated for a distribution analysis 61. 
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3. Results 
 
Figure 19 shows the result of 18F-FLT and FDG dynamic PET data quantification of a patient 
with DCIS. The uptake of the tracers in the lesion is shown in the first column while, in the 
following ones, parametric maps resulted from spectral and graphical analysis are shown. Maps 
have been evaluated on a voxel level on the whole volume (Figure 19 is representative of one 
single slice). In particular, they are Ki and K1 derived from the spectral analysis. 
 
Figure 19: DCIS patient n.3. In the first row, analysis results of the dynamic FLT PET data. From left: phase n. 
of the PET dynamic scan, SA K1, SA on a zoomed section of the breast. In the second row, results from the 
quantification of dynamic FDG PET data. 
Table 7 shows the results of spectral and graphical analysis on DCIS patients in terms of mean 
and standard deviation. 
 
Table 7: Spectral analysis results on 18F-FLT and 18F-FDG dynamic PET data of patients with DCIS. Values 
are expressed in terms of mean and standard deviation (µ ± σ). 
 Spectral Analysis 
 Ki K1 
FLT 0.0010 ± 0.00030 0.013 ± 0.011 
FDG 0.00070 ± 0.00030 0.038 ± 0.035 
 
The fractional retention (FRT) of the tracer in the tissue has been evaluated as the ratio between 
the IRF at 60 minutes and at baseline. 
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Figure 20: DCIS patient n.1: SA results. The first column shows the spectra derived from the ROI level SA 
applied on both FLT (first row) and FDG (second row) dynamic PET data. Both tracers presented an a0 value 
indicating the irreversible trapping of the tracer in the tissue during the time of experiment. The IRFs are shown 
in the second column with their correspondent FRT value evaluated as the ratio of the IRF at 60 minutes ad at 
baseline. The last column shows the tissue uptake curves of the two different tracers. 
Figure 20 is representative of the results of the spectral analysis applied on an ROI level on DCIS 
patient n. 1. On the left side, the spectra of the kinetic components of the two different tracers in 
the lesion are shown. Both spectra present an α0 value indicating the presence of an irreversible 
trapping component of the tracer in the tissue during the time of measurements. The FRTs are 
shown on their correspondent IRF curve (in the middle). On the right side of the figure, the DCIS 
18F-FLT and FDG tissue uptake curves are shown. 
 
Spectral analysis was applied also on 15 patients with breast cancer who underwent dynamic 18F-
FLT scan before and after one or two cycle of docetaxel. Table 8 shows mean values of spectral 
Ki and K1 in tumour (at baseline), DCIS and healthy breast tissue. 
  
Table 8: Spectral Ki and K1 mean values evaluated in breast tumour, healthy tissue and DCIS. 
 Tumour (mean ± std) Healthy Tissue(mean ± std) DCIS (mean ± std) 
Ki [mL/xy]/min] 0.025 ± 0.014 0.0055 ± 0.0036 0.0024 ± 0.0014 
K1 [mL/xy]/min] 0.18 ± 0.14 0.10 ± 0.097 0.016 ± 0.013 
 
Receiver operating characteristic (ROI) curves analysis was applied on spectral Ki and K1 mean 
values in tumour and healthy tissue. Results are shown in Figure 21. A cut-off value of 0.014 
(sensitivity 80%, specificity 100%) resulted for the spectral Ki, with an area under the curve 
(AUC) of 0.90 significantly greater than 0.5.  
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Figure 21: ROC of spectral Ki and K1. 
For spectral K1, ROC curve analysis gave a threshold value of 0.15 with a sensitivity of 71% and 
a specificity of 68% and an AUC of 0.6782 significantly greater than 0.5. 
In order to have a more robust evaluation of cut-off values, a bootstrap analysis was applied on 
the spectral Ki and K1 3D parametric maps (Figure 22). In fact, in the absence of repeated 
measurements, this technique has been shown to be the only consistent method for assessing 
uncertainty in all detected components of the tracer kinetic 103. 
 
Figure 22: ROC on bootstrapped spectral Ki and K1. 
ROC analysis on bootstrapped data confirmed the Ki cut-off value previously found with a 
resulting higher AUC (0.99). In the same way, for the spectral K1, a 0.23 cut-off value was set 
with 66% sensitivity and 92% specificity and the AUC was found to be greater than 0.5 (0.79). 
 
Neither of these value was able to differentiate DCIS as the uptake of the tracer in these areas was 
much lower. As a consequence, perfusion values were under the thresholds.  
Table 9 shows the mean and standard deviation of SA Ki, K1 and the ratio between these two, in 
tumour, healthy breast and DCIS evaluated at 60 minutes. This ratio has been displayed in Figure 
23. The panel in Figure 24 shows the voxelwise analysis of patient n. 4. In particular, Ki, K1 and 
Ki/K1 ratio map for 3 slices (41, 42, and 43) of the DCIS.  
 
Table 9: Spectral Ki and K1 and Ki/K1 ratio values evaluated in breast tumour, healthy tissue and DCIS. 
 Tumour (mean ± std) Healthy Tissue(mean ± std) DCIS (mean ± std) 
Ki [mL/xy]/min] 0.025 (0.014) 0.0055 (0.0036) 0.0020 (0.0012) 
K1 [[mL/xy]/min] 0.18 (0.14) 0.10 (0.097) 0.027 (0.017) 
Ki/K1 
 
0.22 (0.19) 0.082 (0.075) 0.10 (0.088) 
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Figure 23: mean and 95% CI of spectral Ki/K1 map in breast tumour (red), normal breast (green). The blue dots 
represent the six DCIS patients: for two of them, the Ki/K1 ratio fell in the tumour range. 
 
Figure 24: Patient n. 4. The panel shows the voxelwise SA results for three representative slices (in the three 
rows) of the DCIS of this patient. In the second column there is a zoomed section of the original PET data (first 
column). Third, fourth and fifth column are representative of K1, Ki and Ki/K1 maps. 
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4. Discussion 
 
The study investigated the kinetics of the tracer in DCIS compared with breast tumour to assess 
the utility of SA in the early diagnosis of DCIS. A voxelwise SA approach was applied on 7 
patients who underwent dynamic 3’-deoxy-3’-[18F] fluorothymidine PET scan followed by a 
dynamic 18F- fluorodeoxyglucose PET scan within a week. 4 of them were diagnosed with ductal 
carcinoma in situ at biopsy. SA was also applied on 15 breast cancer patients who underwent a 
baseline dynamic 18F-FLT PET scan followed by a scan after 2 weeks after the first or second 
cycle of docetaxel. The application of SA allowed the quantification of two macroparameters: the 
steady state irreversible flux constant Ki and the influx rate constant K1 for the transfer of the 
tracer from plasma to tumour.  
Ductal carcinoma in situ of the breast is a non-invasive carcinoma characterized by proliferation 
of malignant cells in the ductal epithelium that are confined to the basement membrane and are 
not invading the normal breast parenchyma. Diagnosis of DCIS is primarily based on imaging 
results.  While mammography remains the gold standard for diagnosis of breast diseases, MRI is 
frequently used after the detection of lesions by digital or screening mammography 104. MRI can 
help guide surgical decision making among the possible options (breast conserving surgery, 
mastectomy, or bilateral mastectomy) and has a higher diagnostic accuracy for DCIS compared 
with either film or digital mammography. Riedl and colleagues studied 672 imaging rounds in a 
high-risk population and found that the detection rate of DCIS by mammography, ultrasound 
(US), and MRI were 50%, 42.9%, and 85.7%, respectively 105. The aim of this study was the 
characterization of DCIS in breast with a spectral analysis approach. The segmentation of DCIS 
was guided by DCE MRI data as coregistration between PET and MR was not doable because 
data were acquired in two different spaces (patient prone in PET and supine in MRI). MR was 
useful for the identification of the lesion and the following segmentation. In particular, on PET 
data, small DCIS spots were included in a larger VOI covering the entire breast. The retention of 
the tracers was evaluated both at region and voxel level. ROI level SA resulted with a spectrum 
of the kinetic components of the tracer showing the presence of an irreversible trapping 
component during the time of measurements (for both 18F-FLT and FDG) (Figure 20). But, the 
simplified average description obtained by ROI analysis alone cannot provide a fair description 
of tumour heterogeneity. An exhaustive physiological characterization of tumour tissues that 
considers the complexity and the variability of the kinetics is given by a voxel wise approach. 
VOI level SA gave 3D parametric maps of two perfusion parameters: Ki, the irreversible uptake 
rate constant and the K1, the influx rate constant. Graphical plots were also applied on DCIS data 
resulting with Patlak K1 and Logan Vt parametric maps. Figure 19 shows the uptake of the two 
tracers in the DCIS of patient n.3 and the parametric maps resulted from spectral and graphical 
analysis. Compared with 18F-FDG, whose uptake has been reported to be influenced by several 
factors, as the upregulation of glucose transporter 1 receptors 66, the number of viable tumour 
cells 67, microvessel density, or hexokinase expression 68, FLT-PET has been shown to image cell 
proliferation. The uptake of both 18F-FLT and FDG in DCIS was not statistically higher compared 
with the surrounding healthy tissue and the identification of DCIS was not clear. In the same way, 
no statistical difference was found between DCIS and healthy tissue with spectral and graphical 
results.  
 
SA was applied on a dataset of 15 breast cancer patients. The mean value of both spectral Ki and 
K1 in DCIS was found to be really low compared with breast tumour and resulted closer to healthy 
breast values (Table 9). A receiver operating characteristic curve analysis was applied on breast 
tumour patients’ dataset to find a cut-off between lesion and healthy tissue. A more robust result 
was obtained with the application of the bootstrap analysis on spectral approach that resulted with 
a very good discrimination between healthy and tumour tissue given by the Ki (AUC = 0.99) with 
a cut-off of 0.014 (80% sensitivity and 100% specificity). DCIS was not identifiable by this 
threshold as well. This could be explained by the overall high proliferation activity of the breast 
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affected also by the menstrual cycle. Söderqvist and his colleagues analysed the proliferation 
marker Ki67/MIB-1 by immunocytochemical methods in breast epithelial cells to assess 
proliferation in normal breast epithelial cells from healthy women during follicular and luteal 
phases of the menstrual cycle. They found a higher proliferation during the luteal phase and a 
positive correlation with serum progesterone levels 106. Furthermore, Hoque and his colleagues 
did not observe a statistically significant difference in Ki67 labeling indices between DCIS 
associated with invasive breast cancer and DCIS alone 107.  
 
The periductal vascularization is important in determining transformation from in situ to invasive 
disease 108. Since it can be very different among different DCIS as not all of them convert into 
breast tumour, we normalized our SA results by the K1 with respect to their heterogeneous 
delivery mechanism. Results in Table 9 show K1 values in tumour, healthy breast and DCIS. The 
latter results very low, comparable to the healthy tissue. The Ki/K1 ratio was plotted in Figure 23 
where DCIS values were compared to tumour and healthy breast. Two patients resulted to fall 
into the tumour range. 
   
Our results suggest that the difficulty in the identification of DCIS is related to the proliferative 
activity of the normal breast. Neither spectral, nor graphical methods were useful in the diagnosis 
of DCIS as the uptake, and the kinetic parameters as well, resulted with very low values (almost 
comparable to normal breast). As the microvessel density is a key factor in the transformation of 
a DCIS to invasive breast cancer, and as it can be very different among different DCIS, we showed 
the utility of the K1 normalization in the identification of pure DCIS. 
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III. [18F]Fluorothymidine Positron Emission Tomography is a 
sensitive method for imaging hepatocellular carcinoma patients 
undergoing transaterial chemoembolization 
 
1. Introduction 
 
Hepatocellular cancer (HCC) is the most common primary hepatic malignancy worldwide and 
third leading cause of cancer mortality 109. Most cases arise in the context of liver cirrhosis (>80%) 
secondary to hepatitis, alcohol excess and increasingly, non-alcoholic fatty liver disease.  
Cirrhosis is a progressive process characterised by nodules: benign regenerative nodules, 
dysplastic and HCC. Radiologic visualisation of HCC is dependent on typical vascular pattern on 
contrast enhanced-CT or MRI of arterial uptake followed by “washout” on venous phase. 
Multiphase contrast-enhanced CT is the most widely available imaging modality, and is 
considered a reliable method for assessment of tumour viability with a sensitivity 68% 110. MRI 
has marginally improved sensitivity of 80%, but still underestimates pathologic staging of disease 
110. Furthermore, both CT and MRI are unable to effectively differentiate regenerating nodules 
from viable tumour. For intermediate stage HCC, transarterial chemoemobilisation (TACE) has 
been shown to improve clinical outcomes and is also used as a bridge to transplantation 111.  In a 
series of patients undergoing TACE prior to transplantation, response by conventional imaging 
was 35% (range 16% - 61%). Pathologic analysis of explanted livers suggested post-TACE 
necrosis in 75%, highlighting diagnostic uncertainty in response assessment by conventional 
radiology 110. Moreover, there is no consensus as to the optimal imaging modality of extrahepatic 
disease.  
 
PET imaging has been evaluated in HCC both for staging and in assessing response to treatment 
112. Clinically, the most widely used tracer is [18F]Fluorodeoxyglucose ([18F]FDG). Studies 
investigating the utility of [18F]FDG-PET in HCC have shown limited sensitivity (50 – 70%) 113. 
The reason for this limited sensitivity is likely due to less marked differential activities of 
glycolytic enzymes and of glucose 6-phosphatase in liver and well-differentiated HCC, resulting 
in almost equivalent uptake of [18F]FDG and poor differentiation of tumours. Imaging with 
[11C]acetate and [11C]-, [18F]choline are similarly limited 114. 3’-Deoxy-3’-
[18F]fluorothymidine ([18F]FLT) is a surrogate marker of proliferation, with uptake reflecting the 
activity of thymidine kinase (TK-1), the key enzyme in the salvage pathway for thymidine 
monophosphate production; its expression correlating with the S phase of the cell cycle 115. Unlike 
[18F]FDG, the uptake of [18F]FLT is specific for proliferation and is not affected by the presence 
of inflammation116, a particular concern in HCC, as these tumours develop in a pro-inflammatory 
milieu 117. To date there has been a single study of [18F]FLT-PET in HCC which indicated that 
only 69% of patients with HCC had uptake in the liver 118. However, the population studied was 
a heterogenous group including cholangiocarcinoma and no information was given with regards 
to tumour stage or response to therapy. Moreover, no study has considered the differential 
expression of TK-1 in HCC and the surrounding cirrhotic tissue, an important consideration in 
developing a tracer paradigm that will effectively differentiate cirrhotic tissue and HCC.   
 
We therefore conducted a comprehensive study of patients with intermediate stage HCC 
undergoing TACE therapy in order to evaluate the ability of [18F]FLT-PET to visualise HCC 
compared to standard imaging and as a response biomarker. As an initial step we reviewed the 
differential expression of TK-1 in HCC and surrounding cirrhotic tissue in pathologic resection 
samples, and then undertook a retrospective study to illustrate the importance of response 
assessment in assessing treatment outcome for patients. We then undertook a prospective study 
using dynamic [18F]FLT-PET to both visualise the tumours and as a response biomarker, 
incorporating comprehensive kinetic modelling.   
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2. Materials and Methods 
 
2.1 Tissue Microarray 
Combined primary tumor/metastasis TMA blocks were prepared as previously described (15) 
from separate areas of the primary tumors and matched secondary lesions to ensure maximal 
reproducibility. The tissue cores were re-embedded in recipient microarray blocks.  
A tissue microarray (TMA) was constructed from patients (n=36) with a histological diagnosis of 
HCC treated at the Hammersmith Hospital, London as previously described 119. Following 
marking of diagnostic H&E slides, a MTA-1 Manual Tissue Microarrayer (Beecher Instruments, 
USA) was used to obtain 1 mm cores of matched cores of malignant tissue and surrounding 
parenchyma. All primary and metastatic deposits were sampled in triplicate. Adequate sampling 
of the target lesions was confirmed on a freshly cut H&E section from the recipient TMA block 
before immunostaining. Immunohistochemistry (IHC) was performed on the TMA sections using 
an established methodology for TK-1 (1:100, AbCam, Cambridge) at the Department of 
Pathology, Hammersmith Hospital.  
 
2.2 Study Design and participants 
 
2.2.1 Retrospective study 
We conducted a retrospective study of 148 consecutive patients with a diagnosis of HCC, treated 
with conventional TACE at Imperial College Healthcare NHS Trust, London (UK) between 2001 
and 2018 (Table 10). TACE consisted of intrarterial infusion of doxorubicin emulsified in lipiodol 
followed by embolisation with gelatin sponge particles. All patients underwent a tri-phasic 
contrast enhanced computer tomography (CT) scan prior to and 6-8 weeks following TACE. Two 
hepato-biliary radiologists (P.T. and M.P.) blinded to treatment outcome reviewed CT and pre-
treatment angiogram images with concordance reached over the qualification of each radiologic 
feature. Progression free survival (PFS) was calculated from initial TACE to the time of 
progression or last-documented follow-up. The local Research Ethics Committee, Imperial 
College Healthcare NHS Trust, approved the study. 
 
Table 10: Eighteen patients were enrolled (16 men and 2 women).  A tracer production failure meant one patient 
was unable to have baseline scanning and one patient withdrew consent following the first PET scan, therefore 
16 patients were evaluable for treatment outcome (Table 1). Median age was 68 years (range 42 – 79years). All 
patients received TACE for intermediate stage disease. Three patients had had previous TACE and were 
undergoing retreatment. The remaining patients were treatment naïve. One patient did not have radiologic 
evidence of background cirrhosis. Three patients had diffuse disease on conventional imaging. 
 
Patien
t No 
 
Lesion 
location 
SUV60,ave x 
10-5m2mL-1 
(preRx) 
SUV60,max x 
10-5m2mL-1 
(preRx) 
 
mRECIS
T  
response 
Percentage 
Change 
SUV60,ave 
Percentage 
Change 
SUV60,max 
1 Diffuse 
disease, R 
lobe 
3.4 5.115 PD -12.21 13.98 
2a  2.17 7.825 PR -22.81 0.77 
3 Segment VII 5.68 7.97 PR -65.23 -42.60 
4 Segment VI 2.75 5.515 CR -6.00 -14.42 
4b Segment V 4.125 5.8  -0.97 -6.72 
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5 Segment II 7.535 10.335 PR -37.36 1.35 
 
Segment VIc 7.6 9.885  10.92 -0.66 
 Segment IV 7.325 9.82  15.49 26.17  
Segment IV 7.84 10.285  5.93 1.90  
Segment VIII 7.08 9.385  0.07 0.85  
Segment IV 7.8 11.295  -4.68 0.93 
 Segment VIII 7.075 8.205  22.19 36.50 
6  7.57 10.225 CR -45.57 -19.02 
7  10.875 14.28 CR 0.00 -100.00 
8  7.83 11.46 CR -66.41 -41.45 
9  7.965 10.295 CR -58.63 -46.09 
10  8.13 20.355 SD -71.34 -41.00 
11  7.11 10.585 PR -29.04 -21.49 
12 Segment VIII 5.075 10.9 PR -55.76 -32.84 
12 Segment IVd 2.86 8.36  -51.57 -33.85 
13  6.365 8.93 CR -25.06 -30.01 
14 Segment VII 
(sagittal) 
5.315 7.36 PR -33.96 -30.50 
 Segment VIII 6.265 7.505  -33.52 -39.11 
 Segment VII 
(medial) 
6.62 8.015  17.15 30.88 
15  7.295 10.42 SD -52.43 -46.26 
16  6.555 11.6 PR -65.83 -24.09 
aIncidental finding of T12 metastases not visualised on MRI. Confirmed on subsequent bone scan 
bmultiple subcentimetre lesions seen on [18F]FLT-PET 
cLesion untreated 
dPhotopaenic lesion 
 
 
2.2.2 Prospective study 
Eighteen patients with a diagnosis of HCC were included in this prospective study. Eligible 
patients were aged 18-85 years with histological diagnosis HCC or a diagnosis of HCC based on 
American Association for the Study of Liver Diseases (AASLD) criteria, had intermediate stage 
disease suitable for TACE, disease evaluable by modified Response Evaluation Criteria in Solid 
Tumours (mRECIST) and at least 1 target lesion >2cm, an Eastern Cooperative Oncology group 
performance status (PS) of 2 or less, and a life expectancy of at least 6 months 120,121.  
Patients had to have adequate bone marrow function (haemoglobin concentration <90 g/L, 
neutrophils <1500 cells per µL, platelets <100 000 cells per µL), kidney function (creatinine <1·5 
times the normal upper limit; calculated creatinine clearance ≥50 mL/min), and liver function 
(aspartate aminotransferase or alanine aminotransferase ≤2·5 times the normal upper limit, 
alkaline phosphatase ≤2·5-times the normal upper limit, total bilirubin ≤1·5 times the normal 
upper limit).  
Patients were recruited from Hammersmith Hospital Imperial College Healthcare NHS Trust.  
The study was approved by the ethics committees at each institution, and all the patients provided 
written informed consent.  
 
2.2.3 Study Assessments 
All patients received standard TACE with liposomal doxorubicin emulsified in lipiodol followed 
by embolisation with gelatin sponge particles. Baseline staging included CT chest, abdomen and 
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pelvis or MRI liver. The same radiological tests were repeated 6-8 weeks following TACE to 
assess treatment response, and then 3 monthly until disease progression.  Response was assessed 
in accordance with modified RECIST (mRECIST) for HCC 122 by a single experienced 
hepatobiliary radiologist (NPT).   
 
2.2.4 Imaging protocol 
[18F]FLT was manufactured according to standard protocols. All patients were scanned on a 
Siemens Biograph 64-slice PET/CT scanner. [18F]FLT-PET imaging was carried out at baseline 
and at the time of follow-up imaging following TACE. In all cases, the liver was imaged in a 
single abdominal bed position. Patient positioning was followed by a CT scan (300 mA, 120 kVp, 
1.35 pitch, 0.8 s/rotation) for both attenuation correction and co-registration with PET images, to 
allow anatomical visualisation and localisation of [18F]FLT activity. [18F]FLT, mean (±SD) 
208.2 ± 10.4 MBq, was injected as a bolus intravenously, and a dynamic, list mode emission scan 
in the 3D mode, lasting 66 min, was undertaken 123,124. 
 
2.3 Image analysis 
Raw PET data were corrected for scatter, attenuation and reconstructed with an iterative algorithm 
consisting of 8 iterations and 21 subsets. The data were binned into time frames as follows: 1 * 
30 (background), 6 * 10, 4 * 20, 4 * 30, 5 * 120, 4 * 180 and 4 * 600 seconds. The attenuation 
corrected PET images and CT data were fused and analysed on a dedicated workstation (Hermes 
diagnostics, Sweden) by a dual trained radiologist/ nuclear medicine physician (TDB). All SUV 
analyses were conducted using PET uptake parameters generated on Hermes.  
 
Tumour lesions were defined as target lesions by mRECIST on either CT or MRI 125. The lesions 
on the [18F]FLT corresponding to those on the CT or MRI, showing an increased uptake were 
considered as target lesions. All lesions greater than 10mm on CT or MRI imaging were measured 
on PET/CT. The diameter of the target lesions was measured using electronic callipers on the 
PACS workstation. The same target lesions were used for analyses on both the PET/CT and CT 
or MRI, before and after treatment. 
 
Consecutive regions of interest (ROI) were manually defined around the tumours on the summed 
images, employing the patient’s diagnostic imaging. The ROI encompassed the whole tumour for 
SUV analysis. The [18F]FLT radioactivity concentration within the ROIs was then normalised for 
injected radioactivity and body weight (grams) to obtain the mean and maximum SUV at 60 
minutes (SUV60mean, and SUV60max) on baseline and post-treatment [18F]FLT PET/CT studies. 
The percentage change in SUV in both SUVmean and SUVmax was then calculated for each target 
lesion visible on baseline imaging as; (SUVpost – SUVpre)/SUVpre. In each case, a 3 cm ROI was 
placed in the liver in a tumour free area, and the tumour/liver (T/L) ratio determined. 
 
2.3.1 Quantitative analysis 
--  The arterial input function 
For each patient, an additional ROI on the aorta was drawn for the implementation, in the kinetic 
model, of an image derived arterial input function (idAIF)60. Since metabolite data were available 
for 10 patients, the idAIF was corrected for an average metabolite and plasma-over-blood ratio 
for each patient. The total [18F]FLT activity in each blood sample was averaged and used to fit 
the plasma-over-blood (POB) ratio to a mono-exponential curve to provide a continuous POB 
representation. A total plasma activity curve was obtained by multiplying the POB by the tissue-
derived input function. Finally, the average pre- and post-treatment fraction of parent compound 
in each sample was fitted to obtain a continuous representation of the parent tracer concentration 
which was then multiplied by the total plasma function. The result was a tissue-derived parent 
plasma input function for each scan which was subsequently used for compartmental modelling. 
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-- The compartmental model 
The average activity within the tumour ROI was used, for each time frame of the dynamic PET 
imaging sequence. The regional tissue activity curves (TACs), the metabolite corrected idAIF and 
the whole blood activity curve were fitted to a two tissue compartmental model using the 
Levenberg-Marquart least-square minimization algorithm implemented in the PMOD kinetic 
modelling tool PKIN (PMOD version 3.703; PMOD group, Zurich, Switzerland). The two-tissue 
compartment model separates tracer in tissue into two exchanging compartments as described in 
Chapter 2, Quantification techniques. 
2.4 Statistical Analysis 
As this was a pilot study no formal power calculation was undertaken. Summary statistics of the 
associations between PET parameters and clinical outcome were determined. Due to the small 
sample size, patients were grouped as responders (complete and partial response, CR and PR) or 
non-responders (stable disease or progressive disease, SD and PD). ROC analysis was undertaken 
to determine optimal PET uptake predictive of response and progression. The relationship 
between kinetic parameters and response was evaluated using Wilcoxon rank tests. Survival was 
determined by Kaplan-Meier statistics. Chi-squared test was used to evaluate utility of the tracer 
pre and post TACE therapy.  p  0.05 was considered significant. All statistical analyses were 
conducted using SPSS statistical package version 22 (SPSS Inc., Chicago, IL, USA).  
 
3. Results 
 
3.1 Response to TACE is predictive of progression free survival 
As PET parameters were associated with response, we evaluated the relevance and range of 
responses in the context of PFS within our institution. In this regard, we considered a large group 
of consecutive patients who had undergone TACE at our institution. Response to TACE using 
mRECIST was defined as CR, PR, SD, PD. Response was a significant predictor of PFS (median 
PFS 15.4 months, 95%CI: 9.1-21.7, p < 0.001). 
 
3.2 TK-1 is upregulated in HCC compared with cirrhotic tissue 
To confirm that [18F]FLT is an appropriate tracer for the visualization of HCC we investigate the 
expression of TK-1 in HCC compared to surrounding cirrhotic tissue using a TMA of matched 
cores of malignant tissue and surrounding parenchyma. A significantly higher TK-1 expression 
in HCC compared to the surrounding parenchyma was observed confirming that [18F]FLT has 
potential for the differentiation of HCC from the surrounding cirrhotic liver parenchyma (p<0.05). 
 
3.3 HCC is visible above background liver using [18F]FLT-PET imaging 
On visual analysis, 25 lesions were visible above background liver uptake, and one lesion was 
noted to be photopenic. All liver lesions seen on standard radiologic imaging were also seen on 
PET imaging. One patient had a bone metastasis seen at T12 on PET imaging that was not visible 
on conventional imaging but was confirmed 3 months later on a bone scan.    
 
All lesions were included in analysis. The mean SUV60,mean (±SD) and SUV60,max (±SD) on the 
baseline scan were 6.39 (±2.00) and 9.68 (±3.00), respectively. The mean SUV60,mean of the 
background liver was 6.08 (±0.97).  A significant difference was observed between SUV60,max of 
the cancer compared to surrounding, non-cancerous liver tissue (p=0.02), with the mean tumour 
to liver (T/L) ratio being 1.59 (±0.39), confirming that uptake in HCC was above cirrhotic 
background activity thus enabling visualization on [18F]FLT-PET scans. 
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3.4 [18F]FLT uptake parameters and clinical outcome 
In terms of response to TACE, according to mRECIST criteria, five patients (33%) had CR, seven 
patients (47%) had PR, two patients (13%) had SD and one patient (7%) PD. There was a median 
overall reduction in [18F]FLT-PET/CT SUV60, mean (−26.67 ± 29.86%) and SUV60, max 
(−14.27 ± 24.83 %) following TACE. Previous test–retest reproducibility studies in breast cancer 
patients showed that changes in [18F]FLT standardized uptake value (SUV) of more than 20% is 
considered significant with 95% confidence interval (SD: 10%–15%) 126.  Using a 20% reduction 
in SUV60, max as response,, response to PET imaging was 73% (n = 11) and non-response was 27% (n 
= 4). As CR/PR and SD are clinically managed in a similar way, these were subsequently grouped 
as “responders” whilst PD was classified as “non-responders”. Accordingly, 80% of patients were 
responders and 20% were non-responders. Using Cohen’s kappa measures, there was no 
concordance observed between PET response and mRECIST.  
 
3.5 Kinetic quantification of [18F]FLT data 
Kinetic modelling illustrates significant reduction in [18F]FLT uptake and retention following 
TACE 
Fourteen patients had bloods taken for kinetic modelling. The analysis of [18F]FLT dynamic data 
with a two tissue compartmental model resulted in kinetic parameters consistent with 
physiological conditions (Table 11)127.   
 
Table 11: Results of the compartmental analysis done on dynamic [18F]FLT data. The analysis was run on a 
ROI level and results show the parameters extracted from the single TAC (no standard deviation). 
Patient 
Number 
K1 
(mL/min/g) 
k2 (1/min) k3 (1/min) k4 (1/min) vB (mL/g) Ki  
(mL/min/g) 
1 0.16 0.10 0.10 0.11 0 0.082 
2 0.17 0.075 0.074 0.065 0.013 0.086 
3 0.31 0.40 0.24 0.039 0.019 0.11 
4 0.21 0.28 0.13 0.059 0.034 0.066 
5 0.34 0.16 0.096 0.039 0.030 0.12 
6 0.43 0.28 0.085 0.011 0.057 0.10 
8 0.27 0.28 0.13 0.024 0.045 0.089 
9 0.29 0.52 0.32 0.037 0.054 0.11 
11 0.41 0.51 0.16 0.020 0.073 0.10 
13 0.11 0.16 0.038 0.0017 0.10 0.021 
14 0.46 0.42 0.13 0.035 0.0002 0.10 
15 0.58 0.69 0.13 0.024 0.066 0.090 
16 0.26 0.17 0.075 0.024 0.069 0.077 
18 0.23 0.19 0.092 0.023 0 0.074 
 
 
Compartmental modelling provided separate estimates of both transport (K1) and retention (Ki) 
of [18F]FLT.  There was a significant and profound reduction in mean K1 values from baseline, 
0.30±0.13 (mL/min/g), compared to post-treatment, 0.13 ± 0.054 (p < 0.001). This is in keeping 
with the abrupt cessation of blood flow to the tumour following embolization of the feeding 
vessels resulting in reduced transport of [18F]FLT to the tumour.  While all tumours showed some 
degree of reduction in K1, the change in K1 was greater in responders (66% reduction) versus non-
responders (50%), p=0.034 (Figure 2A). Baseline SUV60, mean and baseline Ki were significantly 
correlated (Pearson’s correlation coefficient 0.55, p-0.043) and a significant difference was 
observed in Ki at baseline 0.089 + 0.026 (mL/min/g) compared to post-TACE imaging, 0.043 + 
0.02 (p < 0.001). In responders, baseline Ki and vB were greater compared to non-responders 
(Figure 25B and C) (p < 0.05).   
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Figure 25: A) Change in K1 in responders and non-responders; B) Baseline Ki in responders and non-
responders; C) Baseline vB in responders and non-responders. 
 
 
4. Discussion 
 
Despite numerous studies investigating the utility of PET in HCC, there is still no one tracer 
recommended by international guidelines for either diagnosis or response assessment 128. The 
main limitation of the studied tracers has been poor tumour to background ratio which has 
impacted negatively on the utility of a number of PET tracers and has resulted in the use of dual 
tracers for visualizing HCC, which is both time-consuming for nuclear medicine departments and 
exposes patients to significant radiation 112-114,129. We hypothesized, that as [18F]FLT uptake is 
specific for proliferation, tracer uptake will not be affected by the presence of inflammation, a 
particular concern in HCC, as these tumours develop in a pro-inflammatory milieu 130.  
In order to address this hypothesis, we firstly assessed the expression of TK-1 both in HCC and 
surrounding, matched cirrhotic tissue. TK-1 directly impacts on [18F]FLT trapping within  the cell 
and has been shown in a number of studies to be a surrogate marker of proliferation 131-133. Using 
paired samples of tumour tissue and surrounding cirrhosis, we illustrated a marked upregulation 
of TK-1 in HCC, thereby suggesting that [18F]FLT could be useful in differentiating HCC from 
surrounding background liver. Accordingly, the results of our clinical study illustrate that 
[18F]FLT-PET was accurate in detecting intrahepatic lesions, with increase uptake above tumour 
background consistent with TMA findings. Moreover, in one patient with boney metastasis, 
[18F]FLT-PET was more sensitive in detecting extra-hepatic disease compared to conventional 
imaging.  This is in contrast with the study by Eckels and colleagues who reported only 72% 
sensitivity of [18F]FLT in visualizing HCC 134. The difference may be attributable to the 
heterogeneous study population investigated in the Eckels paper including cholangiocarcinomas. 
Of interest, the median SUV and T/L ratios are consistent between the two studies.  
We also considered the role of dynamic [18F]FLT-PET in response assessment following TACE 
an important clinical situation as conventional imaging has varied accuracy in response 
assessment particularly in defining regenerative nodules from active cancer. The radiologic 
response to TACE by mRECIST was 80%, and by PET was 73%, however there was no 
concordance between imaging modalities. This may reflect differences in the biophysical and 
biochemical measures derived from the different imaging techniques, and/or the small studied 
sample size. In addition we selected a 20% reduction in SUV60max to indicate response, a larger 
study may define a more accurate cut-off. 
A key strength of this study is the use of dynamic PET imaging data that allows us to further 
derive predictive biomarkers of outcome in HCC. We report a significant reduction in Ki and K1 
following TACE, illustrating abrupt reduction in blood supply to the tumour that will affect tissue 
perfusion. This is sharp contrast with some standard chemotherapy where we would have 
expected an increase in the K1 due to a reorganization and normalization in the vascular structure 
of the tissue 135.  Ki is the metabolic flux constant and it is related to the phosphorylation of the 
thymidine in the tissue 136. It has previously found to be correlated to [18F]FLT uptake and our 
results illustrate correlation with SUV uptake 102.  Moreover, we report baseline Ki and vB to be 
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predictive of response to treatment suggesting that these tumours are more actively proliferating 
and have increased vascularity which would be predictive of TACE response.  
Response to TACE has been shown to be predictive of PFS both in our cohort within this 
manuscript and by other authors, therefore accurate response assessment is important. 
Conventional RECIST response criteria using change in size has limitations for targeted therapies 
which can induce tumour necrosis without overall change in size. Therefore, mRECIST criteria 
based on changes in size of the ‘viable’ tumour which is considered to be the arterially enhancing 
component of the tumour on contrast CT or MRI, was introduced 122.  The mRECIST criteria has 
been validated in the assessment of locoregional therapies for HCC, such as TACE/ TACE, with 
a recent meta-analysis of seven studies reporting strong prognostic value of mRECIST criteria in 
terms of overall survival (137). However, these imaging modalities have limited sensitivity 68 – 
80% and have been shown to underestimates pathologic staging of disease 110,138.  
Although there are some reports of FDG PT/CT being useful in assessment of response post 
TACE, the low tumour to background is a limitation 139. 
We have firstly shown that [18F]FLT-PET can be used to accurately predict response to TACE in 
this small case series, and promisingly, was able to able detect extrahepatic disease. Whilst this 
study is a pilot study, the results generated are provocative and should be taken forward to larger 
prospective trials.  
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69. de Molina AR, Rodrıǵuez-González An, Gutiérrez R, et al. Overexpression of choline 
kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and 
colorectal human cancers. Biochemical and biophysical research communications. 
2002;296(3):580-583. 
70. Sarri E, Garcia-Dorado D, Abellan A, Soler-Soler J. Effects of hypoxia, glucose 
deprivation and acidosis on phosphatidylcholine synthesis in HL-1 cardiomyocytes. 
CTP: phosphocholine cytidylyltransferase activity correlates with sarcolemmal 
disruption. Biochemical Journal. 2006;394(1):325-334. 
71. Bansal A, Shuyan W, Hara T, Harris RA, DeGrado TR. Biodisposition and metabolism 
of [18 F] fluorocholine in 9L glioma cells and 9L glioma-bearing fisher rats. European 
journal of nuclear medicine and molecular imaging. 2008;35(6):1192-1203. 
72. Shukla-Dave A, Lee NY, Jansen JF, et al. Dynamic contrast-enhanced magnetic 
resonance imaging as a predictor of outcome in head-and-neck squamous cell 
carcinoma patients with nodal metastases. International Journal of Radiation 
Oncology• Biology• Physics. 2012;82(5):1837-1844. 
73. King AD, Chow K-K, Yu K-H, et al. Head and neck squamous cell carcinoma: 
diagnostic performance of diffusion-weighted MR imaging for the prediction of 
treatment response. Radiology. 2013;266(2):531-538. 
74. Bentourkia Mh. PET kinetic modeling of 11C-acetate from projections. Computerized 
medical imaging and graphics. 2003;27(5):373-379. 
91 
 
75. Marshall RC, Powers-Risius P, Reutter BW, et al. Kinetic analysis of 18F-
fluorodihydrorotenone as a deposited myocardial flow tracer: comparison to 201Tl. 
Journal of Nuclear Medicine. 2004;45(11):1950-1959. 
76. Meikle SR, Eberl S, Iida H. Instrumentation and methodology for quantitative pre-
clinical imaging studies. Current pharmaceutical design. 2001;7(18):1945-1966. 
77. Myers JF, Rosso L, Watson BJ, et al. Characterisation of the contribution of the GABA-
benzodiazepine α1 receptor subtype to [11C] Ro15-4513 PET images. Journal of 
Cerebral Blood Flow & Metabolism. 2012;32(4):731-744. 
78. Hammers A, Asselin M-C, Turkheimer FE, et al. Balancing bias, reliability, noise 
properties and the need for parametric maps in quantitative ligand PET:[11C] 
diprenorphine test–retest data. Neuroimage. 2007;38(1):82-94. 
79. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans 
using PET imaging and Pittsburgh Compound-B. Journal of Cerebral Blood Flow & 
Metabolism. 2005;25(11):1528-1547. 
80. Miederer I, Ziegler SI, Liedtke C, et al. Kinetic modelling of [11C] flumazenil using 
data-driven methods. European journal of nuclear medicine and molecular imaging. 
2009;36(4):659-670. 
81. Zanotti-Fregonara P, Leroy C, Roumenov D, Trichard C, Martinot J-L, Bottlaender M. 
Kinetic analysis of [11 C] befloxatone in the human brain, a selective radioligand to 
image monoamine oxidase A. EJNMMI research. 2013;3(1):78. 
82. Zanotti-Fregonara P, Xu R, Zoghbi SS, et al. The PET radioligand 18F-FIMX images 
and quantifies metabotropic glutamate receptor 1 in proportion to the regional density 
of its gene transcript in human brain. Journal of Nuclear Medicine. 2016;57(2):242-
247. 
83. Gullberg GT, Reutter BW, Sitek A, Maltz JS, Budinger TF. Dynamic single photon 
emission computed tomography—basic principles and cardiac applications. Physics in 
Medicine & Biology. 2010;55(20):R111. 
84. Pencek RR, Bertoldo A, Price J, Kelley C, Cobelli C, Kelley DE. Dose-responsive 
insulin regulation of glucose transport in human skeletal muscle. American Journal of 
Physiology-Endocrinology and Metabolism. 2006;290(6):E1124-E1130. 
85. Puri T, Blake GM, Frost ML, et al. Comparison of six quantitative methods for the 
measurement of bone turnover at the hip and lumbar spine using 18F-fluoride PET-CT. 
Nuclear medicine communications. 2012;33(6):597-606. 
86. Murase K, Tsuda T, Mochizuki T, Ikezoe J. A simplified method for the quantitative 
analysis of 99Tc (m)-GSA liver scintigraphy using spectral analysis. Nuclear medicine 
communications. 1998;19(3):219-227. 
87. Tomasi G, Kenny L, Mauri F, Turkheimer F, Aboagye EO. Quantification of receptor-
ligand binding with [18 F] fluciclatide in metastatic breast cancer patients. European 
journal of nuclear medicine and molecular imaging. 2011;38(12):2186-2197. 
88. Verwer EE, Bahce I, van Velden FH, et al. Parametric methods for quantification of 
18F-FAZA kinetics in non–small cell lung cancer patients. Journal of Nuclear 
Medicine. 2014;55(11):1772-1777. 
89. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast 
cancer with a favorable histology: results of the Iowa Women's Health Study. Jama. 
1999;281(22):2091-2097. 
90. Nakhlis F, Morrow M. Ductal carcinoma in situ. Surgical Clinics. 2003;83(4):821-839. 
91. Mossa-Basha M, Fundaro GM, Shah BA, Ali S, Pantelic MV. Ductal carcinoma in situ 
of the breast: MR imaging findings with histopathologic correlation. Radiographics. 
2010;30(6):1673-1687. 
92. Rostom A, Powe J, Kandil A, et al. Positron emission tomography in breast cancer: a 
clinicopathological correlation of results. The British journal of radiology. 
1999;72(863):1064-1068. 
92 
 
93. Avril N, Rose C, Schelling M, et al. Breast imaging with positron emission tomography 
and fluorine-18 fluorodeoxyglucose: use and limitations. Journal of clinical oncology. 
2000;18(20):3495-3502. 
94. Mavi A, Urhan M, Jian QY, et al. Dual time point 18F-FDG PET imaging detects 
breast cancer with high sensitivity and correlates well with histologic subtypes. Journal 
of nuclear medicine. 2006;47(9):1440-1446. 
95. Azuma A, Tozaki M, Ito K, Fukuma E, Tanaka T, O’uchi T. Ductal carcinoma in situ: 
correlation between FDG-PET/CT and histopathology. Radiation medicine. 
2008;26(8):488-493. 
96. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: 
physiologic and benign variants. Radiographics. 1999;19(1):61-77. 
97. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18] 
FLT and positron emission tomography. Nature medicine. 1998;4(11):1334. 
98. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as 
a measure of thymidine kinase-1 activity in A549 carcinoma cells. Journal of Nuclear 
Medicine. 2002;43(9):1210-1217. 
99. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. 
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in 
breast cancer patients with 3′-deoxy-3′-[18F] fluorothymidine positron emission 
tomography. European journal of nuclear medicine and molecular imaging. 
2007;34(9):1339-1347. 
100. Pio BS, Park CK, Pietras R, et al. Usefulness of 3′-[F-18] fluoro-3′-deoxythymidine 
with positron emission tomography in predicting breast cancer response to therapy. 
Molecular Imaging and Biology. 2006;8(1):36-42. 
101. Herrmann K, Wieder HA, Buck AK, et al. Early response assessment using 3′-deoxy-3′-
[18F] fluorothymidine-positron emission tomography in high-grade non-Hodgkin's 
lymphoma. Clinical Cancer Research. 2007;13(12):3552-3558. 
102. Muzi M, Vesselle H, Grierson JR, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine 
PET studies: validation studies in patients with lung cancer. Journal of Nuclear 
Medicine. 2005;46(2):274-282. 
103. Turkheimer F, Sokoloff L, Bertoldo A, et al. Estimation of component and parameter 
distributions in spectral analysis. Journal of Cerebral Blood Flow & Metabolism. 
1998;18(11):1211-1222. 
104. Badruddoja M. Ductal carcinoma in situ of the breast: a surgical perspective. 
International journal of surgical oncology. 2012;2012. 
105. Riedl CC, Ponhold L, Flöry D, et al. Magnetic resonance imaging of the breast 
improves detection of invasive cancer, preinvasive cancer, and premalignant lesions 
during surveillance of women at high risk for breast cancer. Clinical Cancer Research. 
2007;13(20):6144-6152. 
106. Söderqvist G, Isaksson E, von Schoultz B, Carlström K, Tani E, Skoog L. Proliferation 
of breast epithelial cells in healthy women during the menstrual cycle. American 
Journal of Obstetrics & Gynecology. 1997;176(1):123-128. 
107. Hoque A, Menter DG, Sahin AA, Sneige N, Lippman SM. No increased Ki67 
expression in ductal carcinoma in situ associated with invasive breast cancer. Cancer 
Epidemiology and Prevention Biomarkers. 2001;10(2):153-154. 
108. Teo N, Shoker B, Jarvis C, Martin L, Sloane J, Holcombe C. Vascular density and 
phenotype around ductal carcinoma in situ (DCIS) of the breast. British journal of 
cancer. 2002;86(6):905. 
109. IARC.  http://www-dep.iarc.fr/. Accessed 10/10/2013, 2013. 
110. Chapman WC, Majella Doyle MB, Stuart JE, et al. Outcomes of neoadjuvant 
transarterial chemoembolization to downstage hepatocellular carcinoma before liver 
transplantation. Ann Surg. 2008;248(4):617-625. 
93 
 
111. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation 
versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a 
randomised controlled trial. Lancet. 2002;359(9319):1734-1739. 
112. Bieze M, Klumpen HJ, Verheij J, et al. Diagnostic accuracy of 18F-methyl-choline 
PET/CT for intra- and extrahepatic hepatocellular carcinoma. Hepatology. 2013. 
113. Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography 
for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999;94(11):3314-3319. 
114. Yamamoto Y, Nishiyama Y, Kameyama R, et al. Detection of hepatocellular carcinoma 
using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med. 
2008;49(8):1245-1248. 
115. Toyohara J, Waki A, Takamatsu S, Yonekura Y, Magata Y, Fujibayashi Y. Basis of 
FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and 
[3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. 
Nuclear medicine and biology. 2002;29(3):281-287. 
116. Van Waarde A, Jager PL, Ishiwata K, Dierckx RA, Elsinga PH. Comparison of sigma-
ligands and metabolic PET tracers for differentiating tumor from inflammation. The 
Journal of Nuclear Medicine. 2006;47(1):150. 
117. van Waarde A, Cobben DC, Suurmeijer AJ, et al. Selectivity of 18F-FLT and 18F-FDG 
for differentiating tumor from inflammation in a rodent model. J Nucl Med. 
2004;45(4):695-700. 
118. Eckel F, Herrmann K, Schmidt S, et al. Imaging of proliferation in hepatocellular 
carcinoma with the in vivo marker 18F-fluorothymidine. J Nucl Med. 2009;50(9):1441-
1447. 
119. Pinato DJ, Sharma R. An inflammation-based prognostic index predicts survival 
advantage after transarterial chemoembolization in hepatocellular carcinoma. 
Translational research : the journal of laboratory and clinical medicine. 
2012;160(2):146-152. 
120. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 
2005;42(5):1208-1236. 
121. Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response 
Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients 
treated with sorafenib for hepatocellular carcinoma. Cancer. 2012;118(1):147-156. 
122. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular 
carcinoma. Paper presented at: Seminars in liver disease2010. 
123. Kenny LM, Vigushin DM, Al-Nahhas A, et al. Quantification of cellular proliferation in 
tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-
positron emission tomography imaging: evaluation of analytical methods. Cancer 
research. 2005;65(21):10104-10112. 
124. Contractor KB, Kenny LM, Stebbing J, et al. [18F]-3'Deoxy-3'-fluorothymidine 
positron emission tomography and breast cancer response to docetaxel. Clinical cancer 
research : an official journal of the American Association for Cancer Research. 
2011;17(24):7664-7672. 
125. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumours: revised RECIST guideline (version 1.1). European journal of cancer. 
2009;45(2):228-247. 
126. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. 
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in 
breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission 
tomography. European journal of nuclear medicine and molecular imaging. 
2007;34(9):1339-1347. 
127. Contractor K, Challapalli A, Tomasi G, et al. Imaging of cellular proliferation in liver 
metastasis by [18F] fluorothymidine positron emission tomography: effect of therapy. 
Physics in Medicine & Biology. 2012;57(11):3419. 
94 
 
128. European Association for the Study of the Liver. Electronic address eee, European 
Association for the Study of the L. EASL Clinical Practice Guidelines: Management of 
hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236. 
129. Chalaye J, Costentin CE, Luciani A, et al. Positron emission tomography/computed 
tomography with 18F-fluorocholine improve tumor staging and treatment allocation in 
patients with hepatocellular carcinoma. J Hepatol. 2018;69(2):336-344. 
130. van Waarde A, Cobben DC, Suurmeijer AJ, et al. Selectivity of 18F-FLT and 18F-FDG 
for differentiating tumor from inflammation in a rodent model. J Nucl Med. 
2004;45(4):695-700. 
131. Kenny LM, Vigushin DM, Al-Nahhas A, et al. Quantification of cellular proliferation in 
tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-
positron emission tomography imaging: evaluation of analytical methods. Cancer Res. 
2005;65(21):10104-10112. 
132. Francis DL, Freeman A, Visvikis D, et al. In vivo imaging of cellular proliferation in 
colorectal cancer using positron emission tomography. Gut. 2003;52(11):1602-1606. 
133. Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with 
PET: 18F-FLT versus 18F-FDG. J Nucl Med. 2003;44(9):1426-1431. 
134. Eckel F, Herrmann K, Schmidt S, et al. Imaging of proliferation in hepatocellular 
carcinoma with the in vivo marker 18F-fluorothymidine. Journal of Nuclear Medicine. 
2009;50(9):1441. 
135. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic 
therapy. Science. 2005;307(5706):58-62. 
136. Muzi M, Spence AM, O'Sullivan F, et al. Kinetic analysis of 3′-deoxy-3′-18F-
fluorothymidine in patients with gliomas. Journal of Nuclear Medicine. 
2006;47(10):1612-1621. 
137. Vincenzi B, Di Maio M, Silletta M, et al. Prognostic relevance of objective response 
according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients 
treated with loco-regional therapies: a literature-based meta-analysis. PLoS One. 
2015;10(7):e0133488. 
138. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, 
magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a 
systematic review. Am J Gastroenterol. 2006;101(3):513-523. 
139. Song MJ, Bae SH, Yoo IR, et al. Predictive value of 18F-fluorodeoxyglucose PET/CT 
for transarterial chemolipiodolization of hepatocellular carcinoma. World journal of 
gastroenterology: WJG. 2012;18(25):3215. 
 
  
95 
 
 
 
 
  
96 
 
 
CHAPTER 3 
The basics of MRI 
 
The basis of magnetic resonance (MR) technique is the measurement of radiofrequency radiation 
resulting from transitions induced between nuclear spin states of tissue hydrogen atoms (protons) 
in the presence of a strong external magnetic field 1. The behaviour of a tissue subjected to a 
magnetic field relies on quantum mechanics and pixel intensities, in MR images, are a function 
of proton densities and tissue relaxation times 2. For clinical imaging, hydrogen is the most 
frequently used nucleus, but other possible nuclei are carbon-13, sodium, and phosphorus. Under 
normal circumstances these tiny magnets are randomly distributed in space, the magnetic 
moments cancel each other out, and thus the net magnetic vector is zero (Figure 26A). However, 
when the patient is submitted to a strong external magnetic field (B0) the nuclei adopt one of two 
possible orientations: parallel or antiparallel to the external field (Figure 26B).  
 
 
Figure 26: A) Without a magnetic field the magnetic moments of the nuclei are distributed at random and thus 
the net magnetization factor is zero. (B) When there is a strong external magnetic field the spinning nuclei align 
parallel or antiparallel to the external field (B0) with a few more parallel than antiparallel. This results in a net 
magnetization vector (Mz) parallel to the external magnetic field. 
Parallel alignment is the lower energy state and is thus the preferred alignment, whereas 
antiparallel alignment is the higher energy state 2. Mz is the net magnetization vector aligned to 
the external magnet. Individual nuclei do not actually line up with the magnetic field but precess 
around the direction of the external field (Figure 27A) at the Larmor frequency F: 
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where γ is the gyromagnetic ratio of the nucleus. In the frequently used commercial systems of 
1.5 Tesla (T), the Larmor frequency is 63.75 MHz for hydrogen but the phase of precession 
around the axis of the magnetic field is different for each individual nucleus (Figure 27B) 2. 
The net magnetization vector from the nuclei inside the magnet in its equilibrium state is static 
and does not produce a measurable signal. To obtain information from the spins, the direction of 
the net magnetization vector has to be altered: the precessing spins are excited by applying energy 
in the form of radiofrequency (RF) energy pulses of exactly the Larmor frequency (resonance 
frequency). When an RF signal is given at the resonance frequency into the patient, two 
phenomena occur: first, enough protons absorb energy to jump from the parallel state to the higher 
level of the antiparallel state, and second, the spins are ‘‘whipped’’ to precess in phase 2. As a 
consequence, Mz flips 90° from the positive z-axis to transverse plane, it rotates around B0 at the 
Larmor frequency. This rotating transverse magnetization can be measured, because it will induce 
an alternating current (AC) in the receiver coil placed around the patient (Figure 27). 
 
 
Figure 27: When the spins are exited with an RF pulse of exactly the Larmor frequency, the net magnetization 
flips 90° and the spins are ‘‘whipped’’ to precess in phase. The rotating net magnetization vector induces an AC 
in a receiver coil. 
After the RF frequency transmitter is switched off, Mz decays over time and, consequently, the 
induced signal in the receiver coil. This decreasing signal is called the free induction decay (FID) 
(Figure 28) and the time required for the signal to return to equilibrium is the relaxation time 2.  
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Figure 28: The received signal detected by the receiver coil, the FID, decreases over time when the net 
magnetization vector returns to its original orientation. 
Two relaxation processes exist: transverse relaxation and longitudinal relaxation. Both processes 
are independent. The process of realignment to the external magnetic field is called the 
longitudinal relaxation process (Figure 29) and it is characterized by the relaxation time T1. It is 
defined as the time required for the system to recover to 63% of its equilibrium value after it has 
been exposed to a 90° RF pulse (Figure 29).  
 
 
Figure 29: Longitudinal relaxation is characterized by theT1 relaxation time, which is the time to recover 63% 
of the original net magnetization vector. Transverse relaxation is characterized by the T2 time, which is the time 
it takes to decay the signal to 37% of the original signal. 
Various human tissues have different T1 values (Table 12). 
 
Table 12: Relaxation times T1 and T2 and proton density in different tissues at different magnetic field strength. 
Field strength (T) Tissue T1 (ms) T2 (ms) T2* (ms) Proton Density 
1.5 
White matter 510 67 78 0.61 
Gray matter 760 77 69 0.69 
Arterial blood 1441 290 55 0.72 
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CSF 2650 280 na 1.0 
3.0 
White matter 1080 70 50 0.61 
Gray matter 1820 100 50 0.69 
Arterial blood 1932 275 46 0.72 
CSF 3817 1442 na 1.0 
 
 
The second process of relaxation, the transverse relaxation, depends on the spins precessing 
around the magnetization vector. Initially, after the excitation by the RF pulse, the spins precess 
completely in phase. However, as time passes, the observed signal starts to decrease because the 
spins begin to diphase due to small differences in the Larmor frequency induced by random local 
magnetic inhomogeneities, due to spin-spin interaction and inhomogeneity of the main static 
magnetic field B0. 
The spin-spin relaxation and is characterized by the relaxation time T2, which is the time required 
by the signal to decay to 37% of its original value (Figure 29). There is also a reversible bulk field 
dephasing effect caused by local field inhomogeneities, and its characteristic time is referred to 
as T2* relaxation 3. These additional dephasing fields come from the main magnetic field 
inhomogeneity, the differences in magnetic susceptibility among various tissues or materials, 
chemical shift, and gradients applied for spatial encoding (Figure 30). 
 
Figure 30: Graph shows T2 and T2* relaxation curves. T2* is shorter than T2. 
MRI depends on the signal derived from the H-protons. It contains information about the position 
of these protons in the patient. The image is created in three steps: 
 
1) slice selection 
2) frequency encoding and  
3) phase encoding.  
 
The slice selection is done with the application of a magnetic gradient (for example 25 mT/m) in 
addition to the main magnetic field (usually in the caudal to cranial direction - Gz). Because the 
frequency of precession, and thus the frequency at which the spins can be excited, is dependent 
on the local strength of the magnetic field, a narrow band of frequencies will only excite a thin 
slice (3 to 8mm) of spins through the body. With a change in the excitation frequency another 
parallel slice can be acquired later. It is possible to obtain slices in other directions as the direction 
of gradients for the slice encoding are combinations of gradients in all three directions. The 
frequency and phase encoding are used to obtain information for the individual points within a 
slice, the pixels.  
Since the frequency of the spins procession in the presence of a gradient field is a linear function 
of frequency and thus a linear function of position, the location of a given group of spins (in one 
direction at least) depends on their frequency. The time domain of the NMR signal is 
deconstructed into a histogram of the frequencies present in the signal (a spectrum) via Fourier 
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transform. The frequency encoding is done with a readout gradient (Gx) whose direction (the 
encoding direction) is called “readout direction”. As for the frequency, the phase of the MR signal 
form a voxel full of spins depends on their position and the entire history of the gradients applied 
from excitation to measurements. For the phase encoding, a short temporary change in the 
magnetic field is applied between the RF excitation pulse and the readout of the signal. This 
change in the magnetic field will shift the phase of precessing of the spins and this will be 
dependent on the duration of this gradient switch. By repeating this process with different duration 
of the temporary gradients, signals with a different phase encoding can be acquired. Combining 
phase and frequency information allows the creation of a grid in which each pixel has a defined 
combination of phase and frequency codes: the K-space. With a Fast Fourier Transform, the raw 
data, which represent an amplitude as a function of time, are transformed into a curve that 
represents an amplitude as function of the frequency. The amplitude of each frequency represents 
the intensity of each pixel. The Fourier Transform is performed in both the frequency and phase 
encoding direction 2.  
 
 
 
Figure 31: Pulse sequence technique. 
In an MR experiment, only the RF signal can be determined by measurement, which is induced 
by the rotating transverse magnetization Mxy in the receiver coil. A defined sequence of RF pulses, 
which is usually repeated several times, is called a pulse sequence (Figure 31) 4. The diagram of 
a pulse sequence is composed of several parallel lines (at least four: one for the RF pulse, and one 
each for the x-, y-, and z-axis gradients). The pulse sequence diagram is a schema of the timing 
of instructions sent to the RF generator and gradient amplifiers. There are only two fundamental 
types of MR pulse sequences: spin-echo (SE) and gradient recalled echo (GRE) 5.  
 
MRI Sequences 
 
SE Sequences - In SE sequences, a 90° pulse flips the net magnetization vector into the transverse 
plane. As the spinning nuclei go through T1, T2, and T2*relaxation, the transverse magnetization 
is gradually dephased. A 180° pulse is applied at a time equal to one-half of TE to rephase the 
spinning nuclei. When the nuclei are again spinning in phase (at total TE), an echo is produced 
and read (Figure 32). Most conventional SE sequences are very long and therefore are not used 
frequently. However, advances in MR imaging technology have enabled a reduction in acquisition 
time with the use of fast SE sequences. Sequences that have a short TR and short TE are used to 
obtain T1 weighting. Those with a long TR and short TE result in proton-density weighting. When 
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the TR is long and the TE is long, T2 weighting is achieved. Sequentially increasing the TE of a 
sequence weights it more heavily toward T2 5.  
 
Figure 32: Time diagram of a conventional spin echo sequence 
One of the first SE variant is its fast or turbo version where a single 90° pulse is applied to flip 
the net magnetization vector, after which multiple 180°rephasing pulses are applied, each of 
which creates an echo (Figure 33). All the echoes together are called an echo train, and the total 
number of 180° RF pulses and echoes is referred to as the echo train length. The acquisition time 
is greatly reduced with use of a fast SE sequence as opposed to a conventional SE sequence. It is 
approximately proportional to 1/ETL, where ETL is the echo train length, for imaging of a single 
section or a small number of sections. However, at imaging of larger volumes, the reduction of 
acquisition time is highly dependent on the spatial coverage 5.  
 
Figure 33: Time diagram of a fast spin echo sequence. 
A second variant of SE is given by the inversion recovery sequence (IR) where a 180° preparatory 
pulse is applied to flip the net magnetization vector 180° and null the signal from a particular 
entity (e.g., water in tissue). When the RF pulse ceases, the spinning nuclei begin to relax. When 
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the net magnetization vector for water passes the transverse plane (the null point for that tissue), 
the conventional 90° pulse is applied, and the SE sequence then continues as before (Figure 34). 
The interval between the 180° pulse and the 90° pulse is the inversion time (TI). At TI, the net 
magnetization vector of water is very weak, whereas that for body tissues is strong 5.  
 
 
Figure 34: Time diagram of an inversion recovery sequence. 
When the net magnetization vectors are flipped by the 90° pulse, there is little or no transverse 
magnetization in water, so no signal is generated (fluid appears dark), whereas signal intensity 
ranges from low to high in tissues with a stronger net magnetization vector. Two important 
clinical implementations of the inversion recovery concept are the short TI inversion-recovery 
(STIR) sequence and the fluid-attenuated inversion-recovery (FLAIR) sequence 5. 
 
GRE Sequences - In a GRE sequence, an RF pulse is applied that partly flips the net magnetization 
vector into the transverse plane (variable flip angle). Gradients, as opposed to RF pulses, are used 
to gradients) transverse magnetization (Figure 35). Because gradients do not refocus field 
inhomogeneities, GRE sequences with long TEs are T2*weighted (because of magnetic 
susceptibility) rather than T2 weighted like SE sequences. GRE sequences are sensitive to 
magnetic field inhomogeneity secondary to magnetic susceptibility differences between tissues. 
Magnetic susceptibility–related signal loss, or susceptibility artefact, is caused by magnetic field 
(B0) inhomogeneity and can be described in terms of T2*signal decay. This inhomogeneity (local 
variation in B0) usually occurs at the interface between entities (e.g., tissue and air) that have 
different magnetic susceptibilities. Because magnetic fields vary locally, some spinning nuclei 
precess faster than others; so when the individual vectors are added to obtain the net 
magnetization vector, there is a progressive decrease in the magnitude of the net magnetization 
vector over time. This decrease results in a progressive decrease in signal intensity, which 
eventually leads to a signal void 5. Magnetic susceptibility imaging is the basis of cerebral 
perfusion studies, in which the T2* effects (i.e., signal decrease) created by gadolinium (a metal 
injected intravenously as a chelated ion in aqueous solution, typically in the form of gadopentetate 
dimeglumine) are sensitively depicted by GRE sequences. Magnetic susceptibility is also used in 
blood oxygenation level–dependent (BOLD) imaging, in which the relative amount of 
deoxyhemoglobin in the cerebral vasculature is measured as a reflection of neuronal activity.  
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Figure 35: Time diagram of a gradient echo sequence. 
A variant of the conventional GRE is the spoiled GRE where a spoiler RF pulse or gradient is 
used to eradicate any remaining transverse magnetization after each echo, thereby producing the 
same effect as T1 or proton-density weighting. Spoiled GRE sequences are especially useful for 
contrast material–enhanced MR imaging and cardiac imaging 5. 
 
Recently, multiband or simultaneous multi-slice EPI technique has been introduced6. It 
effectively shortens acquisition time without decreasing TE and, principally, without sacrificing 
SNR by simultaneous acquisition of multiple slices. Similar to parallel imaging, spatial encoding 
critically relies on the spatially varying sensitivities of RF receive coil arrays. The technique 
requires multiband RF pulses which achieve simultaneous excitation of multiple slices, and 
reconstruction is most easily done by means of the SENSE algorithm. This method facilitates a 
considerable shortening of volume acquisition times because the number of simultaneously 
acquired slices, i.e. the multiband factor, directly translates into a reduced number of excitations 
and thus measurement time. Similar to parallel imaging the specified spatial resolution is 
preserved but there is no direct SNR penalty ∼1/√R due to a reduced number of acquisitions with 
acceleration factor R6. 
 
Artefacts in MRI 
 
Artefacts in magnetic resonance imaging may be caused by the MR scanner hardware itself or by 
the interaction of the patient with the hardware7. Artefacts and foreign bodies within the patient’s 
body may be confused with a pathology or just reduce the quality of examinations. The knowledge 
of the artefacts and their sources is extremely important in order to avoid false diagnoses and to 
learn how to eliminate them. Depending on their origin, one can classify them into the following 
groups: 
1) Truncation artefacts which occur near sharp high-contrast boundaries and are also known as 
the Gibbs phenomenon. They appear as multiple, alternating bright and dark lines – “ringing”. 
2) Motion artefacts caused by breathing, cardiac movement, CSF pulsation/blood flow, patient’s 
movement, which create ghost artefacts. They can be reduced by patient immobilization, 
cardiac/respiratory gating, saturation bands, or drugs that slow down the intestinal peristalsis. One 
can also reduce motion artefacts by using echo-planar imaging, a very fast MR imaging technique. 
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3) Aliasing artefacts occur when the anatomical structures located outside the field of view are 
mapped at the opposite end of the image. One can eliminate them by increasing the field of view. 
4) Chemical shift artefacts appear as dark or bright bands at the lipid-water interface and are seen 
especially in case of fluid-filled structures surrounded by fat (e.g. eye balls in the orbits, bladder). 
They tend to by less prominent on T1-weighted images than on T2-weighted images.  
5) Others – technical literature uses many different names for artefacts, e.g. banding artefact, pile-
up artefact, peripheral signal artefact, spike noise artefact, blurring artefact, suppression artefact 
etc.8 
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Perfusion imaging 
 
Perfusion is one of the most important physiologic and pathophysiologic parameters and can be 
assessed non-invasively with MRI 9. There are several techniques to derive perfusion-related 
parameters which can be mainly grouped in three categories. The first approach is called dynamic 
contrast enhanced (DCE-) MRI and acquires a series of rapid (less than 20 seconds per image) 
T1-weighted imaging studies following the bolus administration of a gadolinium-based contrast 
agent. These images are typically acquired using spoiled gradient echo, T1-weighted 
magnetization prepares or echo planar techniques. The second approach is called dynamic 
susceptibility contrast (DSC-) MRI and is useful if the contrast agent remains in the blood vessels 
(such as in cerebral tissues with an intact blood brain barrier). In this case, the paramagnetic nature 
of the contrast agent increases the local tissue susceptibility, causing an increase in the T2* 
dephasing of the nearby tissues. Serial T2*-weighted gradient echo or echo planar sequences are 
acquired, and the well-perfused tissue exhibits a reduction of signal relative to the pre-contrast 
images or the poorly perfused tissues. The third approach does not use any contrast media to 
highlight the flowing spins and is called arterial spin labelling (ASL). It acquires two set of 
images: one set following a region selective inversion pulse that inverts or “tags” the spins outside 
the slice of interest, whereas the other set of images serves as a reference 4.  
 
We will focus on the quantification of dynamic contrast enhanced MRI data. 
 
DCE-MRI 
 
Dynamic contrast enhanced magnetic resonance imaging is based on dynamic T1-weighted 
imaging of contrast reagent (CR) extravasation over several minutes in order to track the first-
pass bolus 10. The acquired signal is used to generate a so-called time intensity curve for the tissue, 
which mirrors the response of the tissue to the arrival of CR in enhancement values. The analysis 
of this curve allow the estimation of physiological properties related to the microvascular blood 
flow, such as vessel permeability, vessel surface area product and tissue volume fractions 11. The 
underlying principal of all variations of DCE-MRI studies is rather simple: as a paramagnetic 
particle enters and disperses through the tissue, it alters the MR signal intensity of the tissue 
depending on its local concentration. MR images are acquired every few seconds before, during, 
and after a CR is intravenously injected. Each image acquired corresponds to one time point, and 
each pixel in each set of images generates its own curve of intensity values. Since the induced 
variation in signal intensity (correlating to the CR concentration in the tissue) at every time point 
after injection depends on tissue vascularization, the permeability of the vessels, the vessels’ 
surface area product, extraction fraction, blood flow, etc., parametric maps of specific 
microvascular biomarkers can be derived. Moreover, absolute values of these parameters can be 
extracted using appropriate mathematical models. These parameters reflect the two-compartment 
pharmacokinetics exhibited by CRs, which are distributed between the intravascular and 
extravascular spaces 11.  
 
- Image acquisition 
The number of measurements required for data acquisition is dependent on the quantification 
method chosen. These measurements include: 
1) Recording a map of pre-contrast native T1 values (T10 map): this map is necessary for the 
calculation of CR concentrations 12. 
2) Acquisition of heavily T1-weighted images prior and following CR introduction: at a 
reasonably high temporal resolution in order to be able to characterize the kinetics of the CR entry 
and exit out of the tissue 13. 
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3) Acquiring the arterial input function (AIF): estimation of the CR concentration in the blood 
plasma of a feeding artery as a function of time. Obtaining the AIF is essential for nearly all 
quantitative analysis methods and remains technically the most challenging part in the process of 
data acquisition. 
For simple semi-quantitative analysis of signal intensity (SI) curves measurement will suffice. 
For additional CA-concentration values measurement must also be included. For quantitative 
pharmacokinetic analysis, which is able to yield absolute metrics, all three measurements are 
necessary 11. 
 
- The arterial input function 
When calculating the various vascular parameters, mathematical pharmacokinetic models assume 
that the CR arrives in a vessel entering the tissue in the form of an ultra-narrow bolus (i.e., impulse 
input of tracer also known as the residue or residual response) 11. Only this curve can be used to 
extract quantitative information pertaining intrinsic tissue properties. In reality however, the 
concentration time course of the CA in a vessel entering the tissue (the AIF) differs substantially 
from the ideal form, therefore the residual function cannot be measured directly. To solve this 
problem concentration time courses of both the tissue and a feeding artery (AIF) are measured 
whereupon these two curves can be used to reconstruct the sought after residual function 14. 
Three main approaches have been developed for AIF estimation (I-III) and two further approaches 
(IV,V) eliminate the requirement for its measurement: (I) invasive 15; (II) assuming an average 
AIF for all subjects; (III) acquiring the AIF from the DCE-MRI data sets 16; (IV) reference region 
models 17 and the (V) step input method 18. 
 
 
DCE-MRI data analysis 
The arrival of CR and thus the enhancement pattern of the tissue depend on a wide variety of 
factors including vascularity, capillary permeability, perfused capillary surface area, volume and 
composition of extracellular fluid, renal clearance and perfusion. The analysis of DCE data can 
provide valuable information concerning the vascular status and perfusion. Analysis of the data 
can be performed using either: simple semi-quantitative methods, analysis of curve morphology 
or quantitative methods 11. 
 
 
- Semi-quantitative analysis 
Simple semi-quantitative metrics are derived directly from the signal intensity curve alone. They 
are easy to calculate and do not have any rigorous requirements in terms of data acquisition 19.  
Semi-quantitative analysis has several advantages: it obviates the need for the measurement of 
the AIF, it is robust, and several parameters such as AUC are relatively independent of injection 
protocols (36). One challenging aspect, however, is the fact that semi-quantitative parameters do 
not necessarily have any obvious physiological correlates. Since they represent a mixture of 
microcirculatory and tissue properties, the degree to which each of these physiological parameters 
contributes to the MR-signal, remains unknown 11. A further limitation is that most Model-free 
parameter extraction methods remain sensitive to variations between different acquisition 
protocols. Parameter metrics will depend on factors such as sequence parameters, hardware 
settings, scan duration, amount of administered CR 20, CA properties, injection protocol and so 
on. This will occur even if identical sequences are used since the baseline signal for any given 
tissue, using a particular sequence, will differ by the choice of imager. As a consequence, 
comparison of semi-quantitative studies is difficult at best. Semi-quantitative analysis has 
demonstrated clear diagnostic value in a number of areas. For instance, in oncological studies 21,22 
including the assessment of tumour angiogenesis 23 but also in studies of rheumatoid illnesses 24, 
the heart 25 and of musculoskeletal perfusion evaluation. 
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- Morphologic analysis 
This method attempt to assign physiological and pathological findings based on tissue activity 
curve patterns 11. Though not quantitative, this approach offers some appealing advantages: (I) it 
is less sensitive to variations in sequence parameters and scanner calibrations; (II) it is not 
computationally demanding as fitting is not involved; (III) it does not rely on any assumptions 
(some more, some less physiological) as model based methods do 11. For example, in the skeletal 
muscle a rapid signal intensity increase followed by a narrow peak and consequent washout is 
evident of an adequate vascular reserve. But if the time intensity curve (TIC) displays a shallow 
increment, a delayed peak and only a weak or absent washout after exercise, this indicates a 
limited vascular reserve 26. 
 
- Quantitative analysis 
DCE-MRIs’ greatest appeal is its ability to produce parameters, directly related to the 
physiological (and pathophysiological) properties of the vascular environment and the 
surrounding tissue, in absolute terms 11. In order to describe and analyse the temporal and physical 
distribution of an inert tracer, the classical pharmacokinetics usually utilizes linear compartmental 
models. A compartment is defined as a distinguishable tracer distribution space (anatomic, 
functional or fictive) within a biological system. Inside this space, the tracer spreads rapidly 
whereas the transport between adjacent compartments is hindered in some way, resulting in 
individual time concentration courses of the tracer in the different compartments. As CRs 
distribute at different rates in blood and tissue, a two-compartment model considers the 
intravascular-extracellular volume fraction (blood plasma) to be the central compartment, and the 
extravascular-extracellular volume fraction (ve) as the peripheral compartment. The fundamental 
physiological variables governing CR movement across the vascular endothelium include vessel 
wall permeability, vessel surface area, blood flow (i.e., perfusion), ratios of the CR concentrations 
across the endothelium as well as intravascular and extracellular-extravascular volume fractions 
11. 
The purpose of the model is to describe the underlying physiological phenomenon in 
mathematical terms in order to enable the estimation of specific tissue parameters from the 
measured signal.  
We will consider the main four pharmacokinetic models implemented in the analysis of DCE-
MRI data. 
 
--  Tofts Model (TM) 
The Tofts model, also known as the standard model, assumes a linear dependence of R1 on [CR] 
(that is the equivalent of assuming the equilibrium transcytolemmal water exchange kinetics in 
the fast exchange limit (FXL)): 
 á>(I) = 	 ú>[?á(I)] + á>u 18) 
 
where r1 is the CR relaxivity. The extravasation of the contrast from the plasma to the 
extravascular extracellular space (EES) is accounted by the Kety-Schmidt rate law 27: 
 [?á+(â)] = =,'(/n ∫ [?á[(I)]DY5ù71h(ûü5)83 HI,u  19) 
 
where Ktrans is the first order rate constant for plasma to interstitium CR transport ([1/min]) and 
ve is a measure of the EES volume fraction. The ratio between Ktrans and ve results in the third 
pharmacokinetic parameter kep, that is the back flux rate constant [1/min]. [CR0] and [CRp] are 
the concentration of CR in the 'outside' space and in the plasma, respectively [CRp] is the arterial 
input function. 
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--  Shutter speed model (SSM) 
Applying equation 1 to the distribution of the CR in the blood, the longitudinal relaxation rate 
results: 
 á>b(I) = 	ú>[(1 − ℎ)°?á[(I)¢ + á>u[ 20) 
 
where b is for the whole blood, p for the plasma and h is the haematocrit. However, about half 
the water in blood is intracellular and cannot be accessed directly by the CR molecules 28. The 
transport outside the erythrocytes is then required. This is described by these two equilibriums:  
 
H2Oi ↔ H2Op                             21) 
H2Op+ CRp↔H2O·CRp               22) 
 
Usually, the mean water molecule lifetime on common CRs is < 10-7 s, leading to the linear 
equation 1 suitable for homogeneous solutions. In case of erythrocytes, (22) is also fast at some 
practical [CRp] values 28,29. After extravasation, CRs commonly distribute into the interstitial 
extracellular space: 
 á>∗(I) = 	 ú>u£u[?áu(I)] + á>u 23) 
 
R1*(t) is the rate constant of the extravascular water signal, r10 is the interstitial CR relaxivity and 
p0 is the fraction of the extracellular tissue water. The application of (23) to biological tissues 
assumes that the interstitium is a homogeneous solution and that the system remains in the fast 
exchange limit. On the contrary, many studies have shown that, even though the equilibrium in 
(22) is fast, it is insufficiently frequent for the FXL assumption to be true at all [CR0] values 
following a bolus injection 28. This depends on the dimensions of the parenchymal cells that are 
generally much larger than erythrocytes and have a less water-permeable cytolemmae. Therefore, 
tissue parenchyma cannot be considered as a single homogeneous solution. It is 
compartmentalized on the scale of the MRI voxel. The main result of this compartmentalization 
is given by:  
 á>§(I) = (1 2⁄ ){2á>* + 	ú>+[?á+(I)] +(á>u + á>* +	1 w*⁄ ) £+ − {(2 w* − ú>+[?á+(I)] −	⁄⁄ (á>u + á>* +	1 w*⁄ ) £+⁄ )B +4(1 − £+) w*B£+⁄ ]OG}          
         24) 
 
where R1L(t) is the long relaxation rate constant of the shutter speed model. R1i is the H2O rate 
constant in the absence of exchange and τi is the average intracellular water lifetime of a water 
molecule.  
 
--  Extended Tofts model (ETM) 
While the TM assumes a negligible volume for the plasma compartment, the extended Tofts 
model introduces the fractional plasma volume vp. This model is able to distinguish enhancement 
effects due to contrast leakage from those due to intravascular contrast. Eq. (19) becomes: 
 [?á+](â) = 	P[?[(I) + 	=,'(/n ∫ ?[(I)mu DEN5ù71h(mE,)/©3HI 25) 
 
--  Extended shutter speed model (ESSM) 
The extended shutter speed model allows the evaluation of the blood water exchange effect on 
the overall signal decrease. The contribution of the water signal from the three compartments 
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(whole blood, EES and intracellular space) is described by the matrix format of the Bloch equation 
30: 
 )™), = ´™+ ¨ 26) 
 
where the column vectors are M = (Mb, Mo, Mi) and C = (Mb0R1b, Mo0R1o, MioR1i) where M ~ to 
the signal S. The exchange matrix X is:  
 ´ = ≠	−(á>b + Ab+)	 A+b 0Ab+ −(á>+ +	A+b + 	A+*) A*+0 A+* −(á>* + A*+)Æ 27) 
 
The subscripts b, o and i stand for blood, outside space and intracellular space, respectively. M 
is the 1H2O magnetization vector and kbo (= 1/τb) represents the blood to interstitium transfer; kio 
(= 1/τi) represents the interstitium to EES transfer; kob (~ 1/τo) the EES to blood transfer and koi 
the EES to intracellular transfer 30. The general solution to eq. 26 is the matrix form of the Ernst-
Anderson relationship 31 which assumes that, if the [CR] change is relatively small during the 
acquisition, at every discrete data acquisition time point, the relaxation time can be well estimated: 
 Ø = [∞ −	DE´m±(cos q)]E>(∞ − 	DE´m±)Øµ(sin q) 28) 
  
 
 
Applications 
 
The application of pharmacokinetic models on DCE-MRI brain data is based on the conference 
paper funded in part by the National Institute for Health Research (NIHR) Imperial Biomedical 
Research Centre (BRC), the Brain Tumour Charity and the Brain Tumour Research Campaign: 
 
Inglese M, Honeyfield L, Aboagye OE, Waldman AD, Grech-Sollars M Comparison of the Tofts 
and the Shutter Speed Model for DCE-MRI in patients with Brain Glioma ISMRM 2018 (magna 
cum laude) 
 
 
I. Comparison of the Tofts and the Shutter Speed Models for 
DCE-MRI in patients with Brain Glioma 
 
DCE-MRI is a powerful technique able to quantitatively measure patho-physiological 
environments through the passage of a contrast reagent (CR) and model-based pharmacokinetic 
analysis. The accuracy of quantitative measurements of perfusion parameters by DCE-MRI is 
crucial as it can significantly impact the clinical care of cancer patients. In this study, we provide 
a method to identify reliable DCE-MRI brain data for perfusion quantification with different 
pharmacokinetic models.  
We analysed DCE-MRI data of 14 patients with primary brain tumours using the Tofts model 
(TM), the extended-Tofts model (ETM), the shutter speed model (SSM) and the extended shutter 
speed model (ESSM). Due to the presence of the blood brain barrier, which can block the leakage 
of the CA into the interstitium, we also implemented the no-exchange model (NEM). For each 
lesion, we produced a 3D model selection map with the evaluation of the Akaike Information 
Criteria. The variability of each pharmacokinetic parameter extracted from the fitting of the model 
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of choice was assessed with a noise propagation procedure, resulting in distributions of the 
coefficient of variation (CV). 
Results showed the NEM to be the most frequent model of choice (35.5%), followed by the ETM 
(32%), the TM (28.2%), the SSM (4.3%) and the ESSM (<0.1%). In analysing the reliability of 
Ktrans, when considering regions with a CV<20%, ≈25% of voxels were found to be stable. The 
remaining 75% of voxels were considered to be unreliable. 
In conclusion, an appropriate model selection, considering tissue biology and its effects on BBB 
permeability and exchange conditions, together with an analysis on the reliability and stability of 
the calculated parameters, is critical in the identification of reliable brain DCE-MRI data.  
 
1. Introduction 
 
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a non-invasive 
methodology that allows tissue perfusion and permeability to be quantified through analysis of 
T1-weighted MR images acquired before, during and after an intra-venous (IV) injection of a 
gadolinium-based contrast agent (CA). These all comprise of highly paramagnetic gadolinium 
(Gd) ions chelated within an organic molecule, with the structure of the latter varying between 
specific contrast agents32. They are hydrophilic compounds and do not cross cell membranes to 
enter the intracellular compartment, nor do they cross the intact blood brain barrier (BBB). As the 
CA perfuses the tissue under investigation, the paramagnetic effect of the Gd-chelate causes a 
decrease in tissue water longitudinal relaxation time approximately linearly-related to the local 
CA concentration (T1). A set of T1-weighted dynamic images are acquired during this time in 
order to extract the voxel-wise characteristic signal intensity time curves which are related to the 
CA concentration time curves33. These curves are then fitted to mathematical models to calculate 
physiological parameters, such as volume transfer constants and volume fractions. The most 
extensively used model is the Tofts model (TM), which expresses the flux of the tracer across 
two well-mixed compartments (blood and the extravascular, extracellular space) through the 
volume transfer constant Ktrans 33. The TM assumes negligible plasma compartment and is ideal 
for the description of weakly vascularized tissue. An extended version of this model was 
introduced by Tofts in 1999 in order to account for highly perfused tissue34. The Extended Tofts 
model (ETM) therefore fits data with an additional parameter: the fractional plasma volume, vp 
34. Both the TM and ETM embed the implicit assumption that equilibrium transcytolemmal water 
exchange (between the intracellular space and extracellular extravascular space) is infinitely fast, 
or that the system is in, what is called, the fast exchange limit (FXL) 35. Water exchange between 
the intracellular space and the extracellular extravascular space effects the degree of T1 shortening 
caused by CA. This effect on the MRI signal amplitude is incorporated within the shutter speed 
model (SSM). The SSM thus introduces a new pharmacokinetic parameter, the mean intracellular 
water molecule lifetime, τi 35. However, similarly to the TM, the SSM ignores any contribution of 
the CA from the plasma compartment. This is accounted for by the extended shutter speed model 
(ESSM), which includes both vb, the fractional blood volume and τb, the intravascular water 
molecule lifetime 30. 
The TM and ETM are regularly applied in the field of oncology to assess treatment response 36 
and in the study of blood-brain barrier disruption 37-44. The SSM has been mainly implemented in 
the study of breast cancer 45, prostate cancer 46 and hepatocellular carcinoma 47. There are few 
examples of the application of SSM in brain tumours in the literature 48,49. The ESSM, also called 
second generation shutter speed model, or BALDERO (blood agent level dependent and 
extravasation relaxation overview), has previously found applications only in hepatocellular 
carcinoma 50 and simulated data 30.  
The above models assume that the CA passes readily between the intravascular compartment and 
the tissue interstitium. However, this assumption is not valid in the presence of the intact BBB, 
where there is negligible leakage. In this case the CA will only affect the intravascular T1 value 
on first pass of the bolus. In the no-exchange model (NEM), we assume that this has negligible 
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effect on the overall T1 value, and therefore the model describes those instances where the CA 
has no effect on the MR signal. 
In this study we propose a method for the identification of reliable DCE-MRI data. DCE-MRI 
data can be affected by a) the acquisition protocol (trade-off between spatial and temporal 
resolution)51, b) the quantification procedure, which, in this specific case of brain tumours, has to 
take into consideration the issue of the BBB. Following on from previous work carried out by 
Bagher-Ebadian et al. 42, we start with a model selection procedure using the Akaike information 
criteria index where we compare the five pharmacokinetic models previously described (NEM, 
TM, ETM, SSM and ESSM) in patients with primary brain tumours. Given that a model selection 
procedure alone cannot guarantee final reliable results, we evaluate the stability of each parameter 
extracted from the model of choice, in terms of coefficients of variations (CVs), with a noise 
propagation procedure. 
 
2. Materials and Methods 
 
2.1 Patient Population 
14 patients (7 male, 7 female; aged 23-73 years, mean 40 years) with primary brain tumours were 
recruited to this study. Ethical approval was given by the local ethics committee and informed 
consent was obtained from all patients. Patients had an MRI at diagnosis, prior to receiving any 
treatment. Following surgery, histopathological data showed 3 patients with WHO grade IV 
glioblastoma, 2 patients with WHO grade III astrocytoma, 2 patients with WHO grade III 
oligodendroglioma,  3 patients with WHO grade II astrocytoma, 3 patients with WHO grade II 
oligodendroglioma,  and 1 patient with a WHO grade I dysembryoplastic neuroepithelial tumour.  
 
2.2 DCE-MRI Data Acquisition 
MR images were acquired on a 3T Siemens Verio MRI system using a 32 channel head coil; 
including pre- and post-contrast T1-weighted images, T2-FLAIR images and a DCE sequence with 
a variable flip angle pre-contrast T1 map acquisition. The DCE-MRI protocol included five pre-
contrast spoiled gradient recalled echo (SPGRE) 3D vibe sequences at five different flip angles 
(2, 8, 12, 15, 20, 26), and a dynamic 3D vibe sequence (TR = 3.34 ms, TE = 0.99 ms, flip angle 
= 26, FOV: 240 x 240 mm, acquisition matrix 128x128, slice thickness 5 mm, slice gap 1 mm, 
80 volumes). To obtain acquisitions before, during and after the injection of the contrast agent, 
0.1 mmol/kg body-weight gadolinium-diethylene triaminepentacetate (Gd-DTPA, Gadovist), was 
injected using a power injector on the 5th acquisition using a flow rate of 3 ml/s. The 3D 
acquisition allowed us to cover the entire brain. 80 time points were acquired with an average 
temporal resolution of 2.89 s and a total acquisition time of » 4 minutes.  
 
2.3 DCE-MRI Data Analysis 
Volumes of interest (VOIs) were drawn by a Radiologist and confirmed by a Consultant 
Neuroradiologist for each patient around T2-FLAIR hyperintense regions and on a 2 cm diameter 
circular region in normal-appearing contra-lateral white matter. DCE-MRI data were analysed 
using a semi-automated in-house software written in MATLAB (Mathworks, R2017a). Before 
the application of any of the aforementioned pharmacokinetic models, we calculated the 
relaxation rate at baseline (R10) and relaxed signal (M0) as 3D maps, with the Ernst formula 
(assuming TE<<T2*) using the set of SPGRE pre contrast images acquired at different flip angles 
52:   "(q) = ∂u	sin(q) >E.ü±Olû±>E∑∏π	(∫).ü±Olû±   1) 
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where α is the flip angle having values [2, 8, 12, 15, 20, 26] and TR is 3.34 ms. Reformulating 
equation 1 as a linear regression system (y = cx + d) following the method described by Liberman 
et al. in 53,gives: 
 ª(∫)πñº(∫) = Ω ª(∫)æøº(∫) + ∂(1 − Ω)    2) 
 
where Ω = DE¿Olm± .  
The slope c = E and intercept d = M0 (1 - E) can thus be estimated and continuing from 53, R10 
and M0 can then be obtained through:  
 á>u =	− ¡∏¬	(-)m± ,  ∂u = )>E-   3) 
 
Then, 4D (x, y, z, t) post-injection longitudinal relaxation rate R1(t) maps for each dynamic phase 
are calculated using signal intensity data from the post contrast dynamic series: 
 á>(I) = 	−(1 â¿√ )ƒ≈∆ >E(«W`)>E∑∏π	(∫)(«W`)     4) 
 
where α = 26, î = "(I) − "(0) ∂usin	(q)⁄ , ö =	 (1 − Ω) 1 − Ω	 ∙ cos	(q)⁄ . S(0) and S(t) are the 
pre contrast injection signal intensity and the signal at the dynamic phase t respectively 54. 
 
The longitudinal relaxation rate is determined in order to calculate the concentration of the 
contrast agent. This is done through a calibration between the concentration of contrast agent 
[CA] and the measured H2O MR signal. This can be modelled by either a linear or nonlinear 
relationship as described below.  
 
2.3.1 Tofts Model (TM) 
DCE-MRI data were fitted with the Tofts model assuming a linear dependence of R1 on [CA] 
(that is the equivalent of assuming the equilibrium transcytolemmal water exchange kinetics in 
the FXL): 
 á>(I) = 	 ú>[?î(I)] + á>u      5) 
 
where r1 is the CA relaxivity.  
The extravasation of the contrast from the plasma to the EES was accounted by the Kety-Schmidt 
rate law 27: 
 [?î+(â)] = =,'(/n ∫ [?î[(I)]DY5ù71h(ûü5)83 HI,u      6) 
 
where Ktrans is the first order rate constant for plasma to interstitium CA transport (min-1) and ve 
is a measure of the EES volume fraction.  
The ratio between Ktrans and ve results in the third pharmacokinetic parameter kep, which is the 
back flux rate constant (min-1). [CA0] and [CAp] are the concentration of CA in the 'outside' space 
(the extravascular extracellular space) and in the plasma respectively. [CAp] is also called the 
arterial input function (AIF). The fitting of equation 6 was performed using the inbuilt MATLAB 
fminsearch function, which uses the Nelder-Mead simplex algorithm as described in Lagarias et 
al. 55. The minimization procedure is done voxel-wise in order to obtain a 3D map for each 
pharmacokinetic parameter. We set input values of 0.1 and 0.01 for the Ktrans and ve, respectively, 
and run the algorithm with 10,000 iterations and a tolerance of 10-8. The fitting procedure was 
also carried out with the user developed MATLAB function fminsearchbnd 56. This function takes 
into consideration boundaries in the output values settings, which were set so as to consider only 
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positive values [0, ∞]. A comparison between the two functions’ results was done in terms of 
goodness of fit by estimating the Akaike Information Criteria (AIC) for each method using 
equation 7: 
 îÜ? = 2A + …ƒ…  ¿ªª/ À + BF(FW>)/EFE>    7) 
 
where n is the number of data points, k the number of fitted parameters and RSS is the residual 
sum of squares 57.  
In general, when performing model selection using the AIC, the model resulting with the lowest 
AIC value is the model that represents the best balance between complexity (i.e., the number of 
parameters) and goodness of fit (i.e., lower RSS). In this case, as the number of parameters is the 
same, only the goodness of fit is being tested. A comparison between the AIC maps relative to 
the bounded and unbounded procedure allowed the estimation of final Ktrans, kep and ve maps 
where the value of each voxel was obtained from the fitting procedure with the best fit (lowest 
AIC) (Figure 36).  
 
Figure 36: The fitting procedure for Ktrans. A bounded and unbounded fitting were calculated together with the 
Akaike Information Criteria (AIC) map (AICb and AICu for the bounded and unbounded procedure, 
respectively). The final value of Ktrans, for each voxel of the map, was the one obtained from the function with 
the lowest AIC (kb when AICb < AICu and ku vice versa). The same procedure was carried out for each 
parameter. 
 
2.3.2 Shutter speed model (SSM) 
In the SSM, equation 5 is applied to the distribution of the CA in the blood, without assuming 
that the equilibrium transcytolemmal water exchange kinetics are in the FXL. The longitudinal 
relaxation rate is measured as: 
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á>b(I) = 	ú>[(1 − ℎ)°?î[(I)¢ + á>u[  8) 
 
where b stands for the whole blood, p for the plasma and h the blood haematocrit . However, 
about half of the water in the blood is intracellular and cannot be accessed directly by the CA 
molecules 28. The transport outside the erythrocytes therefore needs to be considered, as described 
by the two equilibria:  
 
H2Oi ↔ H2Op                        9) 
H2Op+ CAp↔H2O·CAp                10) 
 
The mean water molecule lifetime in common CA is normally < 10-7 s, and the linear equation 5 
is suitable for homogeneous solutions. In the case of erythrocytes, equation 10 is also considered 
fast for some commonly measured [CAp] values 28,29. After extravasation, the CA is commonly 
distributed into the interstitial extracellular space, at a rate defined by: 
 á>∗(I) = 	 ú>u£u[?îu(I)] + á>u     11) 
 
where R1*(t) is the rate constant of the extravascular water signal, r10 is the interstitial CA 
relaxivity and p0 is the fraction of the extracellular tissue water. The application of equation 11 to 
biological tissues assumes that the interstitium is a homogeneous solution and that the system 
remains in the fast exchange limit. However, many studies have shown that, even though the 
equilibrium in equation 10 is fast,  the FXL assumption is not true for all [CA0] values following 
a bolus injection 28. [CA0] depends on the dimensions of the parenchymal cells that are generally 
much larger than erythrocytes and have a less water-permeable cytolemmae. Furthermore, tissue 
parenchyma cannot be considered as a single homogeneous solution and a single MRI voxel will 
constitute a number of compartments. The main result of this compartmentalization is given by:  
 á>§(I) = (1 2⁄ ) Ã2á>* +	ú>+[?î+(I)] +(á>u + á>* +	1 w*⁄ ) £+ − {(2 w* − ú>+[?î+(I)] −	⁄⁄ (á>u + á>* + 	1 w*⁄ ) £+⁄ )B +4(1 − £+) w*B£+⁄ ]OGÕ    12) 
 
where R1L(t) is the long relaxation rate constant of the shutter speed model. R1i is the H2O rate 
constant in the absence of exchange of CA and τi is the average intracellular lifetime of a water 
molecule. The SSM was fitted by substituting equation 12 in equation 6 using the MATLAB 
functions fminsearch and fminsearchbnd, similarly to the TM. The initial estimates for the SSM 
Ktrans and ve where taken as the outputs of the TM, while the initial estimate for τi was set at 0.1 
30. The final Ktrans, kep, ve, and τi maps were obtained from the fitting procedure with the best fit 
(lowest AIC value) as described in Figure 36.  
 
2.3.3 Extended Tofts model (ETM) 
While the TM assumes a negligible volume for the plasma compartment, the fractional plasma 
volume vp is introduced in the ETM. This model is able to distinguish the effects due to contrast 
leakage from those due to intravascular contrast. Equation 6 becomes: 
 [?î+](â) =	 P[?[(I) +	=,'(/n ∫ ?[(I)mu DEN5ù71h(mE,)/©3HI  13) 
 
The ETM was fitted by substituting equation 13 in equation 6 using the MATLAB functions 
fminsearch and fminsearchbnd, similarly to the TM and SSM. The initial estimates for ETM Ktrans 
and ve were again taken from the output of the TM and the initial estimate for vp was set at 0.01 
30. The final Ktrans, kep, ve, and vp maps were obtained from the fitting procedure with the best fit 
(lowest AIC) as described in Figure 36. 
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2.3.4 Extended shutter speed model (ESSM) 
We implemented the ESSM to evaluate the effect of the water exchange between the vasculature 
and the extracellular extravascular space on the overall signal decrease. The contribution of the 
water signal from the three compartments (whole blood, EES and intracellular space) is described 
by the matrix format of the Bloch equation 30: 
 )™), = ´™+ ¨       14) 
 
where the column vectors are M = (Mb, Mo, Mi) and C = (Mb0R1b, Mo0R1o, Mi0R1i) with the 1H2O 
magnetization vector M » to the signal S. The exchange matrix X is given by:  
 ´ = ≠	−(á>b + Ab+)	 A+b 0Ab+ −(á>+ +	A+b + 	A+*) A*+0 A+* −(á>* + A*+)Æ  15) 
 
The subscripts b, o and i stand for blood, outside space and intracellular space, respectively. kbo 
(= 1/τb) represents the blood to interstitium transfer of water; kio (= 1/τi) the transfer of water from 
the intracellular space to the  interstitium; kob (proportional to 1/τo) the EES to blood transfer and 
koi the EES to intracellular transfer 30. The general solution to equation 13 is the matrix form of 
the Ernst-Anderson relationship 31 which assumes that if the change in [CA] is relatively small 
during the acquisition, at every discrete data acquisition time point, the relaxation time can be 
estimated using: 
 Ø = [∞ −	DE´m±(cos q)]E>(∞ − 	DE´m±)Øµ(sin q)    (16) 
 
I is the identity matrix and S0 (= (Sb0, So0, Si0)) is the signal at baseline. 
The ESSM was fitted by considering the measured signal E(t) as a combination of the signals in 
the three compartments (blood, outside space and intracellular space) 50 using: 
 Ω(I) = 	 ªŒWªœWª0ªŒlWªœlWª0l − 1  (17) 
 
Furthermore, equation 16 was simplified to: 
 Ø = sin(K) ∙ –	 ∙ 	Øµ  (18) 
 
where the column vectors are S = (Sb, So, Si) and – = [∞ − 	DE´m±(cos q)]E>(∞ − 	DE´m±).  
The model was fitted by substituting equation 18 into equation 17 using the MATLAB function 
fminsearch function. The outputs of the SSM model were used as the initial estimates for Ktrans 
and vo and one third of the measured signal was used as the initial estimate for Sb0, So0 and Si0. 
Furthermore the initial estimates for kbo, kob, koi and kio, were taken from literature defined values 
as 1.2, 1.5, 1.1 and 1.2 respectively 30. The following parameters were also derived: τb=1/kbo, 
τi=1/kio, vb = (kob – koi – ((kio/vo)*fw) – kio)/((kbo+kio)/vo) where fw is tissue volume fraction 
accessible to mobile aqueous solutes (assumed to be a constant and set to 0.8) and vi = 1 - (vb + 
vo) 30.  
 
2.3.5 No-exchange model (NEM) 
The no-exchange model describes the case where the concentration of the CA in a voxel is so low 
that there is no permeability or vascular filling. In this situation, the MR signal is assumed to be 
unperturbed by the injection of the gadolinium based CA and, as a consequence, the longitudinal 
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relaxation rate does not change from its baseline value (R10). The system is therefore described 
by this value at all times such that the data is fitted by the constant R10. 
 
2.4 Arterial Input Function (AIF) 
An additional ROI was drawn around the external carotid artery for the calculation of the image 
derived AIF (Figure 37). Signal-intensity curves were converted to R1-time curves by using the 
baseline signal intensity before the first pass of the CA as a reference 58, setting the haematocrit 
in the blood to 0.45, and getting the baseline blood T1 from the T10 map (equation 8).  
 
Figure 37: Measurement of the AIF. The VOI was placed in the carotid artery for the extraction of the arterial 
input function (AIF) as shown in the axial T1 VIBE image in (A). The time intensity curve for the concentration 
of contrast reagent in the plasma in the VOI indicated in red in (A) is shown in (B). 
 
2.5 Model comparison 
A model comparison was carried out using the AIC to test for the best model in a given voxel. In 
particular, in the presence of exchange (where the NEM fails in the description of data), a voxel-
wise comparison between models was carried out (with ETM and SSM being an extension of the 
TM, and the ESSM an extension of the SSM) to indicate which model provided the best fit using 
the AIC in each voxel. The selection method is shown in the flowchart in Figure 38. The choice 
was expressed with a value of 1, 2, 3, 4 or 5 for the TM, ETM, SSM, ESSM and NEM 
respectively, in a volumetric mask (same dimensions of the original tumour volume mask). The 
percentage of 1s, 2s, 3s, 4s and 5s in each mask was evaluated to quantify the frequency of model 
choice. The model selection map was used to build final pharmacokinetic maps for the Ktrans, kep 
and ve, where, for each voxel, the value is the result of the fitting of the model of choice (lowest 
AIC).  
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Figure 38: AIC model selection flowchart. The figure shows the hierarchical approach used to determine which 
model provided the best fit when using the Akaike Information Criteria (AIC). 
 
2.5.1 Stability of pharmacokinetic parameters  
Once the model selection was done, the stability of each parameter within the winning models 
was evaluated in a simulation environment. Tissue curves were generated back from the extracted 
pharmacokinetic parameters and signal intensity curves were calculated with the inverse formula 
of eq. 4. White Gaussian noise was added to the signal intensity curves using an SNR of 20. The 
SNR value for the simulated data was set by evaluating the SNR of the acquired data from the 2nd 
and 3rd phase of the dynamic acquisition sequence using the subtraction method59. The simulated 
noisy signal intensity curves were reconverted to noisy tissue concentration curves, and fitted to 
the selected pharmacokinetic model. This procedure was repeated 500 times for every kinetic 
parameter and the variability of each parameter was expressed in terms of coefficient of variation 
(CV): the percentage ratio between the standard deviation and the mean.  
 
3. Results 
 
3.1 Model selection and parameter variability 
The behaviour of each model was assessed by studying the quality of fit for each of the models.  
The input data, together with the fitted curves, were normalized by the maximum value of the 
input data in order to compare results from the different fits. An example of a comparison of fit 
is shown in Figure 39. 
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Figure 39: Normalized signal intensity curves in a voxel of an enhancing lesion fitted with the no-exchange model 
(red), TM (blue), ETM (green), SSM (yellow) and ESSM (pink). The quality of fitting was evaluated with the 
Akaike Information Criteria. AIC value: -103 for the NEM, -445 for TM, -454 for ETM, -531 for SSM and -291 
for ESSM. 
 
For each tumour, a map with the result of the statistical comparison among models was built 
(Figure 40). In this map, each colour represents the model for which the voxel-wise AIC value 
was lowest. The NEM resulted to be the model of choice by the majority of voxels (35.5 %), 
followed by the ETM (32 %), the TM (28.2%), the SSM (4.3%) and the ESSM (< 0.1%). Figure 
40 shows the model selection map evaluated for two different lesions. 
 
 
Figure 40: Statistical model comparison for two lesions. Each colour is representative of the model which best 
fitted the input data. An example of one slice of an enhancing (A, WHO grade IV) and non-enhancing (B, WHO 
grade II) lesion is shown. 
Furthermore, final pharmacokinetic maps, for the Ktrans, kep and ve, were built considering the 
model selection procedure. Within the final pharmacokinetic maps, each voxel was represented 
by the model with the best fit (lowest AIC) within that voxel. For each of these maps, the stability 
of each parameter and for each lesion was presented in terms of CV maps. Figure 6 shows an 
example of two final Ktrans maps with their CV map overlaid on them (A and D).  
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Figure 41: The stability of each pharmacokinetic parameter extracted from the fitting of the model of choice 
was evaluated, for each lesion, in terms of coefficient of variation in a simulation environment. A and D show 
two Ktrans maps. The reliability of DCE-MRI data was evaluated by setting a threshold of 20% for the CV. This 
is overlaid on the Ktrans maps in A and D, shown in red, such that only values of Ktrans under this threshold are 
displayed on the blue/green colour map. Two tissue activity curves (TACs) relative to two reliable (CV = 12% 
and CV = 4%) voxels are plotted in B and E. C and F show the TACs relative to two unreliable voxels (CV = 
128% and CV = 97%). 
 
4. Discussion  
 
Through an IV injection of a gadolinium-based CA, microvascular permeability is assessed by 
DCE-MRI. This is a powerful and valuable technique, which was found to be indicative of tumour 
histological grade in human brain tumours 60. However, the accuracy of quantitative 
measurements of perfusion parameters by DCE-MRI is crucial as it can significantly impact the 
clinical care of cancer patients 61. Usually, the reproducibility of this technique, and, as a 
consequence, its reliability is improved by improving the main sources of variability in 
quantitative DCE-MRI (the acquisition of data, the quantification software)61. In this retrospective 
study we focused on the quantification analysis taking into consideration the particularly 
heterogeneous nature of brain tumour vascular permeability due to the presence of the BBB. We 
provided a method to identify reliable DCE-MRI data based on a model selection procedure and 
a stability test.   
 
4.2 DCE-MRI models 
MR scanners usually employ post processing perfusion tools which fit DCE data with the TM. 
This model (together with its extended versions 34) considers the system in a fast exchange limit 
62,63, assuming an infinitely fast transcytolemmal water exchange between the EES and the 
intracellular space, which does not affect the overall signal decrease 62,63. Therefore, many studies 
on the cell membrane water permeability coefficient have shown FXL to be physically 
unreasonable and inconsistent 64,65. The shutter speed model was introduced to reflect a more 
realistic tissue environment. The model accounts for the intercompartmental water exchange 
effect, modelling this non-infinitely-fast exchange with the mean intracellular water molecule 
lifetime τi. In 2005, Li et al. introduced a second generation of the shutter speed model which 
considers also a non-infinitely-fast equilibrium transendothelial water exchange30. 
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4.3 Model comparison and stability 
The heterogeneity that exists in brain tumours means that one model is insufficient in explaining 
the different biologies that exist in different tumour regions.  Different pharmacokinetic models 
are required for a complete description of the tissue. This variability is testified by the model 
selection procedure which showed how, in a single slice of one tumour, multiple models perform 
better. This result confirms the study of Bagher-Ebadian where they implemented a selection 
method based on nested models 42. They found that in the necrotic core of the tumour, models 
describing vascular filling with no microvascular leakage (similar to the TM) and leakage without 
vascular reabsorption were selected because of the lack of blood flow. They also hypothesized 
that the model describing leakage with reabsorption (similar to the ETM) would be selected in 
the fast growing rims of the lesion. Our results show that there are a number of regions in the 
tumour where the CA exudation is prevented by the BBB and where the concentration of CA is 
so low that the evidence of permeability is missing. In this case, the use of the NEM is 
recommended as, the use of different models could result only in overfitting the data. In fact, our 
results showed that, no leakage of the CA into the interstitium (or the lack of flow of the CA 
through the tissue) made the NEM the model of choice for the majority of regions, particularly in 
the non-enhancing lesions (37.5% of voxels). The result is very close to the ETM (32%), which 
resulted the model of choice in the enhancing lesions (54.8%). This suggests that, in areas where 
there is enhancement, a model with 3 parameters performs better and that the choice is dependent 
on the underlying state of the tissue. In fact, both the ETM and SSM are fitted by three parameters 
but the third parameter is very different between the two models (vp for the ETM describing a 
vascular component in the tissue, and τi for the SSM describing the transcytolemmal water 
exchange). Furthermore, with the implementation of the ESSM, we saw that the transendothelial 
water exchange did not have any impact on the signal (compared with parameters derived by the 
fitting of simpler models). It is necessary to consider that the ESSM required 9 parameters to be 
fitted and that the cost of fitting extra parameters is often contrary to the principle of parsimony. 
In fact, in fitting data to a noise-limited dataset, the estimation could be very poor and dependent 
on the optimization procedure itself (the initial conditions, for example) 42. We compared the AIC 
values from the different fitting procedures to check whether a model with more parameters is 
more appropriate than a simple one. The ESSM was selected as the model of choice by <0.1% of 
voxels, indicating that a model with 3 parameters performed better in the description of brain 
tumours and further confirming the poor quality of fit observed for the ESSM model. Our outcome 
agreed with the results of Duan et al.66. Using representative in silico and clinical (cervical cancer) 
DCE-MRI data, they demonstrated the sensitivity of complicated models (parameters > 3) to 
noise and their decreasing probability of being selected in low signal-to-noise data66. 
The reliability of DCE-MRI data is not only based on the goodness of fit of the chosen 
pharmacokinetic model, but also on the robustness of the extracted parameters. For this reason, 
we assessed, for each lesion and for each parameter, the coefficient of variation. We worked in a 
simulation environment where we added Gaussian noise to our signal and we fitted the noisy 
curves 500 times. This procedure resulted with a heterogeneous distribution of CVs not linked to 
contrast enhancement. In fact, Figure 41 shows the plot of four different tissue activity curves 
together with the Ktrans value and its CV. As we expected, CV resulted to be very high in regions 
where the Ktrans was very low (figure 6, C and F): this is due to the noisy nature of the input data 
and its consequent high variability. On the other hand, the curves in B and C belong to the same 
enhancing lesion and correspond to Ktrans values of 0.81 and 0.52 [1/min]: they correspond to CVs 
of 12% and 128%, respectively.   
Finally, we set a threshold to differentiate between reliable and unreliable DCE-MRI data 
(CV=20%). We saw that Ktrans values under this threshold of CV covered only 25% of voxels (an 
average percentage value evaluated among all patients). This result suggested that only this 
selection of voxels represents robust values, which can be used in the following statistical 
analyses, as, more importantly, in clinical evaluations. The selection of the threshold that makes 
DCE-MRI robust is, however, dependent on the effect size that is being measured and hence will 
vary across studies. 
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4.4 Limitations and future work 
The main limitation of this study is the small size of the dataset. Furthermore, the sensitivity of 
DCE-MRI data to water exchange effect was reduced by the 26° flip angle acquisition (exchange-
minimized approach) 67,68. As a consequence, the precision of the τi parameter extracted is low. 
Another limitation of the study is related to the long computational time for the CV evaluation in 
the simulation environment (500 iterations). This could be improved by implementing the 
technique using other programming languages or through the implementation of an alternative 
method, such as the Cramer Rao lower bounds69. 
Finally, future work needs to assess the physiological basis for selecting a particular model in the 
reliable selection of DCE-MRI data. The applicability of each model depends on the physiology, 
anatomy and heterogeneity of the tumour and the tumour microenvironment. Future studies will 
also need to assess the textural features of the TM and SSM parameters in heterogeneous regions 
of the tumour in order to validate the model selection results. 
 
5. Conclusion  
 
In conclusion, DCE-MRI methods hold great promise for quantitative in vivo evaluation of 
permeability and vascular properties under different pathophysiological conditions. It allows us 
to identify, and quantitatively measure, smaller changes in permeability for pathological 
conditions effecting the BBB, than would be observed through visual assessment of post-contrast 
T1-weighted images. Different models yield different pharmacokinetic parameters and, for this 
reason, a model selection is critical for the appropriate analysis of DCE-MRI time courses based 
on the regional tissue biology, specifically permeability and vasculature. However, due to the 
unreliable nature of DCE-MRI data, a model selection procedure alone is not enough: 
pharmacokinetic parameters need to be validated with a stability test in order to give only robust 
results for statistical analyses and clinical evaluations. 
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CHAPTER 4 
Multiparametric imaging  
 
Tumours are frequently heterogeneous in their presentation and behaviour. Multiparametric 
imaging allows investigation of this heterogeneity in a comprehensive way with the identification 
of tumour sub-volumes with distinct properties [1]. Nowadays it is possible to gather of a large 
amount of information from the available advanced imaging techniques. CT and MRI both 
provide morphological information. In particular, dynamic contrast-enhanced CT or MRI (DCE 
CT/MRI) allows investigation of the vasculature (e.g. tumour permeability and blood flow) 
typically following injection of a contrast agent over time as it passes through the tumour blood 
vessels. Furthermore, diffusion-weighted MRI (DWI MRI) facilitates mapping of diffusion 
patterns of water molecules, a characteristic related to cellular density. These advanced MRI 
techniques have a role in the standard guidelines for distinguishing malignant involvement from 
benign conditions, for instance in prostate cancer and pleural mesothelioma [1]. 
On the other hand, biological processes, which are disregulated in cancer cells and distinguish 
malignant tissue from healthy tissue, can be visualized using nuclear medicine-based techniques. 
The general PET approach includes the use of FDG, a glucose analogue, whose uptake is 
upregulated in tumours as an indicator of their metabolism. There are many tumour hallmarks 
that can be visualized using PET imaging. One of them is the activity of thymidine kinase 1, an 
enzyme involved in DNA synthesis, as a surrogate for most cell proliferation: it is studied with 
Fluorothymidine (FLT). Low oxygen levels, i.e. hypoxia, are imaged with tracers based on 2-
nitroimidazoles (e.g. FMISO, FAZA, HX4), which allow the visualization of increased reductase 
activity in cells with insufficient oxygen.  
 
Until recently, these imaging techniques have mostly been used in isolation. However, functional 
molecular imaging techniques are now increasingly being performed in combinations. 
Multifunctional imaging is becoming an important means for biologic investigation because of 
its multidimensional (multispectral, multispatial and temporally resolved) nature. Combined 
approaches have been made possible by (a) the development of hybrid imaging technologies such 
as single photon emission computed tomography (SPECT)/CT and PET/CT and PET/MR 
imaging, (b) technologic advancements within individual imaging modalities that enable 
multifunctional data acquisitions within short periods of time including the use of PET isotopes 
with very short half-lives, (c) advances in software enabling both fusion of imaging data between 
imaging modalities and derivation of quantitative biologically relevant biomarker data that can 
be coregistered with anatomic images, and last, (d) bioinformatics allowing integration of 
quantitative imaging parameters with other biologic data such as serum cytokines, circulating 
cells, and tissue genomic and protein expressions [2]. 
 
A review of the literature shows that the multiparametric approach has been used in a number of 
ways, including: 
1) Improving the depiction of tumour biology: multifunctional imaging makes it possible to 
correlate observations between techniques at the tumour or voxel level. Such cross-correlations 
have been used (a) to refine the accuracy of imaging observations, (b) to validate an emerging 
biomarker against an accepted standard (by ascertaining the strength of relationships between 
them and by exploring the circumstances under which the strength of relationships may be 
changed), and finally (c) to clarify the nature of relationships between biologic functions at the 
voxel and patient levels [2].  
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2) Clinical characterization of known disease: functional imaging is often used to clarify the 
nature of abnormalities seen at imaging examinations. Multifunctional evaluations are an 
extension of this approach that have been used for the characterization of lesions at a variety of 
anatomic sites including the brain (23,24) and the parotid (25) and prostate gland (26–28). When 
multifunctional assessments are used for disease characterization, it is often found that results 
from individual modalities are discordant at the regional or whole-tumour level [2]. 
3) Assessment of therapy response: monitoring changes with multiparametric imaging can provide 
invaluable information on the in vivo mechanisms of action of therapeutics and so can be of use in 
drug development [2]. 
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Hybrid PET/MRI system 
 
Both positron emission tomography and magnetic resonance imaging are well-established 
imaging modalities that have been clinically available for more than 30 years. However, the 
combination of PET and computed tomography (CT) into PET/CT has heralded a new era of 
hybrid imaging driven by the rapid ascend of PET/CT and the decline of stand-alone PET. The 
integration of PET and CT into a hybrid system has provided added value that exceeds the sum 
of its parts, in particular fast and accurate attenuation correction and the combination of 
anatomical and molecular information. This has been the inspiration for the combined PET/MRI 
[3]. While the integration of PET and CT into a hybrid system was challenging but technically 
feasible, the integration of PET and MRI was considered extremely demanding, if not impossible. 
Two main technical challenges had to be solved: in the first place the development of a PET insert 
that is compatible to high magnetic field strengths normally used in MRI, and vice versa the 
development of a magnetic resonance scanner that guarantees a stable and homogenous magnetic 
field in the presence of a PET insert [3]. Conventional PET detectors consist of scintillation 
crystals and photomultipliers, and the latter, being very sensitive to magnetic fields, cannot be 
used in integrated PET/MRI systems. Hence, one approach was to replace photomultipliers by 
avalanche photodiodes (APDs), which are insensitive to even strong magnetic fields. The 
scintillation crystals used in PET/MRI scanners are usually composed of lutetium ortho-
oxysilicate, with the advantage of only minor disturbances of magnetic field homogeneity. Next 
generation PET/MRI scanners could be based on silicon photomultiplier PET detectors, which 
showed better performance characteristics than the APDs and, in contrast to these, are capable of 
time-of-flight imaging [4, 5]. Secondly, the development of MR-based attenuation correction 
methods is necessary, as the commonly used method for attenuation correction in PET/CT 
systems, which is based on the absorption of X-rays, is not transferable to MRI. In principle, the 
MR-based attenuation map is created with a two-point Dixon sequence, providing water-only and 
fat-only images, which are combined and segmented to form an MR-based attenuation map. The 
method proved its technical feasibility with the limitation that in bone tissue and in its vicinity 
standardized uptake values (SUV) derived from PET/MRI systems should be interpreted carefully 
until a larger experience with the new method of PET/MRI exists [3]. In 2010, the first fully 
integrated whole-body PET/MR hybrid imaging system based on APD technology and MR-based 
attenuation correction became commercially available (Biograph mMR, Siemens Healthcare, 
Erlangen, Germany) [3]. 
As discussed before, in addition to anatomical images, MRI provides functional and quantitative data 
like diffusion-weighted imaging (DWI), spectroscopy, blood oxygenation level-dependent imaging in 
functional MRI, T1/T2 mapping and dynamic contrast-enhanced imaging. Consequently, valuable 
applications of PET/MRI emerge in the field of multiparametric and quantitative imaging. In fact, 
tumour characterization and response evaluation can benefit from multiparametric imaging as tumours 
are spatially heterogeneous and dynamically evolving entities that are often not sufficiently 
characterized by size-based assessment only [3]. PET/MRI offers some unique features like real 
parallel PET and MRI acquisition that enable imaging protocols like integrated functional MRI and 
dynamic PET after presentation of a stimulus or cardiac stress PET/MRI. In combination with the 
ionizing radiation-free nature of MRI, parallel acquisition also allows for the continuous acquisition 
of anatomical images that can be used for motion correction of PET data. Thus, the quality of PET 
images in applications like cardiac, lung, or bowel imaging can be increased while respiratory and/or 
electrocardiography-gating can be potentially omitted [3]. 
 
In addition, PET/MRI offers practical advantages for patients requiring both PET and MRI 
examinations for oncologic assessment by providing both modalities within a single appointment 
and imaging session. Radiation exposure is also reduced because CT is not used in the imaging 
protocol. Finally, PET/MRI allows accurate, temporally and spatially aligned multiparametric 
imaging that combines high-contrast anatomic MR images with the quantitative power of 
molecular imaging of both PET and MRI, including DWI, perfusion MRI, and MR spectroscopy. 
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This potential creates numerous opportunities for characterizing tumour biology across all of the 
dimensions of imaging offered by PET and MRI [6]. Examples of clinical application include, in 
brain glioma, the localization of focal targets for surgical biopsy planning, especially in spatially 
heterogeneous gliomas, with an improved gross tumour volume and tumour margin delineation 
for radiotherapy planning, and improved detection of post-treatment recurrences [6]. 
Furthermore, FDG PET/MRI may offer improvements in both breast imaging and whole-body 
staging for patients with breast cancer.  
Applications 
 
My analysis has mainly focused on the clinical characterization of a known disease with the 
integration of information derived by CT, PET and MR imaging (the latter two in combination or 
not). In particular, I applied pharmacokinetic analysis on dynamic PET data acquired on a 
PET/CT scanner and on dynamic MRI data acquired on a hybrid PET/MRI scanner. The section 
will open with a brief introduction on the characteristics of the scanner and the results of the 
multiparametric study done on breast cancer data acquired on the hybrid PET/MRI scanner based 
on the published article: 
 
Inglese M, Cavaliere C, Monti S, Forte E, Incoronato M, Nicolai E, Salvatore M, Aiello M A 
multi-parametric PET/MRI study of breast cancer: evaluation of DCE-MRI pharmacokinetic 
models and correlation with diffusion and functional parameters NMR in Biomedicine 
2018;e4026 
 
The same dataset has been used for a predictive study, with the relationship also with 
himmunoistochemical markers. I will show the results of this study based on the published article: 
 
Incoronato M, Grimaldi AM, Cavaliere C, Inglese M, Mirabelli P, Monti S, Ferbo U, Nicolai E, 
Soricelli A, Aiello M, Salvatore M Relationship between functional imaging and 
immunohistochemical markers and prediction of breast cancer subtype: a PET/MRI 
study European journal of nuclear medicine and molecular imaging (2018): 1-14. 
 
I will then show the results of a multiparametric study done on brain data acquired both on a 
PET/CT scanner and on an MR scanner, separately. This is based on the conference paper: 
 
Inglese M, Grech-Sollars M, Ordidge K, Vaja V, Honeyfield L, Khan S, Barwick T, Aboagye 
OE, Waldman AD Association between pharmacokinetic parameters from DCE-MRI and 
metabolic parameters from dynamic 18F-fluoromethylcholine PET in human brain glioma 
ISMRM 2018 (second place winner) 
 
I have applied pharmacokinetic analysis on a small dataset of breast and lung cancer patients, 
who have joined a translation study of the 18F-ICMT-11 PET tracer for the evaluation of 
chemotherapy-induced caspase 3/7 activation. I will briefly show the results, based on the 
published article: 
 
Dubash S, Merchant S, Mauri F, Lavdas I, Inglese M, Kozlowski K, Rama N, Masrour N, Steel 
JF, Thornton A, Lim AK, Lewanski C, Cleator S, Coombes RC, Kenny L, Aboagye EO Clinical 
translation of [18 F] ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in 
breast and lung cancer." European journal of nuclear medicine and molecular imaging (2018): 
1-15. 
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Finally, my kinetic analyses have been part of a radiomic study on patients with prostate cancer. 
I will show the results, based on the conference paper: 
 
Monti S, Aiello M, Inglese M, Diomaiuti CT, Ragozzino A, Cavaliere C Multiparametric MRI 
in prostate cancer: a radiomics study on different diffusion and perfusion models ECR 2018 
 
I. A multi-parametric PET/MRI study of breast cancer: evaluation 
of DCE-MRI pharmacokinetic models and correlation with 
diffusion and functional parameters 
 
The objective of this study is to compare perfusion parameters, as measured by both the shutter 
speed and the Tofts model in malignant breast lesions. Also, to investigate the relationship 
between perfusion, morphological and functional parameters extracted by simultaneous 
acquisition of the positron emission tomography (PET) and magnetic resonance imaging (MRI). 
46 patients with histologically confirmed breast cancer were enrolled and imaged with a 3T hybrid 
PET/MRI system, at staging. 18F-FDG PET images were acquired simultaneously to MRI, which 
included DW- and DCE-MRI protocols. Standardized uptake value (SUV), apparent diffusion 
coefficient (ADC) and pharmacokinetic maps (from the Tofts and shutter speed model applied on 
dynamic MRI data) were calculated for each primary lesion and reference area. Wilcoxon and 
Spearman tests were chosen for the statistical analysis. 
Results showed that MRI derived measurements (perfusion and diffusion) and PET SUVmean 
resulted able to statistically discriminate between tumour and reference tissue (p < 0.05). 
Significant correlations were found between the two pharmacokinetic models (p < 0.01) and 
between SUV and pharmacokinetic parameters (Ktrans, kep, ve and τi). No correlation was observed 
between ADC and SUV, as well as between ADC and pharmacokinetic parameters. 
In conclusion, PET/MRI allows for the characterization of primary lesions. Simultaneous analysis 
of perfusion, morphological and functional markers shows good agreement between different 
pharmacokinetic models. Perfusion parameters showed a good correlation with the SUV in breast 
lesions. In particular, the shutter speed ti was found to be significantly correlated to 18F-
fluorodeoxyglucose (FDG) uptake (negative correlation) meaning an association with tumour 
metabolic mechanisms. 
 
1. Introduction 
 
Recent technological developments and advanced imaging techniques can provide early diagnosis 
in breast cancer. However, breast cancer is still the most frequently diagnosed cancer among 
women in 140 of 184 countries worldwide and remains the most common cause of cancer death 
(322,600 breast cancer deaths have been averted in US women  through 2015)[7]. 
 
In the past decades, the significant improvements of integrated and advanced imaging techniques, 
mainly in MRI and PET, have made both modalities clinically relevant in breast cancer staging, 
management and follow-up [8-11]. In particular, the multimodal, combined PET/MRI approach 
allows the integration of anatomic and functional information, thus providing a higher registration 
accuracy when compared to retrospectively coregistered images acquired on separate scanners. 
Thanks to the integration of MRI, excellent soft tissue contrast is combined with the molecular 
information from PET and this approach has been shown to provide a comprehensive clinical 
view for many tissues, including the breast [12-17]. In fact, the imaging parameters derived from 
the two different modalities can give complementary information with regards to the tumour 
environment as they relate to different imaging properties (functional, morphologic). 18F-
fluorodeoxyglucose (FDG)-PET measures the in vivo radiotracer distribution [kBq/ml], which, 
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in the case of FDG -an analogue of glucose- provides functional information based on the 
increased glucose uptake and glycolysis of cancer cells [18, 19]. On the other hand, diffusion 
weighted (DW)-MRI, quantified by the apparent diffusion coefficient (ADC), estimates the rate 
of water diffusion in tissues. It has been shown that the diffusivity of water molecules is restricted 
to environments of high cellularity, where tumour cell proliferation occurs. This results in low 
ADC values within tumours [20-22]. Finally, dynamic contrast enhanced (DCE)-MRI data, fitted 
to an appropriate pharmacokinetic model, results in quantitative physiological parameters, 
relating to tumour permeability and perfusion.  
 
DCE-MRI data are usually quantified with the application of the pharmacokinetic two-
compartment Tofts model (also known as the standard model), which represents the system with 
the plasma and tissue (extravascular extracellular space) compartments and with the contrast 
reagent exchange rates between them. This model considers the system in, what-is-known as, the 
fast exchange limit (FXL)[23] assuming infinitely fast transcytolemmal water exchange kinetics. 
Several measurements done on the cell membrane water permeability coefficient have shown the 
FXL to lead to non physiological and inconsistent results and in particular to pharmacokinetic 
parameters’ misestimation[24, 25]. The shutter-speed model (SSM) admits the system to leave 
the FXL, at rising values of concentration of the contrast media, and to enter the what-is-called 
fast exchange regime (FXR). This model accounts for the effect of finite transcytolemmal water 
exchange kinetics on the overall MR signal decrease. It provides the additional pharmacokinetic 
parameter τi (mean intracellular water molecule lifetime), which has been suggested to be 
associated with tissue metabolic activity [26, 27]. 
 
Several studies investigated the relationship between these two models in the description of 
perfusion mechanisms in breast cancer. For example, Li et al. found that the transient departure 
from FXL to FXR is significant only in malignant tumours, presumably because of angiogenic 
capillary leakiness; they also found FXR models to provide the most complete statistical 
description of dynamic contrast-enhanced MRI with a Bayesian information criteria approach 
[28, 29]. Furthermore, the relationship between parameters resulting from the Tofts model and 
the ADC, or the SUV have been also examined: Arlinghaus et al. found no statistically significant 
correlation between ADC and extravascular extracellular volume fraction on either a voxel-by-
voxel or a region-of-interest (ROI) basis; Semple et al. found a significant association (p < 0.05) 
between pre-therapy DCE-MRI vascular parameters and the reduction in PET metabolism 
resulting from administration of one cycle of chemotherapy in seventeen patients with large or 
locally advanced invasive ductal carcinomas of the breast [30, 31]. 
 
The aim of the study is to investigate the relationship between pharmacokinetic parameters 
derived by the application of both Tofts and SSM to DCE–MRI data and also the relationship 
between perfusion, diffusion and metabolic characteristics of breast tumour estimated by MRI. In 
particular, we investigate SSM DCE-MRI parameters in combination with FDG-PET metabolic 
activity measurements in breast cancer. Data is acquired on a hybrid PET/MR scanner: that 
guarantees, not only the a priori spatial coregistration of the acquired volumes, but also the 
convenience of the patient. Most importantly, the assessment of the lesion is done with 
morphological and metabolic data acquired at the same physiological condition.  
 
2. Materials and methods 
 
2.1 Patient population 
46 patients with positive mammographic reports and histologically proven primary breast cancer 
were enrolled between September 2012 and December 2015 (Table 13), following institutional 
review board and Ethical Committee approval and written informed consent. Exclusion criteria 
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were: blood glucose levels greater than 150 mg/dL, pregnancy, concurrent severe renal failure, 
and standard contraindications for MRI.  
 
Table 13: Population clinical parameters. 
N 
Age 
median 
[range] 
Lesion size 
(cm) 
median [range] 
pT Tumour types  Grading 
Histological 
Subtypes 
   T0 T1 T2 T3 IDC ILC G2 G3 l-A l-B b-l h-l 
46 58 [41, 85] 2.50 [0.2, 7] 3 7 21 15 39 7 31 15 11 29 3 3 
 
Note: Lesion size measured by MR in the axial slice with major lesion extension; pT: histological 
tumour staging; l-A: luminal A; l-B: luminal B; b-l: basal like; h-l: HER2 like. 
 
2.2 PET-MRI Data Acquisition 
Data were acquired on a 3T mMR Biograph hybrid PET-MR system (Siemens, Erlangen).  
All patients fasted at least six hours before PET imaging. 401 ± 32 MBq (mean ± std) of 18F-FDG 
were administered intravenously. After a 60-minute equilibration period, during which the 
patients were at rest, PET images (4 mm spatial resolution) over the tumour were acquired 
simultaneously with MRI.  
 
DW-MRI was acquired in the axial plane with a single shot spin-echo echo-planar imaging 
sequence in three orthogonal diffusion encoding directions with b-values of 0-50-400-800 s/mm2, 
TR/TE = 14500 ms/ 66 ms, FOV 340 mm, base resolution 192, slice thickness 4 mm. 
 
DCE-MRI was performed with an 8 channel dedicated breast coil. Images were acquired in the 
axial plane and included, for all examinations, six pre contrast spoiled gradient recalled echo 
(SPGRE) 3D vibe sequences at six different flip angles (2, 5, 8, 12, 15, 20) and a dynamic 3D 
vibe sequence (TR=5.5 ms, TE=1.7 ms, flip angle = 20, FOV 320 mm, base resolution 192, slice 
thickness 3.6 mm, parallel imaging acceleration factor 2, 36 slices per DCE-MRI image frame) 
to obtain images before, during and after the injection of the contrast agent (0.1 mmol/kg body-
weight gadolinium-diethylene triaminepentacetate (Gd-DTPA), Magnevist). The contrast agent 
was administered using a power injector on the 3rd acquisition with a flow rate of 3 ml/s. Full 
breast coverage was achieved with the 3D acquisition. 60 time points were acquired with an 
average temporal resolution of 9.5 s and a total acquisition of ~9 minutes. Patients were allowed 
to breathe freely. 
 
For clinical evaluation, the protocol included also axial and coronal T2 turbo inversion recovery 
magnitude sequences (TR = 4220 ms, TE = 61 ms, FOV 340 mm, base resolution 256, slice 
thickness 4 mm) and a T2 turbo spin echo (TR = 5440 ms, TE = 81 ms, FOV 340 mm, base 
resolution 448, slice thickness 4 mm). 
 
Following acquisition, PET images were automatically corrected for the tissue attenuation with 
the attenuation maps generated by using the 2-point Dixon MRI sequences[32]. Emission data 
were corrected for randoms, dead time, scatter, and attenuation. A 3-dimensional attenuation- 
weighted ordered-subsets expectation maximization iterative reconstruction algorithm (AW 
OSEM 3D) with 3 iterations and 21 subsets, Gaussian smoothing of 4 mm in full width at half 
maximum, was used. 
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3. Image post-processing: background 
 
3.1 Pharmacokinetic modelling 
DCE-MRI data were analysed using in house code written in Matlab (Mathworks, R2015b). 
Relaxation rate at baseline (R10) and relaxed signal (M0) were calculated, as 3D maps, with the 
Ernst formula (assuming TE<<T2*) using the set of SPGRE pre contrast images at different flip 
angles[33]: 
 "(q) = ∂usin	(q) >E.ü±Olû±>E∑∏π	(∫)∙.ü±Olû± 29) 
 
where α is the  flip angle and can assume values belonging to [2, 5, 8, 12, 15, 20] and TR = 5.5 
ms. Following the method described by Liberman et al., the problem is reformulated as a linear 
regression system (y = ax + b), as follows: 
 ª(∫)πñº	(∫) = Ω ∙ ª(∫)æøº(∫) +∂ ∙ (1 − Ω) 30) 
 
where E = exp(-R10*TR)[34]. The slope a = E and intercept b = M(1-E) can be estimated, from 
which R10 and M0 can be obtained as: 
 á>u = − ¡∏¬	(()m±  , ∂ = b>E( 31) 
 
4D (x, y, z, t) post-injection longitudinal relaxation rate, R1(t) maps are calculated for each 
dynamic phase using signal intensity data from pre and post contrast T1 weighted gradient recalled 
echo (T1w-GRE) dynamic series: 
 
 á>(I) = − >m± ∙ ƒ≈∆ >E(«W`)>E∑∏π	(∫)∙(«W`) 32) 
  
 
where α = 20, A = [S(t) - S(0)]/( M0 sin(α)), B = (1-E)/(1-E  cos(α)). S(0) and S(t) are 
respectively the pre contrast injection signal intensity (the first baseline scan) and the signal at the 
tth dynamic phase[35]. 
 
Data was then fitted with the Tofts and the shutter speed model, as described in Chapter 3. 
 
3.2 Apparent diffusion coefficient computation 
ADC maps were automatically computed by the scanner via Eq. (î—?= −ln	[ª(b)ª(u)]/v 33): 
 î—? = −ln	[ª(b)ª(u)]/v 33) 
 
where S(0) denotes signal intensity in the absence of diffusion gradients, b reflects the strength 
and the duration of a diffusion-sensitizing gradient and S(b) is the signal intensity at non-zero b 
value. Having measured a set of images at four different b-value, the system calculates, pixel-by-
pixel, the ADC using linear regression. On a half logarithmic scale, the signal decay is a straight 
line whose slope provides the ADC. The faster the signal decay the steeper the slope and, so, the 
higher the ADC[36]. 
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3.3 SUV computation 
The FDG uptake in tumours is related to the proliferative activity of a malignant tissue and to the 
number of viable tumour cells. Even though quantification is straightforward in PET imaging, it 
is subject to the variability introduced by differences in patient size, the amount of FDG injected 
and the radiotracer decay. The quantification of FDG uptake is preferably done with the SUV, 
which ideally removes those sources of variability and has a specific role in assessing patient 
response to cancer therapy. The body-weighted SUV is given by the following equation: 
 "#$ = '((“ ”)⁄  34) 
 
where r is the radioactivity concentration [kBq/ml] measured by the PET scanner, a′ is the decay-
corrected amount of injected radio-labelled FDG [kBq], and w is the weight of the patient [g]. 
 
4. Image Analysis 
 
Free-hand regions of interest (ROIs) were drawn around the area of maximal tumour extension 
for each of the 46 subjects by one senior radiologist experienced in breast imaging (CC, 6 years 
of experience) and one nuclear medicine specialist (EN, 7 years of experience). Primary tumour 
location was outlined on the subtracted T1 post-contrast slices, with consideration to avoid 
necrotic areas and/or large feeding vessels[37]. An additional 1-cm2 ROI was drawn in the 
reference area (the contralateral healthy breast). 
 
In order to propagate the drawn ROIs onto the ADC maps and PET images- coregistered to the 
subtracted T1 contrast-enhanced sequence but of different spatial resolution- they were resampled 
to the 1.9 × 1.9 × 3.6 mm MRI voxel size using a fourth degree B-spline interpolation. However, 
DW images are affected by geometrical distortion due to echo planar acquisition[38]: we visually 
double confirmed the traced boundaries, after the ROI propagation onto the ADC maps and, when 
necessary, we made a manual correction to assure a correspondence between the lesion and the 
ADC map. 
 
Then, pharmacokinetic measures for perfusion, diffusion and glucose metabolism evaluation 
were performed across each ROI (maximum and mean values were extracted for each parameter). 
The incremental area under the concentration curve (iAUC) was estimated for each ROI with the 
trapezoidal rule and its mean value was evaluated. An additional ROI was drawn in the aorta for 
the individual evaluation of the concentration of the contrast reagent in the plasma (Figure 
42)[39]. 
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Figure 42: A) Contrast enhanced breast MR image of patient n. 1. The ROI is placed in the aorta for the 
evaluation of the arterial input function. B) Mean plasma contrast reagent concentration time course from the 
ROI placed in the aorta. 
 
The Tofts and shutter speed models fitting of DCE-MRI data was performed using an in-house 
software written in Matlab (MathWorks, R2015b). In particular we chose the fminsearch function, 
which uses the Nelder-Mead simplex algorithm as described in Lagarias et al.[40]. The 
minimization procedure was performed voxelwise in order to obtain a 2D map for each 
pharmacokinetic parameter. We set input values of 0.1 and 0.01 for the Ktrans and ve, respectively, 
and run the algorithm with 10000 iterations and a tolerance of 10-8. Figure 43 shows an example 
of the fitting results for one voxel of the lesion and reference for a representative patient. Data are 
expressed as mean (evaluated averaging the voxel values within the tumour ROI drawn on the 
single image slice with the maximal tumour extension) ± standard deviation. For the following 
analyses, non normative values (negative values and Ktrans, kep > 5, ve > 1) [41] were discarded. 
This resulted with an average loss of 4.26 (±13.42) % of voxels per map. 
 
 
Figure 43: A) Contrast enhanced axial breast MR image of patient n. 14. Two voxels have been selected for 
showing the results of the Tofts and shutter speed model fitting procedure. In particular, the red star is related 
to the lesion where the blue one belongs to the reference area. B, C) Fitting curves (in red) resulted from the 
application of the Tofts and shutter speed model to tumour tissue data (red dots) and reference tissue input 
data (blue dots). 
 
5.  Statistical Analysis 
 
Statistical analysis was performed in Matlab (Mathworks, R2015b). The Kolmogorov - Smirnov 
test was used to assess the normality of each parameter distribution; the Wilcoxon Sum Rank test 
was used to evaluate significant differences between tumorous and reference areas and between 
estimated perfusion parameters obtained with the Tofts and Shutter-speed model; the non-
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parametric Spearman test was used to verify the correlation between parameter distributions. A 
false discovery rate < 0.05 was used for multiple comparison correction. A correlation coefficient 
ρ < 0.35 was considered to represent low correlation, values between 0.36 and 0.67 were 
characterised as low correlation, between 0.68 and 0.90 to high correlation, ρ > 0.90 represented 
excellent correlation[31].  
 
6. Results  
 
Figure 44 shows an example of the parametric maps used in this study. In particular, in the first 
row a post contrast MRI T1-weighted image (8th phase), the MRI subtraction of the baseline scan 
from the 8th phase, the attenuation corrected PET image and the ADC map are shown. Following, 
there are the pharmacokinetic maps evaluated with the Tofts model (Ktrans, kep and ve), the iAUC 
and the pharmacokinetic maps evaluated with the shutter speed model (Ktrans, kep, ve and τi). 
Non-normal distributions were observed for all the parameters. 
 
 
Figure 44: Patient n. 2; 45 years old, IDC. Representative axial images of a) post contrast MRI T1-weighted 
image (8th phase); b) MRI subtraction of the baseline scan from the 8th phase; c) attenuation corrected PET 
image; d) ADC map; e - g) Pharmacokinetic maps evaluated with the Tofts model: Ktrans, Kep and ve; h) iAUC; 
i - n) Pharmacokinetic maps evaluated with the shutter speed model: Ktrans, Kep, ve and τi. 
6.1 Comparison between lesion and reference area 
Table 14 shows mean and standard deviation values for Ktrans, kep, ve (_Tofts and _SSM) and τi 
(_SSM) in the tumour and reference area. Significantly higher SUV and lower ADC values were 
observed in the lesion when compared to reference area (p < 0.01).  
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Furthermore, the analysis of perfusion parameters derived from the application of the 
pharmacokinetic Tofts and shutter speed models to breast lesions showed significant differences 
when compared to the contralateral reference area for the following parameters: Ktrans_Tofts, p < 
0.01; ve_Tofts, p < 0.01; Ktrans_SSM, p < 0.01; ve_SSM, p < 0.01; τi, p < 0.01 (Table 14).  
 
Table 14: Mean and standard deviation of pharmacokinetic estimates, ADC and SUV in tumour and reference 
tissue. A significant statistical difference is marked in bold: * p < 0.05, ** p < 0.01 
 Tumour Reference tissue 
ADC [mm2/s] 1115   312**
 
1453 ± 270
 SUV [kBq/ml / kBq/g] 5.50   3.69**
 
0.71 ± 0.10
  Tofts model SSM Tofts model SSM 
Ktrans [1/min] 0.57   0.48**
 
0.69   0.61**
 
0.04 ± 0.09
 
0.14 ± 0.20
 kep [1/min] 1.14   0.76
 
1.14   0.75
 
0.91 ± 0.73
 
1.03 ± 1.12
 ve 0.50   0.14**
 
0.68   0.09**
 
0.06 ± 0.12
 
0.26 ± 0.24
 τi [s]  0.31   0.15**
 
 1.27 ± 1.06
  
6.2 Multiparametric evaluation 
All patients (n = 46) showed a positive and low correlation between the SUVmean and the 
pharmacokinetic Ktrans_SSM, kep_Tofts (p < 0.05) and a negative high correlation with ve_SSM 
(p < 0.01). The PET SUV showed a negative low correlation also with the shutter speed derived 
τi (p < 0.05). A high and positive correlation was found between the pharmacokinetic parameters 
estimated with the two different models (p < 0.01) (Table 15).  
 
Table 15: Results of the Spearman correlation test applied on the distribution of each parameter. Only the 
correlations for which p resulted < 0.05 have been reported. 
Variable 1 Variable 2  p value Spearman ρ  
SUV Ktrans _SSM < 0.05 0.32 
SUV Ktrans _Tofts < 0.05 0.32 
SUV τi < 0.01 -0.29 
Ktrans _Tofts Ktrans _SSM < 0.01 0.94 
kep _Tofts kep _SSM < 0.01 0.83 
ve _Tofts ve _SSM < 0.01 0.80 
 
 
Finally, no significant correlation was found between the ADC and both the SUV and 
pharmacokinetic parameters derived from the application of TM and SSM to DCE-MRI data (p 
> 0.05). Scatterplots in Figure 45 demonstrate some examples of the relationship between 
different imaging parameters. In particular the relationship between: SUV from PET imaging and 
ADC from DW-MRI; the SUV and kep evaluated with the Tofts model; the ADC and the Ktrans 
evaluated with the Tofts model; and the SUV and τi derived from the application of the shutter-
speed model to DCE-MRI data. 
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Figure 45: Scatterplots showing some relationship between different imaging techniques, with their 
correspondent trend-lines. A) SUV from PET imaging and ADC from DW-MRI; B) SUV and kep evaluated with 
the Tofts model; C) ADC and the Ktrans evaluated with the Tofts model; D) SUV and τi derived from the 
application of the shutter-speed model to DCE-MRI data. 
 
7. Discussion 
 
The aim of this study was to investigate the relationship between pharmacokinetic, 
microstructural and metabolic features in breast tumours, simultaneously evaluated using DCE-
MRI (fitted with the Tofts and the shutter speed model), DW-MRI and 18F-FDG-PET imaging. 
Both Tofts and shutter speed derived perfusion parameters showed a significant correlation with 
the PET SUV, which is typically used in the evaluation of oncological lesions. Although similar 
in correlation coefficients, comparisons with the shutter speed model resulted in lower p values 
suggesting a higher significance. 
  
The uptake of MRI contrast media and PET radiotracers is based on different physiological 
mechanisms, so the application of DCE-MRI and 18F-FDG-PET usually provides complementary 
findings [42-44]. Nevertheless, the metabolism of tumours tissues is highly linked to the related 
neoangiogenesis, and hence, to the delivery of both contrast and/or radiopharmaceuticals to the 
lesion [45]. An et al. have recently demonstrated a significant correlation between the SUVmax 
and kep and ve estimated with the Tofts model in non-triple negative breast cancer[46]. In our 
population, we confirmed this significant positive correlation between the mean SUV value and 
perfusion Ktrans_SSM and Ktrans _Tofts (p < 0.05). This finding is of particular interest, not only 
for staging but, in perspective, for follow-up and treatment response evaluation, considering that 
perfusion parameters, such as Ktrans, have been demonstrated to be potentially predictive of 
patients’ response to therapy [26, 47].  
  
On the contrary, no significant correlation between mean values of metabolic (SUV) and diffusion 
(ADC) parameters were found (Figure 45). The literature results in this, are contradictory. 
Kitajima et al. found a significant, but weak inverse correlation between the SUVmax and ADCmean 
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values[48]. Two other research groups demonstrated a mild correlation between the SUVmax and 
ADCmean values [49, 50]. On the other hand, no correlation between ADC and SUV was found by 
Choi et al. [51], together with other published studies[52-54]. Different tumour tissues have 
different cellular structures, which lead to different ADC values. Literature reports ADC values 
to be inversely correlated with tumour cellularity [55-58]. Therefore, the positive correlation 
between FDG uptake and cellularity[59, 60] suggests SUV and ADC to be inversely proportional, 
confirming Kitajima et al’s study[47]. In our study, the absence of significant correlation between 
SUV and ADC could be attributed to both the small size of the sample and the big dimension (and 
resulting heterogeneity) of many of our lesions. We saw an inverse correlation between the SUV 
and the volume fraction of extracellular extravascular space, which is usually related to tissue 
cellularity, suggesting that regions with high level of glucose metabolism may be characterized 
by high cellularity. Kim et al. [61] and An et al.[44] also found a negative correlation between the 
SUV and the ve. This makes evident that tumour blood flow and vessel permeability are important 
for the FDG intracellular uptake. It certainly needs to be further investigated, possibly with 
additional histological information. 
 
As for perfusion analysis, the standard approach for DCE-MRI employs the Tofts 
pharmacokinetic model, which assumes an infinitely fast equilibrium transcytolemmal water 
exchange kinetics. This assumption has been proven to cause pharmacokinetic parameters 
miscalculations[62, 63]. These results were confirmed by our analysis where the Tofts Ktrans 
(mean and standard deviation, 0.57   0.48 [1/min]) were lower that the shutter speed one (mean 
and standard deviation, 0.69   0.61 [1/min]). In fact, in order to reflect a more realistic tissue 
environment, pharmacokinetic models should consider the intercompartimental water exchange 
effect, even though this involves more complex models with more parameters to be estimated. 
The cellular metabolic activity, evaluated by the SSM parameter τi, has been shown to relate to 
the energetic metabolism driven cell membrane water permeability[64]. In our study, we found 
this parameter to be significantly higher in the reference tissue, confirming an inner lower 
metabolic activity in these tissues, as supported also by SUV values. We also found a negative 
and weak correlation between τi and SUVmean. This contradicts the results of Hectors et al. in the 
assessment of hepatocellular carcinoma[28]. FDG-PET measures cellular uptake of glucose, 
whereas τi is mainly dictated by Na+, K+-ATPase activity sustained by ATP production[26]. This 
negative correlation could mean that, when the metabolic activity of the cell is very high, and it 
takes place when a greater nutrient delivery is present, the metabolism of the cell is faster and, as 
a consequence, lower values of τi are observed[65]. 
 
The main limitation of this study is the limited size of the examined dataset. Moreover, any 
histological characterization was present for the evaluation of the performance of each 
pharmacokinetic model compared to a tissutal ground truth. This was mainly due to the 
heterogeneity of the sample as few Basal Like subjects were available. Finally, the sensitivity of 
DCE-MRI data to water exchange effect was reduced by the 20◦ flip angle acquisition. Li et al. 
suggest that data τi sensitivity can be enhanced by reducing the flip angle (~8◦)[66]. This can 
possibly affect the precision of the τi parameter and, as a consequence, the accuracy of the 
correlation with other imaging metrics. The strength of the analysis is related to the simultaneous 
acquisition of PET and MRI data, because of the soft-tissue contrast resolution of MRI, 
particularly useful in this body area and the acquisition of both metabolic and morphological data 
at the same physiological conditions. Furthermore, pharmacokinetic parameters were evaluated 
with the application of an individual arterial input function, which avoids many problems related 
to the widely used population averaged one[67].  
 
Further work is required to assess the combined information from DCE-MRI, DW-MRI 
and PET, together with biological/histological data, in order to conduct an advanced 
analysis in a radiogenomic framework[68].   
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8. Conclusions 
 
PET/MRI allows breast lesions characterization when using multiparametric analysis of 
perfusion, morphological and functional markers with a good agreement between different 
pharmacokinetic models. Perfusion parameters showed a good correlation with the SUV in breast 
lesions, and, in particular, the shutter speed ti was found to be significantly associated with FDG 
uptake (negative correlation). On the contrary, DW-MRI derived parameters did not correlate 
with either PET or DCE-MRI parameters. These findings give new insights in the use and 
interpretation of quantitative imaging markers in breast cancer, especially when predicting 
response to treatment. 
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II. Relationship between functional imaging and 
immunohistochemical markers and prediction of breast cancer 
subtype: a PET/MRI study 
 
1. Introduction 
 
Breast cancer (BC) is an international public health concern characterized by high tissue 
heterogeneity and complexity that make clinical management a very challenging task. 
Based on gene expression, BC is classified in different subtypes, and their identification 
may contribute to treatment planning. As reported by St. Gallen 2013 guidelines[69], 
there are four major BC molecular subtypes: luminal A (estrogen receptor positive [ER+] 
and/or progesterone receptor positive[PR+], human epidermal growth factor receptor 2 
negative [HER2-]); luminal B (ER+, and/or PR+, HER2+); HER2-like (ER-, PR-, 
HER2+); and basal-like/triple negative (ER-, PR-, HER2-). The main reason for 
attempting to distinguish between ‘luminal A’ (more endocrine sensitive, indolent, better 
prognosis) and ‘luminal B’ (less endocrine sensitive, more aggressive, worse prognosis) 
tumours is because they respond differently to treatment.  
In the last several decades, advanced and integrated imaging techniques (mainly magnetic 
resonance imaging [MRI] and positron emission tomography/computed tomography [PET/CT]) 
have boosted diagnostic accuracy in several stages of cancer management. Histopathologic 
findings still play important roles in BC diagnosis and clinical management, but this approach 
presents limitations related to the invasive bioptic approach, inter- and intra-observer variability, 
limited field of view (FOV), and tissue alteration during the pre-analytical phase (fixation). 
Increasing evidence has suggested a role for imaging-derived morpho-functional parameters for 
predicting tumour malignancy and treatment response. Indeed, many studies have demonstrated 
relationships between 18Fluoro-fluorodeoxyglucose (18F-FDG) uptake on PET/CT and the 
clinicopathological characteristics of tumour lesions [70-77], as well as the role of maximum 
standardized uptake value (SUVmax) in the primary tumour as a predictor of molecular subtype 
[78], and of relapse/survival in BC patients [79]. Similarly, the correlation between imaging 
parameters obtained by dynamic contrast-enhanced MRI (DCE-MRI) and histopathologic 
findings have been reported [80-89]. FDG-PET and DCE-MRI are both functional modalities that 
indirectly represent the biological characteristics of cancer. For prognostic purposes, few studies 
have explored the association between PET and MRI parameters with the clinicopathologic 
subtype of BC [90-95], and the diagnostic power of hybrid PET/MRI system in this field has also 
not been extensively investigated [96, 97]. Several studies have demonstrated PET/MRI 
performance in terms of qualitative lesion detection and semi-quantitative measurement, 
establishing a comparable diagnostic value with PET/CT imaging, the gold standard technique 
for oncologic assessment [8, 98, 99]. 
The purpose of this study was to evaluate the association between imaging biomarkers 
extracted from the hybrid PET/MRI system with histopathologic findings of breast 
tumours, and to determine their ability to predict BC subtypes.  
 
2. Material and Methods 
2.1 Participants  
This study was approved by the institutional Ethics Committee (Prot2-11, IRCCS Fondazione 
SDN). For study enrollment, all participants provided written informed consent. Between June 
2012 and November 2015 at the IRCCS SDN Institute, 221 patients with bioptic-proven diagnosis 
of BC were enrolled for same-day contrast enhanced (CE)-FDG-PET-CT and CE-FDG-PET-
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MRI. Inclusion criteria were: diagnosis of BC by immunohistochemistry (IHC), absence of 
previous oncological diseases, > 18 years of age, and lesions of at least 0.2 cm for a 
comprehensive imaging characterization. Exclusion criteria were: pregnancy, blood glucose 
levels > 140 mg/dl (7.77 mM), and standard contraindications for MRI and/or for contrast agent 
injection, artefacts affecting PET-CT and/or PET-MRI, and the absence of structured IHC reports.  
On the basis of these criteria, only n° 50 patients with invasive ductal (ID) BC diagnosis were 
included in this study.  
 
 
Figure 46: Inclusion and exclusion criteria for eligible patients. 
 
2.2 Immunohistochemistry 
Core needle biopsies were performed under ultrasound guidance by a radiologist with more than 
15 years of experience. Biopsies were fixed in 10% neutral buffered formalin at the time of 
biopsy. Mastectomy specimens, obtained from patients who underwent mastectomy, were sent to 
the department of pathology immediately after resection. Expression of ER, PR, HER2, and Ki67 
(marker of cellular proliferation) was determined by IHC analysis. Each tumour sample was 
classified as ER+, PR+, and/or HER2+, or being triple-negative if negative for all three. Positivity 
for ER and PR was defined as the presence of 1% or more positively stained nuclei. The 
histological grade (G) was determined using the method of Elston and Ellis. Histological subtype 
was determined according to St. Gallen 2013 guidelines [69]. 
 
2.3 PET-MRI data acquisition 
Data were acquired on a 3T hybrid PET-MR system mMR Biograph (Siemens, Erlangen, 
Germany). For PET, all patients fasted at least 6 hours before the procedure. Then they received 
401 ± 32 MBq (mean ± standard deviation [SD]) of 18F-FDG intravenously. After a 60 min 
equilibration period during which the patients were at rest, PET images of the tumour were 
acquired with simultaneous acquisition of an MRI scan. For MRI, breast protocol was optimized 
for accurate detection and staging, providing images acquired with a dedicated breast coil. The 
DCE-MRI protocol for all of the examinations included six axial pre-contrast spoiled gradient 
recalled echo (SPGRE) 3D vibe sequences at six different flip angles (2, 5, 8, 12, 15, 20) and a 
dynamic 3D vibe sequence (repetition time [TR]=5.5ms, echo time [TE]=1.7 ms, flip angle=20, 
FOV of 320mm, base resolution of 192, slice thickness of 3.6 mm) to obtain acquisitions before, 
during, and after injection of the contrast agent (0.1 mmol/kg body weight gadolinium-diethylene 
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triamine pentacetate [Gd-DTPA], Magnevist). The 3D acquisition allowed us to cover the entire 
breast. A total of 60 time points were acquired with an average temporal resolution of 9.5s and a 
total acquisition of ~9 min. Patients were allowed to breathe freely. Axial diffusion-weighted 
(DW)MRI was acquired with a single shot spin-echo echo-planar imaging sequence in three 
orthogonal diffusion encoding directions with b-values of 0, 50, 400, and 800 s/mm2, TR/TE = 
14,500ms/66ms, FOV of 340 mm, base resolution of 192, and slice thickness of 4mm.For clinical 
evaluation, the protocol also included axial and coronal T2 turbo inversion recovery magnitude 
sequences (TR=4220 ms, TE= 61 ms, FOV of 340 mm, base resolution of 256, slice thickness of 
4mm) and an axial T2 turbo spin echo (TR=5440ms, TE=81 ms, FOV of 340 mm, base resolution 
of 448, slice thickness of 4mm). Following the acquisition, PET images were automatically 
corrected for tissue attenuation with the attenuation maps generated on the basis of the 2-point 
Dixon MRI sequences [100]. Emission data were corrected for random events, dead time, scatter, 
and attenuation. A three-dimensional attenuation- weighted ordered-subsets expectation-
maximization (3D AW OSEM) iterative reconstruction algorithm with 3 iterations and 21 subsets, 
Gaussian smoothing of 4 mm in full width at half maximum was used. 
 
2.4 Image processing 
DCE-MRI data were analysed using semi-automated software written in house in MATLAB 
(MathWorks, R2015b, Natick, MA, USA). Relaxation rate at baseline (R10) and relaxed signal 
(M0) were calculated, as 3D maps, with the Ernst formula (assuming TE << T2*) using the set of 
SPGRE pre-contrast images at different flip angles [101].The Tofts pharmacokinetic model, 
which is also called the “standard model” as it is the standard approach for the post processing of 
MRI perfusion data, was applied to DCE-MR images to extract different perfusion maps. Ktrans is 
the first order rate constant for plasma to interstitium transport ([1/min]); ve is a measure of the 
extravascular extracellular space (EES) volume fraction; the ratio between Ktrans and ve results in 
the third pharmacokinetic parameter kep, that is the back flux rate constant [1/min]. DW-MRI data 
were automatically computed for the estimation of apparent diffusion coefficient (ADC) maps. 
Regarding PET activity, FDG uptake in tumours is related to the proliferative activity of a 
malignant tissue and to the number of viable tumour cells. Even though its quantification is direct, 
it is subject to the variability introduced by differences in patient size, the amount of FDG 
injected, and radiotracer decay. For this purpose, SUV was used.  
 
2.5 Statistical analysis 
Two groups, each composed by one senior radiologist experienced in breast imaging (more than 
15 years of experience) and one nuclear medicine specialist (more than 20 years of experience), 
reviewed local tumour staging on PET/MRI in consensus. Free-hand region of interest (ROI) 
boundary was manually drawn around the area of maximal tumour extension for each of the 50 
subjects on the subtracted T1 post contrast image slice, avoiding necrotic areas and large feeding 
vessels. An additional ROI (1 cm2) was drawn on the reference contralateral tissue. After data 
resampling, pharmacokinetic (Ktrans, kep, and ve), ADC, and SUV measures for perfusion, 
diffusion, and glucose metabolism evaluation, respectively, were calculated across each ROI 
(maximum and mean values were extracted for each parameter). All statistical analyses were 
performed using SPSS (IBM SPSS statistics, 20). All p-values were two-sided, and p<0.05 was 
considered statistically significant. For multiple comparisons p < 0.017 was considered 
statistically significant.  
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Figure 47: Examples of multiparametric analysis in women with breast ductal carcinoma. Multiparametric 
imaging evaluation of metabolic (PET), morphological (T1w + C), and functional (ADC, Ktrans, ve , kep) 
parameters in a luminal A BC (a), a luminal B BC (b) and a nonluminal BC (c). With increases in perfusion 
parameters, FDG uptake increases at the tumour site, enhancement increases in the morphological acquisitions, 
and diffusivity decreases in the ADC map. 
 
In particular, the tests chosen were: Cohen’s kappa, to evaluate the agreement between the two 
groups of observers in primary tumour detection and extension assessment; Shapiro–Wilk 
analyses to assess the normal distribution of each parameter; Wilcoxon rank-sum test for 
statistically significant difference between tumours and reference area values; and the non-
parametric Spearman’s rank-order correlation and Mann–Whitney U test to verify the 
correlation/association among biological markers as well as between imaging parameters and 
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biological markers. To assess the association between molecular and imaging parameters, data 
were grouped according to: positive (+) or negative (-) expression of ER, PR, and HER2 
receptors; low or high expression of Ki67 (low ≤ 20% and high > 20%); low or high grade (low: 
G1–G2, high: G3); and tumour-node-metastasis (TNM) classification as T1/T2 versus T3/T4, 
according to BC guidelines. Tests were applied on maximum and mean values obtained for each 
parameter, except for ADC (only ADCmean). The receiver operating characteristic (ROC) curve 
test was performed to evaluate the performance of a binary classifier system. The optimal cut-off 
able to distinguish between two BC subtypes was calculated from the data distribution on the 
ROC curves. Multivariate logistic regression analyses were used to determine if independent 
imaging parameters were able to predict BC subtypes.  
 
3. Results 
 
3.1 Clinicopathological features 
Patient and tumour characteristics are summarized in Table 17. St. Gallen 2013 
guidelines[69]were used to classify BC tumour subtypes (Table 18). In comparing St. Gallen 2013 
guidelines to St. Gallen 2011 guidelines [102], no differences were found in tumour subtype 
classification, with the exception of one patient (luminal B according to St. Gallen 2011 vs. 
luminal A according to St. Gallen 2013). In addition, applying aforementioned criteria, in one 
case it was not possible to determine the tumour subtype. The subtypes of the 49ID-BC cases 
were as follows: 13 (26.5%) luminal A, 29 (59.2%) luminal B, 4 (8.2%) HER2 enriched, and 3 
(6.1%) basal-like. For each patient enrolled, the lesion size was calculated by MRI. The mean 
tumour size and relative range for each subtype is summarized in Table 18. 
 
Table 16: Clinical features of tumour lesions in the 50 selected patients 
Clinical feature value 
Age (years), mean (range) 52.3 (35-80) 
Receptor status, n  
ER+ 42 
ER- 8 
PR+ 43 
PR- 7 
HER+ 19 
HER- 31 
Proliferation index (Ki67), n  
≤20% 12 
>20% 38 
Grade, n  
1 1 
2 27 
3 22 
 
Table 17: Molecular subtypes and relative lesion sizes 
 Subtype 
 Luminal A Luminal B HER2 enriched Basal Like 
Number 13 29 4 3 
Lesion size 
(cm), mean 
3.8 (0.7 – 5.0) 4.1 (2.3 – 7.8) 
 
4.2 (2.9 – 6.6) 4.2 (2.6 – 7.1) 
 
148 
 
3.2 Correlation among immunohistochemical biomarkers 
To assess the relationship between hormonal receptors, Spearman analysis and Mann–Whitney 
U test were performed. For this study, n°50 IHC reports were analysed. We found that the 
expression status of PR and ER was significantly correlated (p < 0.001, r = 0.557) meaning that 
ERs and PRs were frequently co-expressed. The expression level of ER was also significantly 
associated with HER2 expression (p = 0.010) and with grade (p = 0.015). In addition, Ki67 was 
associated with HER2 status (p = 0.009), and with grade (p = 0.006).  
 
3.3 PET/MRI assessment in breast cancer 
Excellent agreement between the two observer groups was found in anatomic allocation and 
extension of lesions by PET/MRI (97%, Cohen’s kappa 0.9). All lesions were identified in both 
FDG-PET and DCE-MR images. The comparison between tumours and reference area provided 
significantly higher SUV values in the lesion (p < 0.0001). Conversely, the mean ADC value in 
tumours was significantly lower than the reference area (p < 0.0001) (Fig 50). Moreover, analysis 
of the perfusion parameters derived from the application of the pharmacokinetic Tofts model to 
the breast lesion showed significant differences for each parameter compared to the reference 
region (mean values): Ktrans, p < 0.001; kep, p < 0.001; ve, p = 0.02 (Fig. 50). 
 
3.4 Association between immunohistochemical markers of tumour lesions and 
PET/MRI parameters 
Correlation analysis between imaging parameters and histological biomarkers was made, 
categorizing IHC biomarkers. In Figure 51 we only report the significant results, and the 
absence of the box plot indicates non-significant results: 
• ER: ER status (ER+ and ER-) was significantly associated with perfusion imaging 
parameters (panel a: Ktransmax, p = 0.003; panel b:Ktransmean, p = 0.009; panel c:kepmax, p < 
0.001; panel d: kepmean, p = 0.002) and metabolic parameters (panel e: SUVmax, 0.026; 
panel f: SUVmean, 0.031) 
• PR: PR receptor status (PR+ and PR-) was associated with both perfusion (panel a: 
Ktransmax, p = 0.019; panel c: kepmax, p = 0.021; panel d: kepmean, p = 0.016) and diffusion 
(panel g: ADCmean, p = 0.011,) imaging parameters. Unlike ER status, PR status was not 
associated with glucose uptake (panels e and f). 
• HER2 receptor: Regarding the association of HER2 status (HER2+ and HER2-) with 
imaging parameters, we found that this receptor was related to Ktransmax (panel a:p = 
0.024), kepmax (panel c: p < 0.001), and kepmean (panel d: p = 0.006). HER2 status, like PR 
status, was not associated with glucose uptake (panels e and f). Ki67 index was associated 
with kepmax (panel c: p = 0.021), glucose uptake as SUVmax (panel e: p < 0.001), and 
SUVmean(panel f: p < 0.001). 
• Tumour grade was only associated with kepmax (panel c: p = 0.017) and ADCmean (panel g: 
p = 0.045).  
• TNM was associated with SUVmax (panel e: p = 0.018) and SUVmean (panel f: p = 0.020), 
and lesion size (panel h: p = 0,006).  
Taken together, these results suggested that ER-/PR-tumour lesions were characterized by higher 
values of perfusion parameters. In addition, only ER status correlated with tumour metabolism, 
while only PR- tumour lesions exhibited increased values of diffusion parameters. Conversely, 
decreased values of some perfusion parameters (Ktransmax, kepmax, and kepmean) were associated with 
HER2- tumour lesions. In addition, tumour lesions with a high proliferation index (≥20%) showed 
higher kepmax and SUV values, and tumours with low cellular differentiation (Grade 3) were 
associated with a higher kepmax and ADCmean. Finally, more severe tumour staging was associated 
with both a higher lesion size and glucose uptake. 
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3.5 Association between BC subtypes and PET/MRI parameters 
The ability of PET/MRI parameters to discriminate between BC molecular subtypes was 
evaluated. Because of small groups size (see Table 18), we merged HER2-like and basal-like 
subtypes to create a group named non-luminal subtype (n°7 patients), and the Kruskal–Wallis test 
and pairwise comparisons were performed. We found that Ktransmax (p=0.006), kepmax (p=0.004), 
SUVmax (p=0.001), SUVmean (p=0.002), and ADCmean (p=0.024) were differently distributed 
across the three subgroups. As reported in Figure 3, the non-luminal subtype showed higher 
values of Ktransmax (panel a), kepmax (panel b), SUVmax (panel c), and SUVmean (panel d) than the 
luminal A subtype. The luminal B subtype showed higher values of kepmax (panel b), SUVmax 
(panel c), and SUVmean (panel d) than the luminal A subtype. We did not find any imaging 
parameters that were able to significantly discriminate between non-luminal and luminal B 
subtypes (p > 0.017, see Materials and Methods).  
 
3.6 Prediction of BC subtypes 
ROC curves of the imaging parameters significantly correlating with BC subtype (see Fig.52) 
were calculated with the relative AUC. As reported in Figure 4,  kepmax, SUVmean, and SUVmax 
parameters were able to discriminate luminal A from luminal B subgroups (panel a).All of the 
analysed imaging parameters, except ADCmean, were able to discriminate luminal A from non-
luminal subgroups (panel b), and Ktransmax, and ADCmean were able to discriminate luminal B from 
non-luminal subgroups (panel c). The AUC, p-value, and cut-off values are reported in the tables 
of Figure 4 (right panels). Multivariate analyses were performed to explore the association 
between molecular subtypes and imaging parameters. Luminal A, luminal B, and non-luminal 
subtypes were defined as dependent variables. Among the different independent variables 
analysed (data not shown), the best model came from using Ktransmax and SUVmax (Table 19). The 
results of the multivariate logistic regression analysis are summarized in Table 4. Logistics 
estimation of the variables was performed for luminal A, luminal B, and non-luminal subtypes. 
As reported, this model was able to correctly identify tumour subtypes in 38/49 biopsies (77.6%, 
p < 0.001), with higher accuracy for the luminal B subtype (86.2%). 
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Figure 48: ROC curve analysis showing the ability of each imaging parameter to discriminate among BC 
subtypes: a) luminal A vs. luminal B, b) luminal A vs. nonluminal, c) luminal B vs. nonluminal. The tables on 
the right show the AUCs, p values, and cut-off values of the imaging parameters taking into account the ROC 
curve analyses (*p < 0.05). 
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Table 18: Estimation parameters summary of variables significantly associated with molecular subtypes. 
  Estimate Std. Error Wald df Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
KtransTmax 1.17 0.37 10.073 1.00 0.002 0.44 1.89 
SUVmax 0.23 0.08 8.28 1.00 0.004 0.075 0.39 
 
Table 19: Multivariate analyses. 
 Number of predicted subtype (%) 
Subtypes defined by IHC (n°) Luminal A Luminal B Non-luminal 
Luminal A (13) 
True  
9 (69.2%) 
False 
4 (30.8%) 
False 
0 (0%) 
Luminal B (29) 
False 
3 (10.3%) 
True 
25 (86.2%) 
False 
1 (3.5%) 
Non-luminal (7) 
False 
0 (0%) 
False 
3 (42.9%) 
True 
4 (57.1%) 
True: correctly predicted cases; False: not correctly predicted cases. 
 
4. Discussion 
 
The usefulness of imaging parameters to identify BC subtypes has become of great interest among 
scientists. Nevertheless, because this methodology has not been validated in clinical practice, 
additional studies are needed to verify its reliability for diagnostic and prognostic purposes. In 
recent years, the hybrid PET/MRI system has proven to be very useful in the diagnostic screening 
of different human pathologies including BC [103]. Integration of the two methods (PET and 
MRI) allows spatial and temporal co-registration of the examined body regions, extracting 
multiple tumour parameters in the same pathophysiological condition. To date, only one study 
using the hybrid PET/MRI system has been performed to predict BC subtypes [104]. In that study, 
the authors analysed 21 IDC patients and found that PET/MR biomarkers (kepmean, ADCmean and 
SUVmax) predicted IHC phenotype in 13 of 21 patients (62%; p = 0.001). Therefore, the purpose 
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of our study was to deepen our knowledge in a wider population, to better understand if imaging 
markers extracted through the simultaneous acquisition of FDG-PET and DCE-MRI (PET/MRI 
technology) correlated with prognostic biomarkers of BC, and were able to predict BC subtypes. 
To this end, 50 BC patients at diagnosis were enrolled in this study and underwent PET/MRI 
before pharmacological and surgical treatments. IHC of the core biopsy was used to determine 
the pathological status of tumour lesions. To determine whether there was a correlation among 
prognostic biomarkers (ER, PR, HER2, Ki67, and grade) and imaging parameters (SUV, Ktrans, 
kep, ve, and ADC), association studies were performed. We found that ER status correlated with 
both metabolic (SUV max and mean) and perfusion imaging parameters (Ktrans and kep, max and 
mean). Specifically, levels of SUV (SUVmax and SUVmean) in the ER- group were significantly 
higher than those in the ER+ group. These results were in agreement with other groups that used 
PET/CT technology [70, 72, 73, 76, 78, 105, 106]. Neither SUVmax nor SUVmean was found to be 
associated with PR status [73, 107]. 
 
DCE-MRI-derived parameters, including Ktrans, ve, and kep, reflect the extent of tumour 
angiogenesis, so their increase correlates with disease severity. Interestingly, we found that the 
highest values of Ktrans (max and mean) and kep (max and mean) correlated with the ER- group. 
Similarly, the highest values of Ktransmax and kep (max and mean) also correlated with the PR- 
group. Taken together, our results suggest that perfusion parameters of tumours increase when 
ER and PR are not expressed, and that ER- lesions have increased metabolic activity. Among the 
analysed receptors, only PR status correlated with the diffusion parameter ADCmean, which 
significantly increased when the PR was not expressed (PR- group). To date, the results of 
association between ADC and PR are somewhat controversial; some groups found a correlation 
between the highest ADC values with the PR- group [85, 108], whereas others did not find a 
correlation between PR status and ADC [84, 109, 110].In this study, we found significant 
correlations between grade and ADCmean, with values increasing in Grade 3 tumour tissues. This 
result is discordant with those reported by Molinari et al.[111], in which lower ADC values were 
associated with more aggressive pathological features. However, Shin et al.[18] demonstrated 
that more and stronger correlations between ADC and prognostic biomarkers were found when 
the ADC tumour boundary was considered, suggesting that the result may change according to 
the lesion outline approach. In addition, the highest kepmax values were associated with Grade 3 
tumours, which is in accordance with other studies [88, 112].  Moreover, we found that a high 
proliferation index (Ki67 ≥ 20) correlated with the highest values of kepmax and SUV [105, 107]. 
 
It is worth noting that proving a biological relationship between imaging and tissue 
biological markers is not simple, above all when many and different parameters are 
analysed, and when the results reported in the literature are still discordant. However, 
compared with ER+/PR+ cancer, ER-/PR- cancer has a poorer clinical outcome and 
shorter median survivor, as determined by the presence of a high proliferation index and 
high grade. It should also be that BC with higher perfusion parameters related to tumour 
angiogenesis and elevated metabolism has poor prognostic factors and is more 
aggressive. Based on these factors and globally considering the data obtained from our 
association studies, we found that tumours with low metabolic activity and low 
angiogenesis are more differentiated, less proliferative, and express both ER and PR, 
conditions that reflect a better prognosis. 
 
The second part of our study focused on the ability to select imaging parameters to predict BC 
subtypes. Because of small size groups, we merged HER2-like and basal-like subtypes creating 
the non-luminal subtype group; therefore, the diagnostic accuracy of the selected imaging 
parameters was calculated to find the best prognostic model able to identify a specific BC subtype 
(luminal A, luminal B, and non-luminal subtypes). By ROC curve analyses, we found that both 
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SUVmax and SUVmean were able to significantly discriminate luminal A from luminal B and 
luminal A from non-luminal subtypes. Interestingly, the lowest SUV values correlated with the 
luminal A subtype, suggesting that SUV values lower than the extracted cut-offs correlated with 
a better prognosis. Our data support the suitability of SUVmax as an imaging parameter that 
predicts the luminal A subtype[78, 90] and discriminates it from non-luminal BC [76]. Similarly, 
by ROC curve analyses, we found that Ktransmax was able to significantly discriminate luminal A 
from non-luminal subtypes, with a diagnostic accuracy of 88.1% and with the lowest Ktransmax 
values (cut-off = 2.76). In addition, kepmax was able to discriminate luminal A from non-luminal 
subtypes and luminal A from luminal B subtypes, with a diagnostic accuracy of 84.5% and 77.9%, 
respectively. The ADC can be used to assess the biological characteristics of tumours based on 
tissue microstructure and cell density. We found that this parameter was able to discriminate 
luminal B from non-luminal subtypes with a diagnostic accuracy of 87.7% and a cut-off value of 
1098.5, with the highest values in non-luminal subtype tumours. This result is in agreement with 
[113], showing that higher ADC values were associated with non-luminal BC subtype. These 
results indicate that the lowest values of metabolism, perfusion, and diffusion markers were found 
in BC subtypes with a better prognosis. Based on these results, we decided to develop a prognostic 
model that was able to predict BC subtypes; to this end, multivariate analyses were performed. 
Among the different independent variables analysed, the best performance came from using 
Ktransmax and SUVmax, which were able to correctly predict 38/49 tumour subtypes (77.6%, p < 
0.001). In addition, this model seemed to work well for discriminating luminal B from the other 
analysed subtypes with a diagnostic accuracy of 86.2%.  
 
Because we had a low sample size, we consider the results of this study to be preliminary; thus 
further studies are needed with a larger sample and a more homogeneous distribution of tumour 
subtypes, considering the prevalence of luminal B in our study. Moreover, BC classification was 
based on IHC, which may have a lower sensitivity and specificity for gene expression profiles 
than other molecular biology methods, although it is cheaper and easier to perform.   
 
The heterogeneity and complexity of BC make challenging to create a unique predictive model 
that uses multiple imaging parameters to discriminate among each tumour subtype with high 
diagnostic accuracy. To this end, we proposed a model that separately analysed each imaging 
parameter. We evaluated the cut-off values of each parameter, based on their ability to 
significantly discriminate among subtypes. The model, schematized in Figure 3, used in a first 
step Ktransmax, SUVmean, and ADCmean parameters. Based on our results obtained by ROC curve 
analyses, we proposed the following hypothesis: if the lesion had Ktransmax, SUVmean, and ADCmean 
values < 2.9, < 2.97, and < 1098, respectively, the subtype was luminal (A or B) rather than a 
non-luminal subtype. In the second step, kepmax, SUVmean, and/or SUVmax parameters were 
evaluated to determine if the luminal subtype (identified in the first step) was luminal A or luminal 
B. Specifically, kepmax < 2.64, SUVmean < 2.93, and/or SUVmax < 4.43indicated that the subtype was 
luminal A. In this way, using a separate analysis of the imaging parameters, we were able to 
predict the three analysed subtypes. We are aware that this is just a hypothesis, as the diagnostic 
validity of a cut-off value is strictly related to the sample size that should exceed hundreds of 
samples per tumour subtype, and in our case the number of samples was too low to make cut-off 
hypotheses. Nevertheless, it is plausible to hypothesize an alternative strategy when the imaging 
parameters are numerous and cannot be exclusively used for discriminating all BC subtypes with 
high specificity and sensitivity.   
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III. Association between pharmacokinetic parameters from DCE-
MRI and metabolic parameters from dynamic 18F-
fluoromethylcholine PET in human brain glioma. 
 
The purpose of the study is to compare pharmacokinetic parameters resulting from the modelling 
of dynamic contrast enhanced (DCE-) MRI data (using the Tofts model (TM) and the shutter 
speed model (SSM)) with metabolic macroparameters derived from the application of the spectral 
analysis (SA) to dynamic 18F-fluoromethylcholine (FMC) PET data.  
14 patients with primary untreated glioma were imaged dynamically with DCE-MRI and 18F-
FMC PET, on the same day. Images were registered and analysed for kinetics on a voxel basis. 
FMC-PET images were analysed with spectral analysis. Additionally, tumour-to-background 
ratio (TBR) maps were evaluated. DCE-MRI data was analysed with the TM and SSM. Voxel-
wise Spearman’s coefficients were calculated for each patient to assess pairwise pharmacokinetic 
parameter correlations. Pearson’s correlation coefficients were evaluated to assess TBR vs. 
pharmacokinetic parameters correlations. 
The non-parametric Spearman correlation test showed strong correlations between spectral K1 
and Ki and pharmacokinetic TM-ve (r = 0.88, r = 0.93), SSM-ve (r = 0.92, r = 0.94) and SSM-ti 
(r = 0.92, r = 0.97). Pearson correlation test between TBR and DCE pharmacokinetic results 
showed a significant correlation for TM-Ktrans, TM-ve, SSM-ve and SSM-w*. 
In conclusions, the combination of DCE-MRI and FMC PET, two imaging modalities commonly 
used in the clinical management of brain cancer, provides a practical and attractive combination 
that may predict treatment response better than either modality alone. Results showed a high 
correlation between the irreversible trapping of the tracer in the tissue and the volume of 
distribution of the gadolinium based contrast agent.  
 
1. Introduction 
 
Primary brain tumours are a heterogeneous group of benign and malignant tumours arising from 
the brain parenchyma and its surrounding structures. These tumours are an important cause of 
morbidity and mortality in both adults and children, often generating severe disabilities and 
producing high burden in both families and health care systems[114]. 23770 new cases have been 
estimated in the United States in 2016 (including both sexes)[115]. 
 
Imaging plays a central role in diagnosis, characterisation, surveillance and therapeutic 
monitoring of intracranial tumours. Magnetic resonance imaging (MRI) is the gold standard in 
the diagnosis of brain lesions. However, this technique only reflects biological activity of the 
tumour indirectly by detecting the breakdown of the blood–brain barrier. The direct 
characterization of tumour metabolism, and in particular of cell proliferation, is given by dynamic 
choline-based positron emission tomography (PET) data acquisition.  
 
In this study, we compared pharmacokinetic parameters resulted from the modelling of dynamic 
PET data with spectral analysis (SA) to dynamic contrast enhanced (DCE) MRI data. The 
multimodal analysis allows the integration of anatomic and functional information provided by a 
coregistration between the PET and the MRI. Imaging parameters derived from the two different 
modalities give complementary information with regards to tumour environment as they relate to 
different imaging properties (functional, morphologic). Choline is the precursor for the 
biosynthesis of phosphatidylcholine, a key component of the cell membrane phospholipids. It is 
transported intracellularly and phosphorylated by the enzyme choline chinase (ChKα) to 
phosphocholine and it is trapped within the cell. Most types of cancer are characterized by 
increased choline transport and by the overexpression of choline kinase in highly proliferating 
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cells in response to enhanced demand of phosphatidylcholine [116-119]. In particular, this has 
been reported in prostate, breast, lung, ovarian and colon cancers [120-123]. 11C-choline has been 
widely used to study metabolic activity in vivo but its short physical half-life (20.4 min) is 
disadvantageous for its routine clinical use. The longer half-life of fluorine 18 (18F) (109.8 min) 
overcomes this limitation allowing also late imaging of tumours when sufficient clearance of the 
parent tracer in systemic circulation occurs.  
Dynamic 18F-FMC PET data, quantified with spectral analysis (SA) result in the expression of 
the uptake and the retain of the tracer in the tissue. In particular, this analysis, introduced by 
Cunningham et al. in the early 90s, allows the extraction of two macroparameters of interest: K1, 
the net uptake of the tracer in the tissue, and the Ki, for irreversible tracers, which is the rate at 
which the tracer is irreversibly trapped by the tissue[124]. 
DCE-MRI is a non-invasive methodology that measures tissue perfusion through the acquisition 
of T1-weighted MR images before, during and after an intra-venous (IV) injection of a 
gadolinium-based contrast reagent (CR)[23]. As the CR perfuses into the tissue under 
investigation, the concentration of the contrast in the tissue increases and the tissue water 
relaxation times decrease. A set of T1-weighted dynamic images are acquired during this time in 
order to extract the voxel-wise characteristic signal intensity time curves which are related to the 
CR concentration time curves[65]. These curves are then fit to appropriate mathematical models 
to calculate physiological parameters, such as volume transfer constants and volume fractions. 
The standard model used is the Tofts model (TM), which expresses the flux of the tracer across 
two well-mixed compartments (blood and extravascular extracellular space) through the volume 
transfer constant Ktrans[65]. The TM assumes negligible plasma compartment and is ideal for the 
description of weakly vascularized tissue. The TM embeds the implicit assumption that 
equilibrium transcytolemmal water exchange (between the intracellular space and extracellular 
extravascular space) is infinitely fast, or that the system is in, what is called, the fast exchange 
limit (FXL)[125]. The effect of the CR on the water exchange between the intracellular space and 
the extracellular extravascular space and therefore on the MRI signal amplitude is incorporated 
within the shutter speed model (SSM). The SSM thus introduces a new pharmacokinetic 
parameter, the mean intracellular water molecule lifetime, τi[125]. 
 
The aim of the study is to investigate the relationship between pharmacokinetic parameters 
derived by the application of both Tofts and SSM to DCE-MRI data, and metabolic characteristics 
of brain glioma described by PET imaging. 
 
2. Materials and Methods 
 
2.1 Subjects and imaging 
14 patients (7 male, 7 female; aged 23-73 years, mean 40 years) with suspected primary 
supratentorial glioma were recruited to this study. Ethical approval was given by the local ethics 
committee and informed consent was obtained from all patients. PET/CT and MR imaging were 
performed prior to surgery. Imaging was acquired on the two modalities on the same afternoon 
in 12 of the 14 patients. Tracer production failed for two patients and in one patient it was possible 
to rescan them the following week prior to surgery, while in the other analysis was carried out 
solely on MR data.  
 
2.1.1 FMC-PET imaging 
PET/CT was performed on a Siemens Biograph 6 scanner with 285 MBq of 18F-methylcholine 
(PETNET Solutions Inc., UK), using a dedicated 45 minute brain dynamic list mode acquisition. 
The administration of radioactivity for the PET scans was approved by the Administration of 
Radioactive Substances Advisory Committee, United Kingdom. In one patient 154MBq of 18F-
FMC were injected and in another patient the acquisition was halted after 38 minutes. 
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Discrete venous blood samples of 5mL were taken during the scan in 8 of the 14 patients. Samples 
were taken at 2.5, 5, 7.5, 10 and 45 minutes post-injection in the first two patients and at 1, 2, 3, 
4, 5, 10 and 45 minutes post-injection in the next 6 patients. The start and end withdrawal times 
for the venous sampling were recorded. 
 
2.1.2 DCE-MRI imaging 
MR images were acquired on a 3T Siemens Verio MRI system using a 32 channel head coil; 
including pre- and post-contrast T1-weighted images, T2-FLAIR images and a DCE sequence 
with a variable flip angle pre-contrast T1 map acquisition. The DCE-MRI protocol included five 
pre-contrast spoiled gradient recalled echo (SPGRE) 3D vibe sequences at five different flip 
angles (2, 8, 12, 15, 20, 26), and a dynamic 3D vibe sequence (TR = 3.34 ms, TE = 0.99 ms, flip 
angle = 26, FOV: 240 x 240 mm, acquisition matrix 128x128, slice thickness 5 mm, slice gap 1 
mm, 80 volumes). To obtain acquisitions before, during and after the injection of the contrast 
agent, 0.1 mmol/kg body-weight gadolinium-diethylene triaminepentacetate (Gd-DTPA), 
Gadovist, was injected using a power injector on the 5th acquisition using a flow rate of 3 ml/s. 
The 3D acquisition allowed us to cover the entire brain. 80 time points were acquired with an 
average temporal resolution of 2.89 s and a total acquisition time of ≈ 4 minutes. 
 
2.2 Image registration and analysis 
Volumes of interest (VOIs) were drawn by a Radiologist and confirmed by a Consultant 
Neuroradiologist for each patient around T2-FLAIR hyperintense regions. An additional ROI was 
drawn around the external carotid artery for the calculation of the image derived AIF (for both 
the PET and MRI post processing, as described above). 
 
2.2.1 DCE-MRI kinetic analysis 
DCE-MRI data were analysed using a semi-automated software written in house in MATLAB 
(Mathworks, R2017a). Before the application of any pharmacokinetic model, we calculated the 
relaxation rate at baseline (R10) and relaxed signal (M0) as 3D maps, with the Ernst formula 
(assuming TE<<T2*) using the set of SPGRE pre contrast images acquired at different flip 
angles[126]:   
 "(q) = ∂u	sin(q) >E.ü±Olû±>E∑∏π	(∫).ü±Olû±  1) 
 
where α is the flip angle having values [2 8 12 15 20 26] and TR is 3.34 ms. Reformulating 
equation 1 as a linear regression system (y = cx + d) following the method described by Liberman 
et al. in[34], gives: 
 ª(∫)πñº(∫) = Ω ª(∫)æøº(∫) + ∂(1 − Ω) 2) 
 
where Ω = DE¿Olm± .  
The slope c = E and intercept d = M0 (1 - E) can thus be estimated and continuing from [34], R10 
and M0 can then be obtained through:  
 á>u =	− ¡∏¬	(-)m± ,  ∂u = )>E-  3) 
 
Then, 4D (x, y, z, t) post-injection longitudinal relaxation rate R1(t) maps for each dynamic phase 
are calculated using signal intensity data from the post contrast dynamic series: 
 á>(I) = 	−(1 â¿√ )ƒ≈∆ >E(«W`)>E∑∏π	(∫)(«W`) 4) 
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where α = 26, î = "(I) − "(0) ∂usin	(q)⁄ , ö =	 (1 − Ω) 1 − Ω	 ∙ cos	(q)⁄ . S(0) and S(t) are the 
pre contrast injection signal intensity and the signal at the dynamic phase t respectively[35]. 
 
The longitudinal relaxation rate is determined in order to calculate the concentration of the 
contrast reagent. This is done through a calibration between the concentration of contrast reagent 
[CR] and the measured H2O MR signal. This can be modelled by either a linear or nonlinear 
relationship as described below.  
 
2.2.1.1 Tofts Model (TM) 
DCE-MRI data were fitted with the Tofts model assuming a linear dependence of R1 on [CR] 
(that is the equivalent of assuming the equilibrium transcytolemmal water exchange kinetics in 
the FXL): 
 á>(I) = 	 ú>[?á(I)] + á>u 5) 
 
where r1 is the CR relaxivity.  
The extravasation of the contrast from the plasma to the EES was accounted by the Kety-Schmidt 
rate law[127]: 
 [?á+(â)] = =,'(/n ∫ [?á[(I)]DY5ù71h(ûü5)83 HI,u  6) 
 
where Ktrans is the first order rate constant for plasma to interstitium CR transport (min-1) and ve 
is a measure of the EES volume fraction.  
The ratio between Ktrans and ve results in the third pharmacokinetic parameter kep, which is the 
back flux rate constant (min-1). [CR0] and [CRp] are the concentration of CR in the 'outside' space 
(the extravascular extracellular space) and in the plasma respectively. [CRp] is also called the 
arterial input function (AIF). The fitting of eq. 6 was performed using the inbuilt MATLAB 
fminsearch function, which uses the Nelder-Mead simplex algorithm as described in Lagarias et 
al.[40]. The minimization procedure is done voxel-wise in order to obtain a 3D map for each 
pharmacokinetic parameter. We set input values of 0.1 and 0.01 for the Ktrans and ve, respectively, 
and run the algorithm with 10,000 iterations and a tolerance of 10-8. 
 
2.2.1.2 Shutter speed model (SSM) 
In the SSM, equation 5 is applied to the distribution of the CR in the blood, without assuming that 
the equilibrium transcytolemmal water exchange kinetics are in the FXL. The longitudinal 
relaxation rate is measured as: 
 á>b(I) = 	ú>[(1 − ℎ)°?á[(I)¢ + á>u[ 8) 
 
where b stands for the whole blood, p for the plasma and h the fraction of haematocrit in the 
blood. However, about half of the water in the blood is intracellular and cannot be accessed 
directly by the CR molecules[128]. The transport outside the erythrocytes therefore needs to be 
considered, as described by the two equilibriums:  
 
H2Oi ↔ H2Op                        9) 
H2Op+ CRp↔H2O·CRp                10) 
 
The mean water molecule lifetime in common CR is normally < 10-7 s, and the linear equation 5 
is suitable for homogeneous solutions. In the case of erythrocytes, equation 10 is also considered 
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fast for some commonly measured [CRp] values [128, 129]. After extravasation, the CR is 
commonly distributed into the interstitial extracellular space, at a rate defined by: 
 á>∗(I) = 	 ú>u£u[?áu(I)] + á>u 11) 
 
where R1*(t) is the rate constant of the extravascular water signal, r10 is the interstitial CR 
relaxivity and p0 is the fraction of the extracellular tissue water. The application of equation (11) 
to biological tissues assumes that the interstitium is a homogeneous solution and that the system 
remains in the fast exchange limit. However, many studies have shown that, even though the 
equilibrium in equation 10 is fast,  the FXL assumption is not true for all [CR0] values following 
a bolus injection[128]. [CR0] depends on the dimensions of the parenchymal cells that are 
generally much larger than erythrocytes and have a less water-permeable cytolemmae. 
Furthermore, tissue parenchyma cannot be considered as a single homogeneous solution and a 
single MRI voxel will constitute a number of compartments. The main result of this 
compartmentalization is given by:  
 á>§(I) = (1 2⁄ ) Ã2á>* +	ú>+[?á+(I)] +(á>u + á>* +	1 w*⁄ ) £+ − {(2 w* − ú>+[?á+(I)] −	⁄⁄ (á>u + á>* +	1 w*⁄ ) £+⁄ )B +4(1 − £+) w*B£+⁄ ]OGÕ 12) 
 
where R1L(t) is the long relaxation rate constant of the shutter speed model. R1i is the H2O rate 
constant in the absence of exchange of CR and τi is the average intracellular lifetime of a water 
molecule. The SSM was fitted by substituting equation 12 in equation 6 using the MATLAB 
functions fminsearch and fminsearchbnd, similarly to the TM. The initial estimates for the SSM 
Ktrans and ve where taken as the outputs of the TM, while the initial estimate for τi was set at 
0.1[27].  
 
2.2.2 Spectral analysis 
Dynamic FMC-PET data were quantified with spectral analysis (SA)[124], which considers the 
tissue tracer activity in a given volume of observation at time t	?,*nno.(I) as the convolution of 
the plasma time activity curve ?[(I) with the IRF: 
 ?,*nno.(I) = ∑ ?[(I) × qrDEb2,srtu  13) 
 qr and vr are assumed to be real and non-negative values. We fixed a grid of 100 vrvalues covering 
a spectral range of [1/3Tf 1/Ti/3] (where Tf is the end time of the experiment and Ti is the duration 
of the first scan) and then estimated the amplitudes 	qr	(the spectral contents). Only a few values 
of qr > 0 (correspondent to non-zero b values) are detected and they constitute the spectrum of 
the kinetic components of the tracer. The components of the spectrum have different meaning 
depending on their position in the spectrum, hence on their correspondent vr value. Components 
with very large vr are proportional to ?[(I) and are seen as high frequency components, while 
components corresponding to vr = 0 become proportional to ∫?[(w)Hw	and are seen as low 
frequency components. In other words, they account for a slower kinetic, for the trapping of the 
tracer in the tissue (irreversible trapping). Lastly, the components with intermediate vr values are 
referred to as the equilibrating components and their number corresponds to the number of tissue 
compartments that exchange material with the plasma. 
The information given by the spectrum allow the estimation of some macro parameters of interest. 
They are: the influx rate constant	=> = ∑ qrsrtu  [mL/xy]/min]; the net uptake of the tracer in the 
tissue, which, for irreversible tracers, can be derived by the limit of the IRF→ ∞, =* =
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lim/→Ö Üáà(I) = qu [mL/xy]/min], and the volume of distribution, which, for reversible tracers, 
can be derived as the integral of IRF, $m = ∫ Üáà(w)HwÖu [124] [mL/xy]]. The algorithm setting 
was implemented in MATLAB, based on the SAKE software by Veronese et al.[130]. 
 
2.3 Arterial input function (AIF) 
Kinetic analysis of both dynamic PET and MRI data requires the quantification of the 
concentration of the tracer and the CR, respectively, in the blood. This function is also called 
arterial input function and has been derived drawing an additional ROI around the carotid 
artery. The correction of the image derived AIF is different for PET and MRI kinetic analysis as 
described below.  
 
2.3.1 DCE-MRI AIF 
Figure 1 shows the additional ROI placed in the external carotid artery for the calculation of the 
image derived AIF. Signal-intensity curves were converted to R1-time curves by using the 
baseline signal intensity before the first pass of the CR as a reference [131], setting the haematocrit 
in the blood to 0.45, and getting the baseline blood T1 from the T10 map. 
 
 
Figure 49: Measurement of the AIF. The VOI was placed in the carotid artery for the extraction of the arterial 
input function (AIF) as shown in the axial T1 VIBE image in (A). The time intensity curve for the concentration 
of contrast reagent in the plasma in the VOI indicated in red in (A) is shown in (B). 
 
2.3.2  FMC-PET AIF 
For each patient, total FMC activity in each blood sample was used to fit the plasma-over-blood 
(pob) ratio to a monoexponential curve to provide a continuous pob representation. Then, a total 
plasma activity curve was obtained by multiplying the pob by our tissue derived input function. 
Finally, the average fraction of parent compound measured in the plasma in each sample was 
fitted to obtain a continuous representation of the parent tracer concentration which was then 
multiplied by the total plasma function. Our result was a tissue derived parent plasma input 
function for each patient, which was used in SA. 
 
2.4 Statistical Analysis 
Pharmacokinetic analysis produced tumour 3D parametric maps of the Tofts model Ktrans (TM-
Ktrans), kep (TM-kep) and ve (TM-ve) and the shutter speed model Ktrans (SSM-Ktrans), kep (SSM-kep), 
ve (SSM-ve) and τi (SSM-τi). Spectral analysis produced tumour 3D parametric maps of K1 and 
Ki. Pearson’s and Spearman’s correlation coefficients were evaluated for each patient and all 
available pairwise combinations of parametric maps and FMC TBR. Mean and standard deviation 
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values for the patient cohort were reported. All statistical analysis were performed in MATLAB 
(MathWorks R2017a). 
 
3.  Results 
 
3D parametric maps of TM and SSM estimates of Ktrans, ve and τi and of spectral K1 and Ki for 
one axial slice of a non-enhancing tumour are shown in Figure 50.  
 
 
 
Figure 50: Patient n. 3 (WHO grade III). A) 18F-FMC PET; B) Spectral analysis K1 and C) Ki; D) Post 
gadolinium T1 MR image; E) TM-Ktrans and F) TM- ve; G) SSM-Ktrans,  H) SSM-ve and I) τi.   
 
Table 21 shows the results of the application of TM and SSM to DCE-MRI data and SA to 
dynamic PET data (mean and standard deviations). 
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Table 20: Estimates of the mean and standard deviation for derived parameters in tumour tissue. The table 
shows the volume transfer constant Ktrans, the intravasation rate constant kep, the EES volume fraction ve, the 
intracellular water molecule lifetime τi obtained with the application of the Tofts model (TM) and shutter speed 
model (SSM). It also shows the net influx rate K1 and in irreversible uptake rate of the tracer Ki evaluated with 
spectral analysis (SA). Results are expressed in terms of mean and standard deviation (µ  ± σ). 
Variables µ  ± σ 
TM-Ktrans 0.27 ± 0.17 
TM-kep 0.74 ± 1.047 
TM-ve 0.023 ± 0.025 
SSM-Ktrans 0.51 ± 0.44 
SSM-kep 0.52 ± 0.71 
SSM-ve 0.084 ± 0.090 
SSM-ti 0.41 ± 0.33 
K1 0.14 ± 0.14 
Ki 0.028 ± 0.058 
 
 
3.1 Comparison between dynamic PET and MRI pharmacokinetic parameters 
The non-parametric Spearman correlation test showed strong correlations between spectral K1 
and Ki with pharmacokinetic TM-ve (r = 0.88, r = 0.93), SSM-ve (r = 0.92, r = 0.94) and SSM-
ti (r = 0.92, r = 0.97) as shown in Table 22.  
 
 
Table 21: Results of the non parametric Spearman correlation test applied between DCE MRI pharmacokinetic 
results and spectral analysis perfusion parameters. 
Parameters p r 
TM-ve vs Ki 0.0070 0.93 
SSM-ve vs Ki 0.0060 0.94 
SSM-ti vs Ki 0.0010 0.97 
TM-ve vs K1 0.021 0.88 
SSM-ve vs K1 0.0090 0.92 
SSM-ti vs K1 0.0080 0.92 
 
3.2 Comparison between static PET and MRI pharmacokinetic parameters 
Pearson correlation test between TBR and DCE pharmacokinetic results showed 
significant correlation (Table 23).  
 
Table 22: Results of the Pearson correlation test applied between DCE MRI pharmacokinetic results and TBR 
 
Parameters p r 
TM-Ktrans vs TBR 0.015 0.65 
TM-ve vs TBR <<0.01 0.86 
SSM-ve vs TBR <<0.01 0.79 
SSM-ti vs TBR <<0.01 0.78 
 
 
 
162 
 
 
4.  Discussion 
 
The  aim of this study was the investigation of the relationship between pharmacokinetic and 
metabolic features in brain tumours, evaluated using DCE-MRI data (fitted with the Tofts and the 
shutter speed model) and dynamic (and static) 18F-FMC PET data. The comparison with the two 
pharmacokinetic models resulted in correlations with both the TBR and SA related parameters. 
A higher significance of the correlations with the SSM is suggested by the resulting lower p values 
(Tables 22 and 23). 
 
The present literature shows 18F-FDG to be the tracer of choice for the management of several 
diseases for its extreme versatility as a glucose analogue. Despite the advantage of that, it has 
been largely demonstrated the possibility of false-positive case of 18F-FDG uptake due to non-
oncological processes as inflammation or benign tumours or false-negative findings associated 
with the low glucose metabolism rate of the examined diseases [132]. In the brain, the 18F-FDG 
is usually highly enhanced in the normal grey and white matters, due to the specific glucose 
metabolism of the neurons, that allows the diagnosis of degenerative diseases [133, 134]. Despite 
this feature, this tracer plays a limited role in the detection or monitoring of brain tumours. In 
fact, brain primitive lesions or metastases usually show a very different pattern of uptake of 18F-
FDG, generally classified as low, mild, or high, being often barely identified from the high 
gradient of physiological tracer uptake in the brain[135]. The choline is a precursor of 
phosphatidylcholine, an important element of cell membrane. The peculiar physiopathologic 
pathway of choline allows to use this tracer as a marker of lipogenesis and synthesis of cell 
membrane, helping to detect tumours with a high synthesis of cellular wall[136]. Therefore, since 
1997, preclinical[137] and clinical settings[138] started to deepen the knowledge about the 
usefulness of radiolabeled choline PET in diagnosing brain tumours. In particular, Coleman et 
al.[139] showed that patients with suspected recurrent brain tumours had more clearly defined 
abnormal accumulation on the choline PET than with the 18F-FDG PET, while the choline uptake 
observed in normal cortex was corresponding only to 10 % of the uptake registered with 18F-
FDG[136]. The kinetic analysis of dynamic 18F-FMC PET data has been mainly done on patients 
with prostate cancer [140-142] but results of the combination between PET and MRI quantitative 
parameters are not available in the present literature.  
The results of the correlation between SA K1 and Ki with TM and SSM parameters is shown in 
table 2. No correlation was found between Ktrans and both K1 and Ki testifying: the delivery of the 
radiotracer and of the gadolinium based contrast agent is based on different physiological 
mechanisms and, as usually happens with the FDG, PET and MR related rate constants provide 
complementary findings[42]. A part form the different permeability over surface area of the 
choline and on the Gd-based CA, the uptake of these two is driven by active[143] and passive[144] 
mechanisms, respectively. On the other hand, we found significant correlations between K1, Ki 
(and TBR) and kep and ve (from both TM and SSM). ve is the volume fraction of extravascular 
extracellular space. Many studies on breast cancer show inverse correlation between ve and the 
SUV, suggesting that regions with high level of glucose metabolism, in these particular examples, 
may be characterized by high cellularity[44, 61]. In our study, we found a positive significant 
correlation between ve and both the delivery rate constant and the rate at which the choline is 
irreversibly trapped by the tissue. This might be related to a different interpretation of the ve, as 
an expression of the space available for the choline to be uptaken and then phosphorilated. Finally, 
PET parameters were found to be correlated to the SSM-τi. This parameter is the result of the 
extension of the Tofts model, which is the standard model for the analysis of DCE-MRI data. In 
the brain, the feasibility of the SSM DCE-MRI pharmacokinetic analysis was investigated by 
Rooney et al. on 6 healthy subjects, 6 patients with multiple sclerosis and 5 patients with 
glioblastoma[145]. Cerebral τi maps were said to represent metabolic activity in the brain as τi is 
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proportional to water permeability [145]. It has been suggested that τi may be related to the NKA 
pump, driven by the P-type ATPase ion pump[146, 147]. In our study, we found a positive 
correlation between τi and the PET related parameters. This contradicts the results of Hectors et 
al. in the assessment of hepatocellular carcinoma with 18F-FDG PET and DCE-MRI[28]. Choline 
PET measures cellular proliferation, whereas τi is mainly dictated by Na+, K+-ATPase activity 
sustained by ATP production[26]. This correlation could mean that the metabolism of the cell is 
faster[65] as cell membrane synthesize their cellular wall. Correlations with the TBR are shown 
in table 3 and confirm the previous results, with the additional moderate correlation with TM-
Ktrans. This finding might be of particular interest as Ktrans has been shown to be predictive of 
patients’ response to therapy, in other types of cancer [47, 148].  
The main limitation of this study is the limited size of the examined dataset. Moreover, any 
histological characterization was present for the evaluation of the performance of each 
pharmacokinetic model compared to a tissutal ground truth. The sensitivity of DCE-MRI data to 
water exchange effect was reduced by the 26◦ flip angle acquisition. Li et al. suggest that data τi 
sensitivity can be enhanced by reducing the flip angle (~8◦)[66]. This can possibly affect the 
precision of the τi parameter and, as a consequence, the accuracy of the correlation with other 
imaging metrics. Furthermore, statistical analyses are based on mean quantitative values, which 
cannot be good description of a heterogeneous tissue, such as the tumour one. On the other hand, 
DCE- pharmacokinetic parameters were evaluated with the application of an individual arterial 
input function, which avoids many problems related to the widely used population averaged 
one[67]. 
 
5.  Conclusions 
 
In conclusion, dynamic contrast-enhanced MRI and dynamic FMC PET are two imaging 
modalities that can provide valuable insight to the characterization of tumour tissue.  
The two imaging techniques are functionally very different and the extent of their agreement or 
discordance is not well understood. Therefore, the primary purpose of this study was to evaluate 
the association between pharmacokinetic parameters resulted from the analysis of DCE MRI data 
with TM and SSM and metabolic parameters derived from the application of the SA to dynamic 
PET data. Results showed a high correlation between the irreversible trapping of the tracer in the 
tissue and the volume of distribution of the gadolinium based contrast agent. The study is a novel 
co-analysis of kinetic MRI and choline PET, which will benefit from a spatial correlation with 
DWI-MRI and tissue biology. 
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IV. Clinical translation of [18F]ICMT-11 for measuring 
chemotherapy-induced caspase 3/7 activation in breast and lung 
cancer 
 
1.  Introduction 
 
Cell death, is recognised for the constant regulation and harmony of biological systems and is 
known to occur by several mechanisms, predominantly necrosis and apoptosis. Necrotic cell 
death is characterised by a non-specific process of events resulting in plasma membrane rupture 
and a localised inflammatory response around the surrounding cells and tissues. Apoptosis 
(programmed cell death, first described by Kerr and colleagues [149, 150], however, is a precise 
series of well executed events with upstream regulators and downstream effector components [3, 
4], leading to the systematic dismemberment of the cell by Bapoptotic triggers. The Bapoptotic 
triggers^ are kept in balance by pro- and anti-apoptotic regulatory proteins, including members 
of the Bcl-2 family [151]. One of the key players in the execution of apoptosis is a family of 
caspases (cysteine aspartate specific proteases) [152]. Caspases 8 and 9, known as the initiator 
caspases, are responsible for initiating a cascade of proteolysis by cleavage of procaspases 3, 6, 
and 7 to their activated form. The controlled demolition of cellular components resulting in DNA 
fragmentation is unique to apoptosis, and one that is driven by caspase 3, a central effector 
caspase. It is this unique feature of caspase-3 that permits its potential use as a non-invasive 
biomarker of apoptosis [153]. Imaging the apoptotic process may prove to be invaluable for the 
following reasons: a) by enabling anti-cancer therapy response assessment at earlier time-points 
than current response criteria allows with conventional imaging, apoptosis imaging may aid the 
decision to implement changes to treatment in the context of drug resistance sparing the unwanted 
side-effects of ineffective treatment, and b) secondly, by allowing for the pharmacodynamic 
assessment of drugs that target the apoptotic machinery in early-phase trials during drug 
development. There has been a handful of pre-clinical and clinical PET imaging studies 
attempting to image molecular and biochemical events of the apoptotic process [154-162]. Studies 
with [18F]ML-10 [163-165] and [99mTc]Annexin V [166-168] showed promising results in 
humans. A study of [18F]ML-10 — a member of the aposense family of biomarkers that measures 
‘apoptotic imprint’ — in human subjects reported favourable dosimetry and biodistribution, and 
binding to apoptotic sites in testicular tissue of mice, confirmed by terminal deoxynucleotidyl 
transferase (TdT) dUTP nick-end labeling (TUNEL) of apoptotic cells; initial studies reported 
correlation of early changes of tumour [18F]ML-10, and later changes in anatomical tumour 
dimension following radiotherapy. Annexin V, a 36 kDa calcium-dependent protein with the 
ability to bind to cells during all stages of the apoptotic process, has high affinity for 
phosphatidylserine (a phospholipid, normally located on the inner leaflet of cell membranes). 
During apoptosis, phosphatidylserine is exposed to the extracellular surface and provides an 
opportunity for annexin V binding. To date, [99mTc]HYNIC-annexin V has been investigated 
widely for the imaging of apoptosis, and has provided invaluable information in several disease 
settings. Both [18F]ML-10 and [99mTc]Annexin V imaging, however, pose limitations. [18F]ML-
10 remains undefined in its specific target and [99mTc]Annexin V in its non-specific uptake, 
which has proved difficult in distinguishing between apoptosis and necrosis. Clinical studies 
evaluating apoptosis in breast cancer therapy have shown an increase in apoptosis within biopsies 
taken at 24 h post-chemotherapy (comparing six cycles of epirubicin, cisplatin, and fluorouracil 
with six cycles of doxorubicin and cyclophosphamide) compared to baseline [169-172], as well 
as at 48, 72, and 96 h post-treatment (combination of epirubicin, cisplatin, and fluorouracil, 
doxorubicin and cyclophosphamide and weekly paclitaxel) [173]. In the small numbers of patients 
studied, the authors highlighted the wide variation of changes in apoptosis and or/necrosis and 
importantly, no correlation of the changes with clinical response to treatment. Breast cancer is, to 
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an extent, the ideal clinical setting to obtain tissue pre- and post-therapy. Biopsies offer a snapshot 
of caspase activation at microscopic levels; however, PET and MRI provide dynamic and perhaps 
more robust non-invasive methods for assessment of apoptosis across the entire lesion volume. 
The fundamental requirements of any PET radiolabeled probe are ease of synthesis, robust and 
reproducible facile radiolabelling procedure, and high specificity and selectivity. [18F](S)-1-((1-
(2-fluoroethyl)-1H-[1,2,3]-triazol4-yl)methyl)-5-(2(2,4-difluorophenoxymethyl)-pyrrolidine-1-
sulfonyl), [18F]ICMT-11 (Figure 51a), an activated caspase-3/7 specific PET imaging 
radiotracer, was designed from a library of isatin-5-sulfonamides, a chemical class known to have 
caspase inhibitory activity. With regard to the mechanism of action in relation to selectivity for 
binding activated caspase-3/7, the dicarbonyl functionality of isatin sulfonamides, including 
[18F]ICMT-11, is thought to form an intracellular enzyme– tracer complex with the cysteine 
residue of the active site of caspase-3/7 — forming a thiohemiketal via the electrophilic C-3 
carbonyl of the isatin sulfonamide and the nucleophilic cysteine thiol functionality [174]. 
[18F]ICMT-11 was selected for further evaluation, due to its subnanomolar affinity for activated 
caspase-3, high metabolic stability, reduced lipophilicity, and facile radiolabelling [175]. Here, 
we report the results of the first clinical study investigating [18F]ICMT-11 as a noninvasive 
biomarker to assess tumour apoptosis in locally advanced breast cancer pre- and post-first-cycle 
of - and in locally advanced lung cancer patients receiving chemotherapy as first-line treatment. 
 
2.  Materials and methods  
 
2.1 Radiopharmaceutical preparation 
[18F]ICMT- 11 synthesis and radiolabelling was performed by Imanova Ltd., as previously 
described [176].  
2.2 Patients  
Two independent phase 1 non-randomised open-label prospective feasibility studies (breast and 
lung cancer) were recruited from 2013 to 2016. The aim of this study was to assess the effect of 
chemotherapy on [18F]ICMT-11 uptake by PET and relationship between this variable and blood 
and tissue activated caspase-3/7 markers. Inclusion criteria in the breast cohort required patients 
18 years or older, newly diagnosed with locally advanced potentially operable breast cancer 
receiving NCT followed by surgery. At least one measurable breast lesion ≥ 20 mm was required 
on conventional imaging. Patients were excluded from the study if they had received any 
chemotherapy, immunotherapy, biologic therapy, or investigational therapy within 14 days prior 
to the first dose of [18F]ICMT-11 injection. Exclusion also applied if the subject was undergoing 
occupational monitoring of ionising radiation exposure, was lactating or pregnant, or was taking 
any anticoagulation therapy, a prolonged prothrombin time, or had a positive Allen’s test. All 
breast patients, as per standard routine diagnostic and staging procedures, had a pre-treatment 
core-needle biopsy and ultrasound (USS) for histological confirmation with characterisation of 
hormone receptor status alongside imaging with mammogram, and if indicated an MRI of the 
breasts. Patients had a sentinel lymph node biopsy prior to NCT if deemed appropriate by their 
clinical team. NCT consisted of six cycles of FEC-T (5-fluorouracil, epirubicin, 
cyclophosphamide and docetaxel) alongside trastuzumab (Herceptin) in those with HER2-
positive breast cancer. Patients were treated at Imperial College Healthcare NHS Trust, and one 
patient was treated at their local oncology unit. Clinical response using RECIST 1.1 after three 
cycles of NCT using USS and after six cycles of chemotherapy on surgical histopathology 
specimens (post wide local excision or mastectomy ± axillary lymph node clearance) was 
documented. Patients underwent a baseline dynamic [18F]ICMT-11 PET/ CT prior to start of NCT 
for 65 min followed by a repeat PET/CT scan performed 24–48 h (early) or within 2–14 days 
(late) post-chemotherapy and repeat breast biopsy within 24 h of the second PET/CT to correlate 
apoptosis in breast tissue utilising cleaved (active) caspase-3 staining by immunohistochemistry. 
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In the small cohort of lung patients (n = 2), subjects diagnosed with non-small cell lung cancer 
undergoing platinumbased chemotherapy treatment (both patients were treated with pemetrexed 
and cisplatin) were enrolled. At least one measurable lung lesion ≥ 20 mm was required on 
conventional imaging. Patients were required to have a PET/CT, as well as DW- and DCE-MRI 
at baseline and post-chemotherapy (24–48 h (early) and within 6–8 days (late) post-treatment). A 
baseline DW- or DCE-MRI over the area of interest was followed by a 61-min dynamic 
[18F]ICMT-11 PET/CT scan. The Harrow and Westminister London Research Ethics Committees 
approved the breast and lung study, respectively. All subjects signed a written informed consent 
form. The study was conducted according to the Declaration of Helsinki. The administration of 
radioactivity was approved by the Administration of Radioactive Substances Advisory 
Committee, U.K. 
 
Figure 51: Chemical structure of [18F]ICMT-11 and) study design in breast and lung cancer cohorts. a Schematic 
diagram of chemical structure of [18F]ICMT-11. b Study design in breast cancer patients receiving neoadjuvant 
chemotherapy. Patients underwent a baseline and follow-up scan with a repeat second breast biopsy under USS 
guidance, within 24 h of the second PET/CT scan. The cohort of lung cancer patients recruited to study all 
received first-line chemotherapy (combination chemotherapy with a platinum-based compound — Cisplatin). 
[18F]ICMT-11 PET/CT and MRI (DWand DCE) were performed at three time-points (baseline, follow-up at 24–
48 h, and within 6–8 days post-chemotherapy. FEC= 5- fluorouracil, epirubicin and cyclophosphamide, USS = 
ultrasound, MRI magnetic resonance imaging, DW= diffusion-weighted, DCE= dynamic contrast-enhanced. 
 
2.3 Imaging acquisition  
Images were acquired on a Biograph 6 TruePoint PET/CT scanner (with TrueV; extended field 
of view [Siemens]) with 21.6 cm axial and 60.5 cm transaxial fields of view. Patients in both 
studies underwent an attenuation CT scan (CT settings: tube potential, 130 kV; exposure, 15 
effective mAs; pitch 1.5; slice thickness, 5 mm; rotation time, 0.6 s; effective dose of 2.5 mSv) 
of the thorax before administration of [18F]ICMT-11 injection. [18F]ICMT-11 was injected with a 
target dose of 300 MBq (maximum dose 370 MBq) as a slow bolus in 1– 20 mls of saline over 
30s.  
Dynamic PET imaging was performed in a single bed position over 65 min with blood and plasma 
radioactivity measurements at specified time-points. Data were binned into 35 frames and 
reconstructed using the ordered subset expectation maximization algorithm (3 iterations and 21 
subsets). In the lung cohort, dynamic PET imaging was performed in a single bed position over 
61 min. Data were binned into 36 frames and reconstructed using the ordered subset expectation 
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maximization algorithm (3 iterations and 21 subsets). Radioactive blood data were taken but were 
not analysed in this study.  
Lung  MRI was performed on a moving-table 3T system (Siemens Verio with Syngo MR B17, 
Erlangen, Germany), using the body coil for transmission and a matrix phased array coil as 
receive coil. Axial slices were acquired during free-breathing for DW-MRI, while DW-MRI slice-
matched T2-w imaging was also performed. Dynamic contrast enhanced MRI (DCE-MRI) was 
performed on the sagittal plane using a VIBE acquisition (0.1mmol/Kg) DOTAREM®. 
2.4 Image analysis  
All volumes of interest on PET/CT were outlined manually on Hermes (Hermes Diagnostics, 
Stockholm, Sweden) by a single investigator (SD) to avoid any interobserver variation. For the 
breast study, volumes of interest (VOIs) were drawn on fused PET/CT datasets by outlining the 
whole primary breast tumour and any involved axillary lymph nodes [regions of interest (ROIs) 
over several slices]. VOIs were also drawn using a 2-cm fixed sphere to outline contralateral 
breast tissue, normal lung, bone, muscle, and aorta. In the lung study, VOIs were drawn outlining 
the primary lung tumour lesion, normal contralateral lung, bone, muscle, and aorta. SUV60ave, 
SUV60max, tumour to breast ratio (TBR60max) and tumour to muscle ratio (TMR60max) were 
obtained at baseline and postchemotherapy in both studies. In both studies, all VOIs were also 
outlined on fused PET/ CT images to create binary object masks using Analyze software (version 
11; Biomedical Imaging Resource, Mayo Clinic). The object masks created for tumour and lymph 
nodes, alongside respective dynamic PET data, were used within Matlab 16a (The MathWorks®) 
for analysis and characterisation of the VOIs by voxel intensities sorting. Voxelwise analysis of 
PET data was done as previously described [177]. Briefly, this involved extraction of all the 
voxels within each VOI and sorting as per their intensity frequency. PET-based voxel intensity 
sorting (PVIS) identifies any shifts in voxels, as would otherwise be difficult to observe by using 
only ROI analyses, where any spatially discrete areas of effect may be averaged. Any shifts 
observed (higher intensity voxels) were presumed to be in keeping with apoptosis and shifts to 
lower intensity voxels representing necrosis. The highest voxel intensities (taken as a cut-off at 
the 95th percentile) are more indicative of high radiotracer retention than the voxel mean, and 
were taken to biologically represent apoptotic cells. Histogram analysis was then performed using 
in-house software developed in Matlab 15a (The MathWorks(R)), to calculate first-order 
statistics.  
2.4.1 DW-MRI and DCE MRI  
ADC maps were generated in Matlab 15a (The MathWorks(R)) using monoexponential, non-
linear fittings to the equation: S=S0·exp(-b·ADC) and all ten b-values (0, 10, 20, 30, 50, 80, 100, 
150, 400 and 800 s/mm2). ADC values are expressed in µm2/s. For voxels in which the ADC 
calculation software failed to converge or returned negative values, the ADC value was set to 
zero (processing software: Medical Image Processing, Analysis and Visualisation, National 
Institutes of Health, US), where the regions of interest (ROIs) were drawn, with consideration to 
avoid regions affected by artefacts and partial volume effects. Multiple-slice ROIs were used (i.e. 
volumes of interest-VOIs), as opposed to single-slice ones for the analysis, to avoid observer bias 
and reduce ADC measurement variability. Volumetric assessment is also expected to capture 
lesion heterogeneity more effectively than single-slice assessment and, as a result, is better suited 
for voxel-wise characterisation with histogram analysis. VOIs were drawn by an MRI physicist 
(IL) on the b=800 s/mm2 images and then copied to the ADC maps. Histogram analysis was then 
performed using in-house software developed in Matlab 15a (The MathWorks(R)), to calculate 
mean, skewness, kurtosis, 25th, 50th and 75th percentiles. Voxels with zero ADC values were 
excluded from the analysis. 
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For DCE-MRI, the shutter speed model was used (as described in Chapter 3). VOIs were drawn 
by a single investigator (SD) on the dynamic scan of the lung patients DCE MRI data using the 
Analyze software (Biomedical Imaging Resource, Mayo Foundation, Rochester, MN). All 3D 
parametric maps were generated in Matlab R2015a (The MathWorks(R)) using a standard non-
linear least square curve fitting algorithm. Mean, standard deviation, kurtosis and skewness values 
were evaluated for each parameter. Voxels with biologically implausible results were excluded 
from the analysis (e.g. Ktrans > 5 1/min, ve > 1, τi > 3 s as any negative value). Implicit in the 
analysis is the requirement of the AIF which, in this study, has been evaluated, for each subject, 
drawing a region of interest in the aorta. 
2.5 Cytokeratin-18 measurements  
Blood samples were taken in breast patients to measure CK18. Two samples, each 7.5 mls, of 
blood from all patients were taken at baseline and at follow-up scan to measure M65 (measuring 
caspase-cleaved and intact CK-18) and M30 (measuring caspase-cleaved CK-18) using ELISA 
kits obtained by PEVIVA (BIOAXXESS, UK). 
2.6 Cleaved (active) caspase-3 immunohistochemistry  
A core biopsy was taken post-chemotherapy by a consultant interventional radiologist within 24 
h of the second [18F]ICMT-11 PET/CT scan. All diagnostic and research breast biopsies obtained 
were processed as previously described [177]. 
3.  Results  
 
3.1 Radiopharmaceutical  
The  radiolabelling of [18F]ICMT-11 was performed as previously described [176]. 
Radiochemical purity was > 99% on completion of synthesis with a mean (± SD) specific activity 
of 1373 ±1605 GBq/µmol (range, 199-9317 GBq/µmol) and pH of 5.02 ± 0.22 (range 4.57–5.66). 
The mean (range) doses injected in all breast patients pre- and post-chemotherapy were 335.6 
MBq (278.4–353.3 MBq) and 343.1 MBq (282.4– 359.1 MBq).  
3.2 Patients  
The study was designed: (a) in breast cancer to assess the effect of chemotherapy on [18F]ICMT-
11 uptake correlated with blood cytokeratin-18 assessment and biopsy-derived caspase-3/7 tissue 
expression within 24 h of the first dose of neoadjuvant FEC-T treatment, and (b) in lung cancer 
to measure the longitudinal effect of first-line chemotherapy on [18F]ICMT-11 correlated with 
diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging (DW- and DCE-
MRI) at each time point; notably, the latter was more difficult to recruit to, as a result only 
descriptive data are presented. A total of 23 patients were recruited, 20 breast cancer patients and 
three lung cancer patients. Seventeen patients were evaluable (15 breast cancer patients, all of 
whom were female, and two lung cancer patients, both male). Five breast patients withdrew from 
the study (two due to tracer failure, two due to patient’s personal decision, and one due to needle 
phobia), and one lung patient also withdrew (due to extreme fatigue). Study design and patient 
characteristics are shown in Figure 51b and Table 23 respectively. All breast patients had a diagnosis 
of invasive ductal carcinoma. Ten patients were found to have positive axillary lymph nodes on 
ultrasound (USS) and/or sentinel lymph node biopsy. All 15 patients completed a total of six 
cycles of FEC-T (three cycles of 5- fluorouracil, epirubicin, and cyclophosphamide, followed by 
three cycles of docetaxel). Four patients then commenced trastuzumab (Herceptin) concomitantly 
with docetaxel, after the first three cycles of FEC chemotherapy, for 1 year, as per standard local 
hospital guidelines. Fourteen patients received radiotherapy post-surgery, and one patient did not 
require radiotherapy. Oestrogen (ER), progesterone (PR), and human epidermal growth factor 
(HER2/neu) receptor status are documented in Table 23. Response was measured after three 
cycles of NCT by USS and after six cycles on histopathology at surgery. Fourteen out of 15 
patients were classified as responders — partial response (PR) or complete response (CR) post-
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treatment — and one patient had stable disease (SD); no patient showed evidence of disease 
progression. Both lung cancer patients had a diagnosis of non-small cell carcinoma 
(adenocarcinoma). Clinical response in the patients with lung cancer were reported with 
computerized tomography (CT) using RECIST 1.1 [178] midway through their chemotherapy 
and at the end. One lung patient had a PR post four cycles of chemotherapy and proceeded to 
radiotherapy treatment (55Gy in 20 fractions over 4 weeks), the second patient, had a PR after 
three cycles and completed five cycles with SD after initial PR. This patient subsequently died 
due to infection, unrelated to tumour or treatment received.  
3.3 [18F]ICMT-11 uptake in breast tumours at baseline and post-chemotherapy  
[18F]ICMT-11 was well tolerated by all patients, with no immediate or delayed complications 
observed. The median time (range) between baseline [18F]ICMT-11 PET/CT and start of NCT in 
breast patients was 6 days (1–14 days), and that between first cycle of NCT and post-treatment 
[18F]ICMT-11 PET/CT was 12 days (24 h–14 days). All primary tumours and involved axillary 
lymph nodes were visible on conventional imaging and PET; however, not all lesions 
demonstrated uptake on [18F]ICMT-11 PET (Figure 52a). For analysis, patients were divided into 
early (24– 48 h) and late (2–14 days) imaging post-chemotherapy. There were four patients in the 
early imaging group and 11 in the late imaging group. The mean and maximum SUV at 60 min 
(SUV60ave and SUV60max) pre- and post-chemotherapy are illustrated in Figure 52b and c. The 
median (range) pre-treatment SUV60ave and pre-treatment SUV60max were 0.56 (0.33–0.94) and 
0.91(0.53–1.24) respectively. Post-treatment SUV60ave and post-treatment SUV60max were 0.50 
(0.38– 1.07) and 0.75 (0.41–1.59) respectively. Pre- and post chemotherapy ratios (± standard 
deviation, SD) of tumour o-normal breast tissue (TBR60max), were 3.65 (± 1.71), 3.34 (± 1.52); 
corresponding tumour-to-muscle ratios (TMR60max) were 1.63 (± 0.43), 1.57 (± 0.49) respectively. 
Seven first-order statistics were extracted (mean, standard deviation, min, max, range, skew, and 
kurtosis), and none showed a change in the variables, irrespective of whether they were in the 
early or late imaged breast tumour group (Figure 52d). 
3.4 Voxel-wise analysis of [18F]ICMT-11 PET imaging data  
As previously described, the analysis of apoptosis in PET imaging at the tumour level using a 
PET-based voxel intensity sorting (PVIS) approach allows for the overall spatial distribution of 
voxel intensities within the tumour to be assessed; higher Δ intensity in treated tumours compared 
to baseline (right shift) is assigned PVIS apoptosis-dominant signature (PADS), while lower Δ 
intensity (left shift) is assigned PVIS necrosis-dominant signature (PNDS). Four patients (e.g., 
patients 1 and 2 in Figure 52) displayed PADS (Figure 53a); patient 3 in particular had a 
substantial right shift in voxel intensities. Mean percentage shift in voxel intensities for all four 
patients was 71%, and all had a PR after three cycles of chemotherapy on USS and after six cycles 
confirmed on histopathological correlation at surgery. The area under the curve (AUC) 
differences for all patients (numbered 1–15) are shown (Figure 53c). Thus, it appears that despite 
a lack of change in SUV60ave there were regional changes in tumour radiotracer uptake. Of the 11 
patients that did not demonstrate PADS, nine displayed ≥ 25% lower voxel intensities post-
treatment indicating a PNDS. Examples of patients with PNDS — patients 5 (with post-treatment 
imaging at 24 h) and 6 (post-treatment imaging at 6 days) are shown in Figure 53b. The mean 
percentage shift in voxel intensities was 68%; eight out of the nine patients had either a PR or CR 
post-chemotherapy, while one patient (patient 10) had SD (Figure 53d), suggesting that either 
PADS or PNDS can be associated with response to therapy The remaining two patients 
(exemplified by patient 14) showed no change in voxel intensity Figure 53b), despite showing PR 
to therapy. Notably, a snapshot of tumour [18F]ICMT-11 localisation is detected by our 
methodology; thus, presently we do not know whether the necrosis-dominant signature or indeed 
the no change in voxel intensities despite PR/CR, represents outright necrosis or a dynamic 
transition of cell death via an apoptosis dominant signature. In the cohort of patients studied, no 
patients demonstrated progressive disease.  
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Table 23: Patient characteristics. 
 
The median age (mean; range) of all patients: 54y (52; 37-67y), median weight 71.9 kg (73; 52.3-95.3 kg) 
-  Light grey shading (patients 1-4, found to show a predominant apoptotic signature) 
-  Mid-grey shading (patients 5-13, found to show a predominant necrotic and/or necrotic/apoptotic signature) 
-  Dark grey shading (patients 14 and 15, found to show neither a predominant apoptotic nor necrotic shift) 
IDC Invasive ductal carcinoma, HG DCIS High grade ductal carcinoma in-situ, IM DCIS Intermediate grade 
ductal carcinoma in-situ, ER Oestrogen receptor, PR Progesterone receptor, HER2 Human epidermal growth 
factor receptor 2 
*AJCC staging (7th edition) used for TNM staging in breast and lung cancer 
 
3.5 Cytokeratin-18 and caspase cleaved cytokeratin-18  
All breast patients had blood taken for cytokeratin-18 (CK-18) analysis. Circulating full-length 
(M65) and caspase-cleaved CK 18 (M30) fragments were assessed by ELISA pre- and post-
treatment at the time of the PET scan. Typical data are shown in Figure 53e. Ratios of cleaved to 
total CK-18 varied considerably in this cohort of breast patients, with the lowest ratio post-
chemotherapy 0.27 observed in patient 10, in whom there was no response to NCT. The median 
pre- and post-chemotherapy values of M65 were 141.5 U/l (range 50.3–359.7), and 180.8 U/l 
(range 66.9–369.7), and those for M30 were 78.8 U/l (range 32.2–207.9) U/L and 102.7 U/l (range 
47.8–207.7) respectively. Overall M30 or M65 did not correlate with PADS or PNDS (Figure 53f). 
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Patient 3, who had the highest PADS, also showed the only consistent increase of M30/M65 ratio, 
increasing from 0.35 pre-chemotherapy to 0.52 post-chemotherapy, perhaps suggesting that the 
levels of apoptosis or necrosis were not sufficiently high to generate robust changes of M30/M65 
in blood.  
 
Figure 52: [18F]ICMT-11 uptake in primary breast tumours. a Axial CT and fused [18F]ICMT-11 PET/CT 
images of primary breast tumours in two patients, 1 and 2,at baseline (pre-) and post-chemotherapy. Low-level 
uptake is noted. b Pre- and postchemotherapySUV60ave andSUV60max values of breast tumours imaged at an 
early time point(24–48 h) or c late time point(2–14 days). Small changes were seen pre- and post-chemotherapy. 
d First-order statistics were extracted using in house software under Matlab 15a [The MathWorks(R)], and a 
subset of features were selected to detect changes in early and late imaged breast tumours 
3.6 Cleaved caspase-3 expression  
Acknowledging that pre- and post-treatment biopsies could have been taken from different parts 
of the tumour, we assessed if there was some general association between the PVIS data and 
histopathology in the breast patients. All diagnostic (pre-) and post-chemotherapy biopsies were 
stained for cleaved (active) capsase-3 expression. The diagnostic tumour blocks of two patients 
(patients 2 and 5) were not available. Typical cleaved caspase-3 immunostains in patients 
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assigned PADS and PNDS are shown in Figure 54a and b. Whole tissue mount analysis of 
percentage cleaved caspase-3 showed variable baseline and posttreatment expression. Cleaved 
caspase-3 expression was low at baseline with levels below 0.45%; expression increased from a 
mean of 0.13% (95% CI 0.12–0.13) to 0.81% (95% CI 0.79– 0.83). Such low levels of caspase-3 
activation despite a mean fold-change of 15.7% may prove difficult to detect by PET.  
 
Figure 53:  Voxel–wise tumour [18F]ICMT-11 intensity histogram analysis and blood cytokeratin-18 in all breast 
cancer patients. a PET-based voxel intensity sorting (PVIS) histogram analysis in patients 1, 2, and 3. All patients 
are late-imaged, (2–14 days) except patient 5* (early imaged 24–48 h). The intensities of all voxels within the 
tumour volume of interest (VOI) have been expressed as histogram plots of normalised voxel intensities pre-and 
post-chemotherapy. These patients demonstrated a predominant PVIS apoptotic signature with right shifts of 
all voxel intensities within the tumour VOI post-chemotherapy. b PVIS histogram analysis inpatients 5 and 6, 
showing a predominant PVIS necrotic signature with shift in voxel intensities to the left. Patient 14, showing no 
dominant signature on PVIS histogram analysis. These results have been analysed statistically and are 
represented through box-plot diagrams (minimum, maximum, median, 10th and 90th percentile statistical 
parameters). The differences in AUC shifts noted in each patient are shown in c, demonstrating tumours with a 
predominant dominant PVIS apoptotic signature (black) or dominant PVIS necrotic signature (white), and d 
associated outcomes in all fifteen breast patients post 3 and 6 cycles of NCT. Patients are shown as having SD 
(stable disease), PR (partial response) or CR (complete response). * denotes patients who received trastuzumab 
alongside their 4th–6th cycle of chemotherapy. Light grey shading (patients1–4, who showed a predominant 
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PVIS apoptotic signature). Mid grey shading (patients 5–13, who showed a predominant PVIS necrotic 
signature). Dark grey shading (patients 14 and 15, who showed neither a predominant apoptotic nor necrotic 
shift). e Corresponding CK-18 analysis(M65 and M30) pre-and post-chemotherapy in patients 1, 2, and 
3.Graphs highlight the variation in levels, with only patient 3 demonstrating an increase in post-chemotherapy 
levels ofM65 andM30. f CK-18 (M65and M30) analysis in patients 5 and 6, showing no clear increase post-
chemotherapy, and patient 14, who despite showing no dominant signature on PVIS histogram analysis, was 
found to have an increase in M65and M30 levels post-chemotherapy. 
 
Figure 57 (continued) 
 
 
3.7 Longitudinal studies in lung cancer patients  
 
3.7.1 [18F]ICMT-11 uptake in lung tumours at baseline and post-chemotherapy  
Three lesions from two lung cancer patients (a large left upper lobe tumour in patient 16; a primary 
lesion in the right upper thoracic mediastinum and a mediastinal lymph node in patient 17) were 
analysed at three time-points; the lesions were all visible on PET (Figure 55a). The interval 
between baseline [18F]ICMT-11 PET/CT/MRI and start of chemotherapy in both lung cancer 
patients was between 2 and 8 days. Patients were scanned at 24 h and at 7 days after the first cycle 
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of chemotherapy. Median (range) SUV60ave and SUV60max were 0.41 (0.33–0.61) and 0.85 
(0.52–0.87) at baseline, 0.39 (0.35–0.62) and 0.87 (0.47–0.88) early after chemotherapy, and 0.45 
(0.42–0.66) and 0.94 (0.64–0.98) late after chemotherapy. First-order statistics showed no 
differences in the features extracted. With regard to voxel-wise analysis, patient 16 demonstrated 
an initial PNDS shift followed by a PADS shift (61%) to higher voxel intensities at 7 days post-
chemotherapy (Figure 55a and b). Patient 17, had a PNDS in the primary thoracic lesion, at 24 h 
and 7 days post-chemotherapy (Figure 55c and d). Both patients had a partial response to 
combination platinumbased chemotherapy (Figure 55e and f).  
 
Figure 54: Cleaved caspase-3 expression in breast patients. a Expression of cleaved caspase-3 detected by 
immunohistochemistry in breast tissue taken by USS-guided biopsy post-chemotherapy in patients with a 
predominant PVIS apoptotic signature. b Similar cleaved caspase-3expression in patients with a predominant 
PVIS necrotic signature no change on PVIS. Arrows (black) demonstrate cleaved caspase-3staining on tissue 
biopsy post-chemotherapy. c Graph indicates the percentage (%) cleaved caspase-3 expression in breast tissue 
in all patients taken at baseline (blue bars) and post-chemotherapy (yellow bars). * denotes early imaged (24–48 
h) breast patients. 
3.7.2 Diffusion-weighted (DW) and dynamic contrast enhanced (DCE) MRI in lung cancer  
The diffusion of water molecules embodied in the variable Apparent Diffusion Coefficient (ADC; 
mean and percentiles), increased in patient 16 but not in patient 17 (Table 24) consistent with cell 
death-related increase in extracellular space in the former after the initiation of therapy (Figure 
55A and B). Histogram analysis demonstrated increase in skewness and kurtosis in patient 16, 
particularly at 7d, while these variables decreased or were unchanged in patient 17 (Figure 55C 
and D). A reduction of ADC and skewness could be related to increases in extracellular matrix 
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(ECM) constituents, which introduces additional obstructions and hydrogen-bonding sites to the 
tumour microenvironment, thus reducing the ADC.  
Table 24: ADC histogram analysis results of lung cancer patients 16 and 17. 
 
 
Figure 55: Detection of tumour cell death in lung cancer by DW-MRI. (A and B) DW-MRI images for patient 
16 and 17 at baseline, 24h and 7d post-chemotherapy. Corresponding apparent diffusion coefficient (ADC) maps 
in jet colour scale (µm2/s) are shown. (C and D) ADC tumour histograms in patient 16 and 17 depicting the 
distribution of the voxels as per their intensities at baseline, 24h and 7d post-chemotherapy with histogram 
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analysis using in-house software developed in Matlab 15a (The MathWorks(R)), to calculate mean, skewness, 
kurtosis, 25th, 50th and 75th percentiles. Voxels with zero ADC values were excluded from the analysis. 
DCE-MRI pharmacokinetic analysis using the shutter speed model was conducted to verify 
whether large changes in perfusion/permeability accompanied [18F]ICMT-11. Ktrans is a variable 
that reflects permeability and blood flow, and measured as the accumulation of contrast agent into 
the extravascular-extracellular space. In general, Ktrans increased at 24h followed by a decrease to 
below baseline values at 7d (Table 25), suggesting that changes in [18F]ICMT-11 tumour uptake 
in the lung patients could not be explained by perfusion/permeability changes. Other DCE 
variables including Kep, ve and τi (mean and histogram values) are summarised in Table 25. 
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Table 25: Results of the application of the shutter speed model on DCE-MRI data. 
Shutter Speed Model 
Patient #1 
   
 
 Mean Std Kurtosis Skewness Mean Std Kurtosis Skewness Mean Std Kurtosis Skewness Mean Std Kurtosis Skewness 
Baseline 0.76 1.12 5.78 1.90 1.53 1.38 2.49 0.85 0.79 0.14 10.99 -2.14 0.22 0.32 18.04 3.48 
24 hours 0.94 1.27 4.44 1.65 2.05 1.52 1.76 0.48 0.81 0.11 8.74 -1.15 0.18 0.21 28.66 4.08 
7 days 0.57 0.70 12.018 2.80 0.78 0.87 7.76 2.19 0.68 0.20 2.091 -0.30 0.19 0.13 4.59 0.45 
Variation 
-0.39 
-
0.45 1.70 0.69 -0.62 
-
0.43 3.41 3.53 -0.16 0.88 -0.760 -0.74 0.09 -0.37 -0.83 -0.88 
 Patient #2 
   
 
Mean Std Kurtosis Skewness Mean Std Kurtosis Skewness Mean Std Kurtosis Skewness Mean Std Kurtosis Skewness 
Baseline 1.26 1.19 4.016 1.3075 1.98 1.29 1.90 0.29 0.74 0.24 2.83 -1.088 0.087 0.35 176.37 12.62 
24 hours 1.18 1.16 3.75 1.3269 1.45 0.96 4.16 1.07 0.69 0.25 2.12 -0.79 0.10 0.075 4.82 0.90 
7 days 1.12 1.32 3.77 1.4103 0.80 0.74 4.80 1.65 0.68 0.28 3.0041 -1.087 0.15 0.29 11.066 2.84 
Variation 
-0.05 0.13 0.0031 0.062 -0.44 
-
0.23 0.15 0.53 -0.02 0.13 0.42 0.36 0.51 2.88 1.29 2.15 
 
 
  
transK epK ev it
transK epK ev it
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4.  Discussion  
 
In the first patient study of the caspase 3/7-specific isatin sulphonamide PET radiotracer, we show 
that the lack of significant global tumour [18F]ICMT-11 dependent PET changes, despite some 
regional voxel changes, reflect a lack of significant apoptosis induction following chemotherapy. 
This study to our knowledge is the first to investigate the use of a caspase 3/7-specific PET 
radiotracer for imaging of chemotherapyinduced apoptosis in cancer Chemotherapy response has 
often been associated with cell death via apoptosis [169, 171, 172]; however, such studies have 
often been semi-quantitative and based on biopsy samples with variable output. Several studies 
have reported that spatial and temporal heterogeneity exist in breast and other cancers [179, 180]. 
Repeat biopsy of breast tissue at a single point in time is not representative of the whole tumour. 
Thus, approaches aiming to image whole-tumour apoptosis for the purposes of assessing 
therapeutic response (to chemotherapy, targeted therapies, and radiotherapy) were embraced. 
These imaging methods include MRI [181], magnetic resonance spectroscopy (MRS) [182], USS 
[183], novel fluorescence imaging [184], scintigraphy [159, 166]and PET [158, 164, 165]. Studies 
using [99mTc]Annexin V, in particular, led the way for nuclear imaging of apoptosis [159, 166, 
167]. In the current study, we report that caspase-3/7 activation as determined by [18F]ICMT-11 
was not a dominant mechanism of pharmacological activity following chemotherapy in breast 
cancer. Two pieces of information enabled us to reach this conclusion. 
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Figure 56: Detection of tumour cell death in lung cancer by [18F]ICMT-11PET/CT. Patient 16 (a) and Patient 
17 (c) axial CT and fused [18F]ICMT-11 PET/CT images of primary lung cancer at cancer at baseline, 24 h and7 
days post-chemotherapy. PVIS histogram analysis at 24 h and 7 days post-chemotherapy in patient 16 (b) and 
17 (d), with clinical outcomes (e and f). 
First, cytokeratin-18 analysis in blood samples, a method that has been previously reported to 
have high sensitivity and specificity for detecting apoptosis [185, 186], showed a positive change 
— increased M30/M65 ratio — only in one patient (patient 3). Indeed, Olofsson et al. indicated 
based on their M30/M65 data that FEC chemotherapy, also used by us, causes predominantly 
necrotic death compared for instance to taxane-based therapy [186]. Whether necrotic death was 
secondary to apoptosis was not determined. Furthermore, the absolute proportion of apoptotic 
cells in biopsy samples obtained from patients soon after [18F]ICMT-11 PET scanning was 
generally in the 1% range, albeit an increase from pretherapy levels (Figure 54c). This low 
proportion of apoptotic cells may not generally lead to detection by nuclear methods. While 
cytokeratin-18 methodology can be influenced by apoptosis of chemotherapy-sensitive healthy 
tissue [187], we were surprised by the low proportion of apoptosis from histology. In comparison 
to routine oncology nuclear medicine radiotracers, the (baseline) pre-chemotherapy uptake of 
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[18F]ICMT-11 in tumour was low, with SUV60max values around 1. With simultaneous 
acquisition of anatomical information, by CT in our case, segmentation of tumour is still possible 
and in view of this, low baseline uptake presumably representing the no/low apoptosis state is 
inconsequential. However, SUV parameters did not change following treatment, attributed to the 
low level of apoptosis seen in these tumours. In preclinical studies, [18F]ICMT-11 demonstrated 
high specificity to apoptosis versus necrosis [177]; thus, it is unlikely that the lack of changes is 
a reflection of lack of specificity. It is possible to rationalise a highly heterogeneous response of 
tumours to chemotherapy whereby clusters of tumours respond more avidly to the therapy than 
the bulk of the tumour. Indeed, we demonstrate this phenomenon in preclinical models of lung 
cancer imaged with [18F]ICMT-11 PET, whereby the global tumour tracer normalised uptake 
value returned no changes following effective therapy. In contrast, PVIS histogram analysis 
showed a clear right shift over 48 h post-treatment, with a 1.5-fold increase in the number of 
voxels having high intensity uptake [188]. Consequently, PVIS analysis allows extraction of the 
Bcell-death^ signal by allowing the capture of heterogeneous [18F]ICMT-11-detectable activated 
caspase-3/7 within the tumour, compared with simple uptake values derived from the volume of 
interest. The over-reliance on voxel-based analysis for apoptosis data is predicated on pre-clinical 
studies for ICMT-11 [188] and clinical studies with [18F]ML-10 [164, 165], intimating a manner 
in which apoptosis data should be presented in view of its heterogeneous presentation. All 
patients, except one, responded to treatment; hence, we were unable to correlate PADS in 
particular, but also PANS to clinical outcome. All four patients with PADS responded to therapy; 
however, patients showing PANS or no change also responded to therapy, indicating that PADS 
is not a pre-requisite for response in this patient group. Notably, however, the only patient 
showing a positive M30/M65 also showed the highest PADS. Equally, we cannot infer a more 
appropriate time for [18F]ICMT-11 measurement, although the second window (2-14d) is perhaps 
more practical. The lack of ‘non-responders’ is a limitation of our study; however, this could not 
be influenced due to the prospective nature of the study; thus, all outcomes were reported. The 
main aim — the investigation of the changes in ICMT-11 uptake and relationship with 
biochemical/histological caspase-3 activity — was, however, not compromised. It is worth 
considering the difficulties within this study both from a logistics and scientific perspective. The 
timing of apoptosis has been elusive and fraught with difficulties when using functional imaging 
such as PET. Parton et al. [170] reported apoptosis in tissue biopsies rising within 24 h of 
chemotherapy in breast patients, a finding consistent with other studies [169, 171]. Due to 
logistics of imaging and availability of the patient, 24 h post-chemotherapy imaging was not 
feasible in all patients. In our study cohort, patients underwent imaging with [18F]ICMT-11 
PET/CT at various time-points post-chemotherapy. Two patients imaged at 24 h post-
chemotherapy failed to show an apoptotic dominant signature or significant increase in caspase-
3 expression. Apoptosis may not be the sole mechanism of cell death in treatment response. 
Although it is known to play a key role, cell death can occur by necrosis, mitotic catastrophe, 
senescence, autophagy, pyroptosis, and DNA damage [189]. As the majority of patients in our 
study showed a dominant necrotic or mixed apoptotic/necrotic signature phenotype, the balance 
between apoptosis and necrosis may be one in favour of the latter. This could in part, account for 
the lack of a predominant apoptotic signal on PET and histology. Longitudinal, multi-parametric 
imaging studies in the lung cancer patients permitted us to verify simultaneously [18F]ICMT-11, 
ADC as a measure of cell death, and DCEMRI as a measure of perfusion/permeability. The 
increase in ADC values seen with DW-MRI in patient 16, 24 h and 7 days post-chemotherapy, 
infers increased cell death induced increases in water mobility as previously reported [51]. This 
is consistent with the increase in tumour [18F]ICMT-11 in the same patient. Conversely, the 
decrease in ADC variables in patient 17 may be linked to increases in ECM constituents [190] 
that can accompany response (necrosis, fibrosis, or mixed inflammatory infiltrate) and associated 
cell swelling [51]. Accordingly, in the two patients there appears to be congruence of [18F]ICMT-
11 and ADC data. Significant changes in perfusion/permeability could perturb PVIS 
measurements. Assessment of the pharmacokinetics rate constant Ktrans from the DCE-MRI study 
showed that perfusion/ permeability dynamics could not explain the [18F]ICMT-11 dynamics 
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within the time frame of the study. Beyond this proof of concept study, future prospective studies 
in a larger cohort should examine the role of [18F]ICMT-11 in assessing chemotherapy response, 
to also include a fair mix of responders and non-responders. The outcome of the lung cancer 
cohort study when confirmed in a larger cohort may support use of combined PET-MRI in 
monitoring ADC-detectable cell death and [18F]ICMT-11-detectable caspase-3/7 activation.  
 
 
5. Conclusion  
 
In aggregate, initial studies using [18F]ICMT-11 were promising in preclinical and first-in-man 
healthy volunteer studies [8, 29, 41, 45]. We report the first use of [18F]ICMT-11 in a small cohort 
of patients diagnosed with breast or lung cancer and receiving first-line chemotherapy. The results 
show that only a small proportion of apoptosis was induced by drug treatment and that this level 
did not induce global changes in tumour [18F]ICMT-11 uptake. Voxel-wise analysis showed 
regional increases of [18F]ICMT-11 intensity regions in some tumours, and while patients having 
this phenotype responded to therapy, it was not an exclusive marker of response. Thus, tumour 
response could occur in the absence of predominant chemotherapy-induced caspase-3/7 
activation measured non-invasively across entire tumour lesions in patients with breast and lung 
cancer. 
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V. Multiparametric MRI in prostate cancer: a radiomic study on 
different diffusion and perfusion models 
 
The aim of this study was to evaluate radiomics features extracted from T2-weighted, diffusion 
weighted imaging (DWI), diffusion kurtosis imaging (DKI), dynamic contrast enhanced (DCE) 
MRI data fitted with the Tofts (TM) and shutter speed model (SSM), benign prostatic hyperplasia 
(BPH), and benign peripheral zone (PZ). Furthermore, the comparison between the diagnostic 
performances of advanced prostate radiomics to PI-RADS v2 classification was under 
investigation. 
 
1. Materials and Methods 
 
40 foci of PCa, 48 BPH nodules, and 36 benign PZ from 40 patients who underwent 
multiparametric MRI of prostate, to eventually address a target-biopsy, were evaluated. 
 
MRI exam was performed without endorectal coil with a 3T mMR Biograph scanner. DWI was 
performed using 7 b-values (0-2500 s/mm2): classical apparent diffusion coefficient (ADC) map 
was generated using b values up to 1500 s/mm2; the entire range of b values was used to compute 
non-Gaussian diffusion coefficient (D) and deviations from normal distribution (K) maps.  
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters (Ktrans, ve, kep [TM 
& SSM] and intracellular water molecular lifetime τi [SSM]) were also determined.  
2D regions of interest were manually outlined on the axial T2w that was also used as reference 
image to coregister other maps. 13 first-order statistical features were extracted for each map.  
Feature selection was performed to identify 5 features for each model [191]. A logistic regression 
classifiers were used to identify features discriminating clinically significant tumours (PIRADS 
4-5) from benign PZ with an intra- and inter-model approach. The area under the receiving-
operating characteristic curve (AUC), the sensitivity, the specificity and the accuracy were used 
to evaluate the performances of models. The intermodel approach was also tested to discriminate 
between BPH and other groups. 
 
2. Results 
 
Identified radiomic features differentiated PCa from benign PZ. Prediction performances were 
higher for diffusion features (extracted for both DWI and DKI – Fig61) than for perfusion ones 
(extracted for both the TM and the SSM – Fig62).  
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Figure 57: Prediction performances of logistic regression models for diffusion features. 
 
Figure 58: Prediction performances of logistic regression models for perfusion features. 
 
These differences were confirmed independently by the number of features included in the 
logistic model (i.e., Model order). Intermodal approach lead to logistic regression models with 
very high discrimination performances (AUC values close to 1) with best results for sensitivity, 
specificity and accuracy (more than 0.99) in the models including 4, 5, and 7 features (Fig63,64).  
 
184 
 
 
Figure 59: Prediction performances of logistic regression models for intermodel approach. 
 
MODEL 
ORDER 
SELECTED 
FEATURES 
AUC SENSITIVITY SPECIFICITY ACCURACY 
1 T2w - median 0.99 0.97 0.97 0.97 
2 T2w - median 
ve (SSM) - 
uniformity 
0.99 0.99 0.99 0.99 
3 ADC - energy 
T2w - median 
ve (SSM) - 
uniformity 
0.99 0.99 0.99 0.99 
4 D - maximum 
T2w - median 
T2w - skewness 
ADC - skewness 
0.99 0.99 0.99 0.99 
5 D - maximum 
T2w - median 
T2w - skewness 
ADC - skewness 
T2w - energy 
0.99 0.99 0.99 0.99 
6 T2w - mean 0.99 0.99 0.99 0.99 
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ve (SSM) - 
uniformity 
ADC - energy 
D - maximum 
kep (TM) - entropy 
T2w - skewness 
7 D - maximum 
T2w - median 
T2w - skewness 
ADC - skewness 
D - skewness 
Ktrans (SSM) - 
uniformity 
0.99 0.99 0.99 0.99 
8 D - maximum 
T2w - median 
T2w - skewness 
ADC - skewness 
D - skewness 
Ktrans - uniformity 
ve (TM) - maximum 
0.99 0.98 0.99 0.98 
9 D - maximum 
T2w - median 
T2w - skewness 
ADC - skewness 
D - skewness 
Ktrans - uniformity 
ve (TM) - maximum 
ADC - median 
0.99 0.98 0.99 0.99 
10 D - maximum 
T2w - median 
T2w - skewness 
ADC - skewness 
D - skewness 
Ktrans - uniformity 
ve (TM) - maximum 
0.99 0.98 0.99 0.98 
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ADC - median 
kep (TM) - entropy 
Figure 60: AUC, Sensitivity, Specificity and Accuracy values for intermodel approach. 
These models were also able to significantly discriminate BPH from other groups (p < 0.001 – Fig65). 
 
 
 
Figure 61: Discriminating power of prediction model of order 7 between BPH and other groups. 
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Conclusions 
 
“If we knew what it was we were doing, 
it would not be called research, would it?” 
Albert Einstein 
 
 
The analysis of tissue kinetics of intravenously injected contrast agents or tracers is the 
most widely used technique for the evaluation of tissue perfusion and permeability. In 
fact, microcirculation is affected by both pathological conditions and treatment and, for 
this reason, the analysis of tissue microvascular network could be very informative of the 
state of the lesion. 
This thesis shows the application of quantification methods for the analysis of dynamic 
PET and MRI data. It involves well known and new PET tracers as well as standard and 
new pharmacokinetic models for the extraction of parametric maps from DCE-MRI data. 
The first application of kinetic modelling on D4-Choline and 18F-FLT PET data of lung 
and liver tumour tissues, respectively, reinforced the idea that 18F-FDG, which is the most 
widely used tracer in PET clinical protocols, may be inappropriate for too many reasons 
where the choice of more specific tracers works for both tumour assessment and treatment 
response evaluation. On the other hand, the analysis of DCIS with both 18F-FDG and FLT 
showed many limitations, mainly due to the limited dataset and the inner proliferative 
activity of the breast, which made the detection and identification of these small lesions, 
complicated.  
In the third chapter, the feasibility of DCE-MRI analysis in primary brain glioma was 
investigated. These tumours are different as in the healthy brain the blood brain barrier 
blocks the leakage of the contrast agent from the vessel. The implementation of multiple 
models (the non exchange, the Tofts, the extended Tofts, the shutter speed model) with 
the additional first implementation of the extended shutter speed model showed that the 
complexity of the model does not guarantee a fair description of the tumour. In fact, in 
this particular case where both the heterogeneity and the blood brain barrier play 
important roles in the analysis of the lesion, we showed how a model selection procedure 
can be crucial in the description of these tissues. In fact, different models yield different 
pharmacokinetic parameters and it is crucial to select the appropriate model to analyse 
DCE-MRI time courses based on the regional tissue biology, specifically permeability 
and vasculature. 
The last part of the thesis involves several multiparametric studies where the kinetics of 
both PET tracers and MRI contrast agent have been analysed. These two imaging 
techniques are functionally very different and the extent of their agreement or discordance 
is not well understood yet. Therefore, the evaluation of the association between 
pharmacokinetic parameters resulted from the analysis of DCE-MRI data with multiple 
models and metabolic parameters derived from the application of graphical or spectral 
analysis to PET data, is important for the integration and validation of methods. In fact, 
the kinetic analysis of PET data could benefit from the pharmacokinetic parameters 
extracted from DCE-MRI data and vice versa. This thesis shows associations between 
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these two modalities in both brain and breast cancers but would benefit from a spatial 
correlation with DW-MRI and tissue biology. 
The quantification methods used in this thesis are not currently implemented in the 
routine clinical practice. Additional studies are needed for the verification of the 
reliability of models and parameters for diagnostic and prognostic purposes with the final 
aim of biomarker validation. 
This thesis is in agreement with a number of published works and it shows the potential 
of the kinetic analysis of tracers in pathological conditions and before and after treatment. 
It represents a step towards the validation of these models, which can finally provide a 
novel clinical tool to aid clinicians in tumour diagnosis, treatment planning and in the 
improvement of patients’ outcomes.  
 
